|
US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
|
US5731168A
(en)
*
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US6066617A
(en)
*
|
1996-04-03 |
2000-05-23 |
Human Genome Sciences, Inc. |
Human cystatin F
|
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
JP4274581B2
(ja)
*
|
1996-07-12 |
2009-06-10 |
ジェネンテック・インコーポレーテッド |
キメラヘテロ多量体接着体
|
|
WO1998002541A1
(en)
*
|
1996-07-12 |
1998-01-22 |
Genentech, Inc. |
Gamma-heregulin
|
|
DE69739673D1
(de)
*
|
1996-11-27 |
2009-12-31 |
Genentech Inc |
Affinitätsreinigung von Polypeptid-Proteinen auf einer Protein A Matrix
|
|
US20040038894A1
(en)
*
|
1996-12-31 |
2004-02-26 |
Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) |
Compounds for modulating cell negative regulations and biological applications thereof
|
|
US6045774A
(en)
*
|
1997-01-10 |
2000-04-04 |
Epicyte Pharmaceutical Inc. |
J chain polypeptide targeting molecule linked to an imaging agent
|
|
CN1191276C
(zh)
|
1997-04-07 |
2005-03-02 |
基因技术股份有限公司 |
人源化抗体和制备人源化抗体的方法
|
|
CN100480269C
(zh)
|
1997-04-07 |
2009-04-22 |
基因技术股份有限公司 |
抗-血管内皮生长因子的抗体
|
|
CA2288600C
(en)
*
|
1997-05-02 |
2010-06-01 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20020062010A1
(en)
*
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
DK0998486T4
(da)
|
1997-06-13 |
2012-05-14 |
Genentech Inc |
Proteinoprensning ved kromatografi efterfulgt af filtrering på en ladet fase
|
|
DE69714035T2
(de)
|
1997-08-14 |
2003-03-06 |
Sulzer Innotec Ag, Winterthur |
Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
|
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
ATE293994T1
(de)
*
|
1997-12-01 |
2005-05-15 |
Fang Fang |
Multivalente rekombinante antikörper zur behandlung von hrv infektionen
|
|
US6451977B1
(en)
*
|
1998-02-26 |
2002-09-17 |
Genentech, Inc. |
Fused polypeptides
|
|
EP1941905A1
(en)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Ligand-anti-her-2 antibody synergism
|
|
US6528624B1
(en)
*
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
*
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
|
JP3577586B2
(ja)
|
1998-05-15 |
2004-10-13 |
ジェネンテック・インコーポレーテッド |
Ｉｌ−１７相同的ポリペプチドとその治療用途
|
|
CA2328498A1
(en)
|
1998-06-12 |
1999-12-16 |
Genentech, Inc. |
Monoclonal antibodies, cross-reactive antibodies and method for producing the same____________________________________
|
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
|
AU1727500A
(en)
*
|
1998-11-17 |
2000-06-05 |
Tanox, Inc. |
Bispecific molecules cross-linking itim and itam for therapy
|
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
|
EP1820859B9
(en)
|
1998-12-22 |
2009-10-28 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0104865A3
(en)
*
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
WO2004009618A2
(en)
|
2002-07-18 |
2004-01-29 |
Crucell Holland B.V. |
Recombinant production of mixtures of antibodies
|
|
AU4369000A
(en)
*
|
1999-04-26 |
2000-11-10 |
Duke University |
Inhibition of complement action
|
|
CA2370466C
(en)
|
1999-06-25 |
2011-02-08 |
Sharon Erickson |
Methods of treatment using anti-erbb antibody-maytansinoid conjugates
|
|
EP1953173B1
(en)
|
1999-06-15 |
2009-11-18 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
|
|
CH694589A5
(de)
|
1999-06-25 |
2005-04-15 |
Genentech Inc |
Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern.
|
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
GB9919597D0
(en)
*
|
1999-08-18 |
1999-10-20 |
Oxford Glycosciences Uk Ltd |
Methods and compositions for diagnosis of hepatoma
|
|
IL148114A0
(en)
|
1999-08-27 |
2002-09-12 |
Genentech Inc |
DOSAGES FOR TREATMENT WITH ANTI-ErbB2 ANTIBODIES
|
|
CA2490853A1
(en)
|
1999-12-01 |
2001-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
EP1897946B1
(en)
|
1999-12-23 |
2012-07-11 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
|
KR20080006002A
(ko)
|
2000-01-13 |
2008-01-15 |
제넨테크, 인크. |
신규 Ｓｔｒａ6 폴리펩티드
|
|
AU3458401A
(en)
|
2000-01-25 |
2001-08-07 |
Genentech Inc. |
Compositions and methods for treatment of cancer
|
|
US6740520B2
(en)
|
2000-03-21 |
2004-05-25 |
Genentech, Inc. |
Cytokine receptor and nucleic acids encoding the same
|
|
HUP0300369A2
(hu)
|
2000-04-11 |
2003-06-28 |
Genentech, Inc. |
Többértékű antitestek és alkalmazásuk
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
US6696620B2
(en)
*
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
|
AU6836301A
(en)
|
2000-06-20 |
2002-01-02 |
Idec Pharma Corp |
Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
EP1303293B1
(en)
|
2000-07-27 |
2008-12-03 |
Genentech, Inc. |
Sequential administration of cpt-11 and apo-2l polypeptide
|
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
|
DE60136281D1
(de)
|
2000-08-24 |
2008-12-04 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
NZ524329A
(en)
|
2000-09-26 |
2008-04-30 |
Genentech Inc |
IgE receptor antagonists that compete with IgE134 for binding to the receptor
|
|
US8178304B2
(en)
*
|
2000-10-06 |
2012-05-15 |
Smith Terry J |
Diagnostic methods relating to Graves' disease and other autoimmune disorders
|
|
US8153121B2
(en)
|
2000-10-06 |
2012-04-10 |
Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center |
Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
|
|
PT1324776E
(pt)
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Formulações de proteína concentradas de viscosidade reduzida
|
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
AU2002246632B2
(en)
|
2000-12-08 |
2007-04-05 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US9249229B2
(en)
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
|
US6492327B2
(en)
*
|
2000-12-19 |
2002-12-10 |
Sulzer Biologics Inc. |
Isolation of purified TGF- β1 and TGF -β2 from bone tissue
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
AU2002238052A1
(en)
*
|
2001-02-20 |
2002-09-04 |
Zymogenetics, Inc. |
Antibodies that bind both bcma and taci
|
|
US20020155109A1
(en)
*
|
2001-04-20 |
2002-10-24 |
Lynch David H. |
Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
|
|
IL158920A0
(en)
|
2001-05-24 |
2004-05-12 |
Zymogenetics Inc |
Taci-immunoglobulin fusion proteins
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
CA2633171C
(en)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
|
UY27373A1
(es)
*
|
2001-07-09 |
2003-02-28 |
Schering Ag |
Formulaciones de interferón beta-humano
|
|
EP1578917A4
(en)
|
2001-07-19 |
2008-01-23 |
Perlan Therapeutics Inc |
MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
|
JP2005536439A
(ja)
|
2001-09-18 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断及び治療のための組成物と方法
|
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
|
MXPA04003057A
(es)
|
2001-10-04 |
2005-06-20 |
Immunex Corp |
Proteina 4 de enlace ul16.
|
|
US20030228319A1
(en)
|
2002-04-16 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
JP2005506073A
(ja)
*
|
2001-10-19 |
2005-03-03 |
ザイモジェネティクス，インコーポレイティド |
二量体化された成長因子及びそれを生成するための材料及び方法
|
|
US20030157108A1
(en)
*
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US7175983B2
(en)
*
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
|
ES2624547T3
(es)
|
2001-11-14 |
2017-07-14 |
Janssen Biotech, Inc. |
Anticuerpos anti il 6, composiciones, métodos y usos
|
|
WO2003057881A1
(fr)
|
2001-12-28 |
2003-07-17 |
Chugai Seiyaku Kabushiki Kaisha |
Procede de stabilisation d'une proteine
|
|
NZ556415A
(en)
|
2002-01-02 |
2009-02-28 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
|
DK1472275T3
(da)
|
2002-02-05 |
2009-04-14 |
Genentech Inc |
Proteinoprensning
|
|
EP2388265A1
(en)
|
2002-02-22 |
2011-11-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
ES2401428T3
(es)
|
2002-04-10 |
2013-04-19 |
Genentech, Inc. |
Variantes de anticuerpos anti-HER2
|
|
US7622562B2
(en)
|
2002-06-26 |
2009-11-24 |
Zimmer Orthobiologics, Inc. |
Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
|
|
EP2383278A1
(en)
|
2002-07-08 |
2011-11-02 |
Genentech, Inc. |
Method to determine B cell mediated diseases
|
|
EA011686B1
(ru)
|
2002-07-15 |
2009-04-28 |
Уайт |
Способ модуляции развития и функций т-клеток-хелперов
|
|
ES2392525T3
(es)
|
2002-07-15 |
2012-12-11 |
F. Hoffmann-La Roche Ag |
Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
EP1590363A4
(en)
|
2002-09-09 |
2006-11-02 |
Dana Farber Cancer Inst Inc |
BH3-PEPTIDES AND METHOD FOR THEIR USE
|
|
JP5303092B2
(ja)
|
2002-09-11 |
2013-10-02 |
ジェネンテック， インコーポレイテッド |
タンパク質精製
|
|
US20060199181A1
(en)
|
2002-09-11 |
2006-09-07 |
Genentch, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
ATE493433T1
(de)
|
2002-09-11 |
2011-01-15 |
Genentech Inc |
Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
|
|
AU2003291625B2
(en)
|
2002-09-16 |
2009-10-08 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
DE10244457A1
(de)
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
|
US20070042945A1
(en)
|
2002-09-25 |
2007-02-22 |
Genentech, Inc. |
Nouvelles compositions et methods de traitement du psoriasis
|
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
|
EP2322201A3
(en)
|
2002-10-29 |
2011-07-27 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
WO2004042017A2
(en)
*
|
2002-10-31 |
2004-05-21 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
|
JP2006516094A
(ja)
|
2002-11-08 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
ナチュラルキラー細胞関連疾患の治療のための組成物と方法
|
|
WO2004047728A2
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
AU2003237792A1
(en)
|
2003-04-01 |
2004-11-23 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
HUE030579T2
(en)
|
2003-04-04 |
2017-05-29 |
Genentech Inc |
High Concentration Antibody And Protein Products
|
|
WO2004091657A2
(en)
|
2003-04-09 |
2004-10-28 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
PL2298347T3
(pl)
*
|
2003-05-06 |
2016-03-31 |
Bioverativ Therapeutics Inc |
Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
|
|
AU2004238263A1
(en)
*
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
|
WO2005000896A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
EP2395017A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
RS20160203A1
(sr)
|
2003-05-30 |
2016-10-31 |
Genentech Inc |
Tretman sa anti-vegf antitelima
|
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
|
PT1631313E
(pt)
|
2003-06-05 |
2015-07-02 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
|
WO2004108159A2
(en)
*
|
2003-06-05 |
2004-12-16 |
The University Of Iowa Research Foundation |
Gb virus c (hepatitis g virus) for the treatment of hiv
|
|
DK1636593T5
(da)
|
2003-06-06 |
2009-07-27 |
Genentech Inc |
Modulering af vekselvirkningen mellem HGF-beta-kæde og c-met
|
|
WO2005042582A1
(ja)
*
|
2003-11-04 |
2005-05-12 |
Chugai Seiyaku Kabushiki Kaisha |
抗体の製造方法
|
|
JP4794301B2
(ja)
|
2003-06-11 |
2011-10-19 |
中外製薬株式会社 |
抗体の製造方法
|
|
CA2530388A1
(en)
*
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Modified binding molecules comprising connecting peptides
|
|
ES2751414T5
(es)
|
2003-07-08 |
2024-04-23 |
Novartis Pharma Ag |
Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F
|
|
AU2004261941B2
(en)
|
2003-07-25 |
2008-04-10 |
Amgen Inc. |
Antagonists and agonists of LDCAM and methods of use
|
|
EP3095793B1
(en)
|
2003-07-28 |
2020-03-25 |
Genentech, Inc. |
Reducing protein a leaching during protein a affinity chromatography
|
|
WO2005012531A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody cdr polypeptide sequences with restricted diversity
|
|
US20080153104A1
(en)
|
2003-08-08 |
2008-06-26 |
Hiroyuki Aburantai |
Gene Overexpressed in Cancer
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
WO2005027966A2
(en)
*
|
2003-09-05 |
2005-03-31 |
Genentech, Inc. |
Antibodies with altered effector functions
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
CN1326881C
(zh)
*
|
2003-09-29 |
2007-07-18 |
中国人民解放军军事医学科学院基础医学研究所 |
一种三价双特异性抗体，其制备方法及用途
|
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
|
NZ547558A
(en)
|
2003-11-17 |
2009-06-26 |
Genentech Inc |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
|
EP1692178A1
(en)
|
2003-12-11 |
2006-08-23 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
|
TW200530269A
(en)
*
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Anti-Mpl antibodies
|
|
US7371381B2
(en)
*
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
|
JPWO2005056602A1
(ja)
*
|
2003-12-12 |
2008-03-06 |
中外製薬株式会社 |
アゴニスト活性を有する改変抗体のスクリーニング方法
|
|
WO2005056605A1
(ja)
*
|
2003-12-12 |
2005-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
３量体以上の受容体を認識する改変抗体
|
|
MXPA06006985A
(es)
*
|
2003-12-19 |
2006-08-31 |
Genentech Inc |
Fragmentos de anticuerpo monovalente utiles como terapueticos.
|
|
EP1697520A2
(en)
*
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
|
MXPA06007856A
(es)
|
2004-01-07 |
2007-03-23 |
Chiron Corp |
Anticuerpo monoclonal especifico de factor de estimulacion de colonias de macrofagos (m-csf) y usos del mismo.
|
|
JP5912211B2
(ja)
|
2004-01-20 |
2016-04-27 |
メルス ビー．ヴィー． |
結合タンパク質の混合物
|
|
AU2005214382B2
(en)
|
2004-02-19 |
2011-08-04 |
Genentech, Inc. |
CDR-repaired antibodies
|
|
US7381794B2
(en)
*
|
2004-03-08 |
2008-06-03 |
Zymogenetics, Inc. |
Dimeric fusion proteins and materials and methods for producing them
|
|
EP2053062A1
(en)
*
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
|
ZA200608130B
(en)
|
2004-03-31 |
2008-12-31 |
Genentech Inc |
Humanized anti-TGF-beta antibodies
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
US20050276803A1
(en)
*
|
2004-04-16 |
2005-12-15 |
Genentech, Inc. |
Method for augmenting B cell depletion
|
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
|
US20060002930A1
(en)
*
|
2004-04-16 |
2006-01-05 |
Genentech, Inc. |
Treatment of disorders
|
|
CA2567520A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Maytansinoid-antibody conjugates
|
|
KR20070029733A
(ko)
|
2004-06-04 |
2007-03-14 |
제넨테크, 인크. |
다발성 경화증의 치료 방법
|
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
EP1771474B1
(en)
|
2004-07-20 |
2010-01-27 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
|
WO2006017673A2
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
|
RU2398777C2
(ru)
*
|
2004-08-05 |
2010-09-10 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
|
|
US7655229B2
(en)
*
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
|
AU2005282700A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
US7662926B2
(en)
*
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
|
ZA200701783B
(en)
*
|
2004-09-02 |
2009-10-28 |
Genentech Inc |
Anti-Fc-gamma RIIB receptor antibody and uses therefor
|
|
PL2322556T3
(pl)
*
|
2004-09-03 |
2016-04-29 |
Genentech Inc |
Humanizowani antagoniści anty-beta7 i ich zastosowania
|
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
NZ596663A
(en)
|
2004-10-21 |
2013-07-26 |
Genentech Inc |
Use of vegf antagonists in intraocular neovascular disease treatment
|
|
CN102746404B
(zh)
*
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
对FcRn的结合被改变的Fc变体
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
|
CA2595169A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
|
WO2006078307A1
(en)
|
2005-01-21 |
2006-07-27 |
Genentech, Inc. |
Fixed dosing of her antibodies
|
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
EP1853718B1
(en)
|
2005-02-15 |
2015-08-05 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
|
WO2006089141A2
(en)
|
2005-02-18 |
2006-08-24 |
Dana-Farber Cancer Institute |
Antibodies against cxcr4 and methods of use thereof
|
|
BRPI0606542A8
(pt)
|
2005-02-23 |
2018-03-20 |
Genentech Inc |
métodos para aumentar o tempo de progressão de uma doença (ttp)
|
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
|
WO2006106903A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2構造異性体
|
|
CA2603408C
(en)
*
|
2005-03-31 |
2018-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
|
EP2221316A1
(en)
|
2005-05-05 |
2010-08-25 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
|
PL1879573T3
(pl)
|
2005-05-10 |
2013-05-31 |
Incyte Holdings Corp |
Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
|
|
EP1899364B2
(en)
|
2005-05-17 |
2024-10-30 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
AU2006255686A1
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
|
JP5085322B2
(ja)
|
2005-06-10 |
2012-11-28 |
中外製薬株式会社 |
ｓｃ（Ｆｖ）２を含有する医薬組成物
|
|
US20090028854A1
(en)
*
|
2005-06-10 |
2009-01-29 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 SITE-DIRECTED MUTANT
|
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
|
EP2452694B1
(en)
|
2005-06-30 |
2018-11-14 |
Janssen Biotech, Inc. |
Anti-IL-23 antibodies, compositions, methods and uses
|
|
JP5171621B2
(ja)
|
2005-07-07 |
2013-03-27 |
シアトル ジェネティックス， インコーポレイテッド |
フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
|
|
WO2007008848A2
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
|
SG10201508322SA
(en)
|
2005-07-08 |
2015-11-27 |
Biogen Ma Inc |
Sp35 antibodies and uses thereof
|
|
WO2007016285A2
(en)
|
2005-07-28 |
2007-02-08 |
Novartis Ag |
M-csf specific monoclonal antibody and uses thereof
|
|
CA2618765A1
(en)
|
2005-08-09 |
2007-02-15 |
Zymogenetics, Inc. |
Methods for treating b-cell malignancies using taci-ig fusion molecule
|
|
US8808696B2
(en)
|
2005-08-09 |
2014-08-19 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
|
JP2009504183A
(ja)
|
2005-08-15 |
2009-02-05 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
|
US20090220564A1
(en)
*
|
2005-08-19 |
2009-09-03 |
Baumbach William R |
Methods of treating and preventing acute myocardial infarction
|
|
EP1934867A2
(en)
|
2005-08-31 |
2008-06-25 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
|
AU2006299429B2
(en)
*
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
|
US7422899B2
(en)
*
|
2005-10-05 |
2008-09-09 |
Biogen Idec Ma Inc. |
Antibodies to the human prolactin receptor
|
|
JP4860703B2
(ja)
*
|
2005-10-06 |
2012-01-25 |
ゼンコー・インコーポレイテッド |
最適化された抗ｃｄ３０抗体
|
|
TW200732350A
(en)
*
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
|
DK2500360T3
(da)
|
2005-10-31 |
2015-10-26 |
Oncomed Pharm Inc |
Sammensætninger og fremgangsmåder til diagnosticering og behandling af cancer
|
|
WO2007056441A2
(en)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
|
BRPI0618488A2
(pt)
*
|
2005-11-10 |
2011-08-30 |
Receptor Biologix Inc |
proteìnas de fusão de ìntron de fator de crescimento de hepatócito
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
PL1948798T3
(pl)
|
2005-11-18 |
2015-12-31 |
Glenmark Pharmaceuticals Sa |
Przeciwciała przeciwko integrynie alfa2 i ich zastosowania
|
|
US20090293137A1
(en)
|
2005-11-21 |
2009-11-26 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
|
CA2631327C
(en)
*
|
2005-12-02 |
2015-10-13 |
Genentech, Inc. |
Her2 binding polypeptides and uses thereof
|
|
WO2007064919A2
(en)
*
|
2005-12-02 |
2007-06-07 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
|
CA2631961A1
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22
|
|
US20070136826A1
(en)
*
|
2005-12-02 |
2007-06-14 |
Biogen Idec Inc. |
Anti-mouse CD20 antibodies and uses thereof
|
|
JP5358187B2
(ja)
|
2005-12-15 |
2013-12-04 |
ジェネンテック， インコーポレイテッド |
ポリユビキチンを標的とする方法と組成物
|
|
JP5193881B2
(ja)
|
2005-12-29 |
2013-05-08 |
セントカー・インコーポレーテツド |
ヒト抗ｉｌ−２３抗体、組成物、方法および用途
|
|
JP5580535B2
(ja)
|
2006-01-05 |
2014-08-27 |
ノバルティス アーゲー |
癌転移および癌転移に関連する骨量減少を予防および処置するための方法
|
|
EP2463305B1
(en)
|
2006-01-12 |
2016-05-11 |
Alexion Pharmaceuticals, Inc. |
Antibodies to OX-2/CD200 and uses thereof
|
|
CA2642419A1
(en)
|
2006-02-06 |
2007-08-16 |
Rhode Island Hospital |
Gpr30 estrogen receptor in breast cancers
|
|
ZA200807714B
(en)
|
2006-02-17 |
2010-01-27 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
|
EP1999253B1
(en)
*
|
2006-03-02 |
2019-05-22 |
Viacyte, Inc. |
Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
|
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
CA2646478A1
(en)
|
2006-03-10 |
2007-09-20 |
Zymogenetics, Inc. |
Antibodies that bind both il-17a and il-17f and methods of using the same
|
|
EP2010569A4
(en)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
FOR GASTRIN SPECIFIC HUMAN ANTIBODIES, MATERIALS AND METHODS
|
|
US8940871B2
(en)
*
|
2006-03-20 |
2015-01-27 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
|
|
KR20080110810A
(ko)
|
2006-03-23 |
2008-12-19 |
노파르티스 아게 |
항-종양 세포 항원 항체 치료제
|
|
HUE067285T2
(hu)
|
2006-03-24 |
2024-10-28 |
Bioverativ Therapeutics Inc |
PC5 mint IX-es faktor propeptidet feldolgozó enzim
|
|
AU2007229698B9
(en)
*
|
2006-03-24 |
2012-11-08 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
JP5624276B2
(ja)
|
2006-03-31 |
2014-11-12 |
中外製薬株式会社 |
抗体の血中動態を制御する方法
|
|
CN105177091A
(zh)
|
2006-03-31 |
2015-12-23 |
中外制药株式会社 |
用于纯化双特异性抗体的抗体修饰方法
|
|
WO2007123791A2
(en)
|
2006-03-31 |
2007-11-01 |
Dana-Farber Cancer Institute |
Methods of determining cellular chemosensitivity
|
|
AU2007297565A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
MX2008014365A
(es)
|
2006-05-15 |
2008-11-27 |
Ares Trading Sa |
Metodos para tratar enfermedades autoinmunitarias utilizando una molecula de fusion del activador de transmembrana-inmunoglobulina.
|
|
PL2446904T3
(pl)
|
2006-05-30 |
2015-10-30 |
Genentech Inc |
Przeciwciała anty-CD22, ich immunokoniugaty oraz ich zastosowania
|
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
|
US20100055093A1
(en)
*
|
2006-06-12 |
2010-03-04 |
Receptor Biologix Inc. |
Pan-cell surface receptor-specific therapeutics
|
|
US20080305111A1
(en)
*
|
2006-06-22 |
2008-12-11 |
Vaccinex, Inc. |
Anti-C35 antibodies for treating cancer
|
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
|
JP2009543579A
(ja)
|
2006-07-19 |
2009-12-10 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
|
|
KR101437188B1
(ko)
|
2006-08-04 |
2014-10-02 |
노바르티스 아게 |
Ｅｐｈｂ3-특이적 항체 및 이의 용도
|
|
WO2008021290A2
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
|
EP2059536B1
(en)
|
2006-08-14 |
2014-01-08 |
Xencor, Inc. |
Optimized antibodies that target cd19
|
|
KR101368596B1
(ko)
|
2006-08-18 |
2014-03-17 |
조마 테크놀로지 리미티드 |
Ｐｒｌｒ 특이적 항체 및 그 용도
|
|
CN101506237B
(zh)
|
2006-08-22 |
2014-05-07 |
G2炎症私人有限公司 |
具有改进性能的抗-C5aR抗体
|
|
US20100292090A1
(en)
|
2006-08-25 |
2010-11-18 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
US8394374B2
(en)
|
2006-09-18 |
2013-03-12 |
Xencor, Inc. |
Optimized antibodies that target HM1.24
|
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
|
SI2066694T1
(sl)
*
|
2006-09-29 |
2016-02-29 |
Oncomed Pharmaceuticals, Inc. |
Sestavki in postopki za diagnosticiranje in zdravljenje raka
|
|
PE20080980A1
(es)
*
|
2006-10-12 |
2008-09-02 |
Genentech Inc |
Anticuerpos anti-linfotoxina alfa
|
|
GB0620705D0
(en)
|
2006-10-18 |
2006-11-29 |
Opsona Therapeutics |
Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
|
|
ES2524059T3
(es)
|
2006-10-27 |
2014-12-03 |
Lpath, Inc. |
Composiciones y procedimientos de unión a esfingosina-1-fosfato
|
|
KR20140116546A
(ko)
|
2006-10-27 |
2014-10-02 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
|
US8614103B2
(en)
|
2006-10-27 |
2013-12-24 |
Lpath, Inc. |
Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
|
|
MX2009004757A
(es)
|
2006-11-14 |
2009-05-21 |
Genentech Inc |
Moduladores de regeneracion neuronal.
|
|
US8444971B2
(en)
|
2006-11-27 |
2013-05-21 |
Diadexus, Inc. |
OVR110 antibody compositions and methods of use
|
|
EP2120998B1
(en)
|
2006-11-28 |
2013-08-07 |
HanAll Biopharma Co., Ltd. |
Modified erythropoietin polypeptides and uses thereof for treatment
|
|
BRPI0720437A2
(pt)
|
2006-12-07 |
2014-01-07 |
Novartis Ag |
Anticorpos antafonísticos contra ephb3
|
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
|
WO2008079280A1
(en)
|
2006-12-21 |
2008-07-03 |
Millipore Corporation |
Purification of proteins
|
|
AR064464A1
(es)
*
|
2006-12-22 |
2009-04-01 |
Genentech Inc |
Anticuerpos anti - receptor del factor de crecimiento insulinico
|
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
|
WO2008083228A2
(en)
*
|
2006-12-27 |
2008-07-10 |
The Johns Hopkins University |
Compositions and methods for treating inflammation and auto-immune diseases
|
|
EP2740744B1
(en)
|
2007-01-09 |
2018-03-28 |
Biogen MA Inc. |
Sp35 antibodies and uses thereof
|
|
WO2008092002A2
(en)
*
|
2007-01-24 |
2008-07-31 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
|
EP2125896A2
(en)
|
2007-02-09 |
2009-12-02 |
Genetech, Inc. |
Anti-robo4 antibodies and uses therefor
|
|
US7919594B2
(en)
|
2007-02-14 |
2011-04-05 |
Vaccinex, Inc. |
Human anti-CD100 antibodies
|
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
|
DK2436781T3
(da)
|
2007-02-22 |
2016-01-11 |
Genentech Inc |
Fremgangsmåder til detektering af inflammatorisk tarmsygdom
|
|
ES2477497T3
(es)
|
2007-03-02 |
2014-07-17 |
Genentech, Inc. |
Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
|
|
EP1972639A3
(en)
|
2007-03-07 |
2008-12-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
|
US20090068684A1
(en)
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
|
CA2681974C
(en)
|
2007-03-29 |
2019-12-31 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
KR101626988B1
(ko)
*
|
2007-04-03 |
2016-06-02 |
암젠 리서치 (뮌헨) 게엠베하 |
종간 특이적 이중특이적인 결합제들
|
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
EP1983002A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
|
EP2392597B1
(en)
|
2007-04-27 |
2014-04-02 |
ZymoGenetics, Inc. |
Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
|
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
|
JP5575636B2
(ja)
|
2007-05-07 |
2014-08-20 |
メディミューン，エルエルシー |
抗ｉｃｏｓ抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
|
|
US20090252729A1
(en)
*
|
2007-05-14 |
2009-10-08 |
Farrington Graham K |
Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
|
|
CA2724432A1
(en)
|
2007-05-30 |
2008-12-11 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
|
EP2592156B1
(en)
|
2007-06-08 |
2016-04-20 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
|
CN101849001B
(zh)
*
|
2007-06-25 |
2014-07-16 |
艾斯巴技术-诺华有限责任公司 |
修饰抗体的方法和具有改善的功能性质的修饰抗体
|
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
|
DK2173379T3
(da)
|
2007-07-02 |
2015-12-07 |
Oncomed Pharm Inc |
Sammensætninger og fremgangsmåder til behandling og diagnosticering af cancer
|
|
KR20100061442A
(ko)
|
2007-07-09 |
2010-06-07 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
|
JP2010533495A
(ja)
|
2007-07-16 |
2010-10-28 |
ジェネンテック， インコーポレイテッド |
ヒト化ＣＤ７９ｂ抗体およびイムノコンジュゲートならびにそれらの使用
|
|
TWI439286B
(zh)
|
2007-07-16 |
2014-06-01 |
Genentech Inc |
抗－ｃｄ７９ｂ抗體及免疫共軛物及使用方法
|
|
EP2185593B1
(en)
|
2007-07-25 |
2017-12-13 |
Alexion Pharmaceuticals, Inc. |
Compositions for treating autoimmune disease
|
|
CA2694488A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
PT2182981E
(pt)
|
2007-08-02 |
2013-04-18 |
Gilead Biologics Inc |
Métodos e composições para tratamento e diagnóstico de fibrose
|
|
CA2695237A1
(en)
|
2007-08-02 |
2009-04-30 |
Novimmune S.A. |
Anti-rantes antibodies and methods of use thereof
|
|
DK2190987T3
(da)
*
|
2007-08-21 |
2013-02-18 |
Morphosys Ag |
Fremgangsmåder til dannelse af disulfidbindinger
|
|
CA2698343C
(en)
*
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
|
MY163473A
(en)
|
2007-09-26 |
2017-09-15 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
|
HUE029635T2
(en)
|
2007-09-26 |
2017-03-28 |
Chugai Pharmaceutical Co Ltd |
A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
|
|
ES2565202T3
(es)
|
2007-10-16 |
2016-04-01 |
Zymogenetics, Inc. |
Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
|
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
|
SI2514436T1
(en)
|
2007-11-07 |
2018-04-30 |
Genentech, Inc. |
IL-22 for use in the treatment of microbial diseases
|
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
EP2062920A3
(en)
|
2007-11-21 |
2009-06-17 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
|
|
AU2008329529B2
(en)
|
2007-11-27 |
2015-02-19 |
The University Of British Columbia |
14-3-3 eta antibodies and uses thereof for the diagnosis and treatment of arthritis
|
|
JP5490714B2
(ja)
*
|
2007-11-28 |
2014-05-14 |
メディミューン，エルエルシー |
タンパク質製剤
|
|
JP2011509071A
(ja)
|
2007-11-29 |
2011-03-24 |
ジェネンテック， インコーポレイテッド |
炎症性腸疾患のための遺伝子発現マーカー
|
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
|
US20110129459A1
(en)
|
2007-12-05 |
2011-06-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-nr10 antibody and use thereof
|
|
US8242247B2
(en)
*
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
EP2235058A2
(en)
|
2007-12-21 |
2010-10-06 |
Amgen, Inc |
Anti-amyloid antibodies and uses thereof
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
CA3147069A1
(en)
|
2007-12-26 |
2009-07-09 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
|
US8637026B2
(en)
|
2007-12-26 |
2014-01-28 |
Vaccinex, Inc. |
Anti-C35 antibody combination therapies and methods
|
|
ES2539026T3
(es)
|
2007-12-27 |
2015-06-25 |
Abbott Laboratories |
Anticuerpos anti-T. cruzi y métodos de uso
|
|
MX350962B
(es)
|
2008-01-07 |
2017-09-27 |
Amgen Inc |
Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
|
|
HUE050958T2
(hu)
|
2008-01-15 |
2021-01-28 |
Univ Leland Stanford Junior |
Akut mieloid leukémia õssejtek markerei
|
|
EP2080770A1
(en)
*
|
2008-01-21 |
2009-07-22 |
MorphoSys AG |
Proteinaceous binding molecules comprising purification tags
|
|
CA2711826C
(en)
|
2008-01-25 |
2018-02-27 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
EP4427805A2
(en)
|
2008-01-31 |
2024-09-11 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
NZ617520A
(en)
|
2008-02-25 |
2015-05-29 |
Nestec Sa |
Drug selection for breast cancer therapy using antibody-based arrays
|
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
|
CN102014913A
(zh)
*
|
2008-03-06 |
2011-04-13 |
健泰科生物技术公司 |
C-met和egfr拮抗剂的联合疗法
|
|
EP2260056A1
(en)
*
|
2008-03-06 |
2010-12-15 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
|
US7982012B2
(en)
|
2008-03-10 |
2011-07-19 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
|
WO2009124090A1
(en)
*
|
2008-03-31 |
2009-10-08 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing asthma
|
|
AU2009233708B2
(en)
|
2008-04-09 |
2015-06-04 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
|
WO2009126306A2
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
|
TW202423982A
(zh)
|
2008-04-11 |
2024-06-16 |
日商中外製藥股份有限公司 |
重複結合複數個抗原的抗原結合分子
|
|
EP2816059A1
(en)
|
2008-05-01 |
2014-12-24 |
Amgen, Inc |
Anti-hepcidin antibodies and methods of use
|
|
ES2533480T3
(es)
*
|
2008-05-16 |
2015-04-10 |
F. Hoffmann-La Roche Ag |
Uso de biomarcadores para evaluar el tratamiento de trastornos inflamatorios gastrointestinales con antagonistas de la integrina beta7
|
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
|
EP2671891A3
(en)
|
2008-06-27 |
2014-03-05 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
MX2011000233A
(es)
|
2008-07-08 |
2011-05-19 |
Oncomed Pharm Inc |
Agentes de union del receptor notch1 y metodos para su uso.
|
|
US8834875B2
(en)
|
2010-01-13 |
2014-09-16 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
|
EP2824100B1
(en)
|
2008-07-08 |
2018-02-21 |
Incyte Holdings Corporation |
1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
|
|
EP2315779A2
(en)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
|
US20100069616A1
(en)
*
|
2008-08-06 |
2010-03-18 |
The Regents Of The University Of California |
Engineered antibody-nanoparticle conjugates
|
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
|
NZ591130A
(en)
|
2008-08-25 |
2012-09-28 |
Amplimmune Inc |
Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
|
|
EP4071169A2
(en)
|
2008-08-25 |
2022-10-12 |
Dana Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
|
EP2328919A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
|
EP2344536A1
(en)
|
2008-09-19 |
2011-07-20 |
MedImmune, LLC |
Antibodies directed to dll4 and uses thereof
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
WO2010039832A1
(en)
|
2008-10-01 |
2010-04-08 |
Genentech, Inc. |
Anti-notch2 antibodies and methods of use
|
|
US9493564B2
(en)
|
2008-10-02 |
2016-11-15 |
Aptevo Research And Development Llc |
CD86 antagonist multi-target binding proteins
|
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
|
US20110217302A1
(en)
*
|
2008-10-10 |
2011-09-08 |
Emergent Product Development Seattle, Llc |
TCR Complex Immunotherapeutics
|
|
PE20110707A1
(es)
|
2008-10-14 |
2011-10-11 |
Genentech Inc |
Variantes de inmunoglobulinas
|
|
CN104689316A
(zh)
|
2008-10-22 |
2015-06-10 |
弗·哈夫曼-拉罗切有限公司 |
轴突变性的调节
|
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
|
AU2009314311B2
(en)
|
2008-10-29 |
2013-01-10 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
|
RU2481824C2
(ru)
|
2008-10-29 |
2013-05-20 |
Аблинкс Н.В |
Препараты однодоменных антигенсвязывающих молекул
|
|
NZ592436A
(en)
|
2008-11-06 |
2012-10-26 |
Glenmark Pharmaceuticals Sa |
Treatment with anti-alpha2 integrin antibodies
|
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
|
LT2894165T
(lt)
|
2008-11-10 |
2023-03-10 |
Alexion Pharmaceuticals, Inc. |
Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
|
|
BRPI0921150B1
(pt)
|
2008-11-11 |
2022-05-10 |
The Regents Of The University Of Michigan |
Uso de um antagonista de cxcr1 para o tratamento de tumor
|
|
CA2743469C
(en)
|
2008-11-12 |
2019-01-15 |
Medimmune, Llc |
Antibody formulation
|
|
PL2365987T3
(pl)
|
2008-11-25 |
2015-04-30 |
Genentech Inc |
Przeciwciała anty-HER4 swoiste dla określonej izoformy
|
|
US8211434B2
(en)
|
2008-11-26 |
2012-07-03 |
Allergan, Inc. |
KLK-13 antibody inhibitor for treating dry eye
|
|
JP2012511026A
(ja)
*
|
2008-12-05 |
2012-05-17 |
エルパス・インコーポレイテッド |
抗脂抗体結晶構造を用いた抗体設計
|
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
|
KR20180089573A
(ko)
|
2008-12-09 |
2018-08-08 |
제넨테크, 인크. |
항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
|
|
EP2370561B1
(en)
|
2008-12-16 |
2019-08-07 |
EMD Millipore Corporation |
Stirred tank reactor and method
|
|
EP2358734A1
(en)
|
2008-12-16 |
2011-08-24 |
Millipore Corporation |
Purification of proteins
|
|
AU2009335788A1
(en)
|
2008-12-17 |
2011-07-07 |
Genentech, Inc. |
Hepatitis C virus combination therapy
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
CA2748158A1
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
|
|
JP6039183B2
(ja)
|
2008-12-23 |
2016-12-07 |
ジェネンテック， インコーポレイテッド |
プロテインａに対する結合が変化した免疫グロブリン変異体
|
|
WO2010078526A1
(en)
|
2008-12-31 |
2010-07-08 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
|
ES2712732T3
(es)
|
2009-02-17 |
2019-05-14 |
Cornell Res Foundation Inc |
Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
|
|
WO2010096394A2
(en)
*
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP2826789A1
(en)
|
2009-03-19 |
2015-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
WO2010108154A2
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Selective and potent peptide inhibitors of kv1.3
|
|
SG174344A1
(en)
|
2009-03-20 |
2011-11-28 |
Amgen Inc |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
|
EP2411411B1
(en)
|
2009-03-25 |
2016-08-31 |
F.Hoffmann-La Roche Ag |
Novel anti-alpha5beta1 antibodies and uses thereof
|
|
TWI474833B
(zh)
|
2009-04-01 |
2015-03-01 |
Genentech Inc |
胰島素阻抗性疾病之治療
|
|
RU2587621C2
(ru)
|
2009-04-01 |
2016-06-20 |
Дженентек, Инк. |
АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
WO2010112194A1
(en)
|
2009-04-02 |
2010-10-07 |
F. Hoffmann-La Roche Ag |
Antigen-binding polypeptides and multispecific antibodies comprising them
|
|
MX2011010159A
(es)
|
2009-04-02 |
2011-10-17 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla.
|
|
PT2417156E
(pt)
*
|
2009-04-07 |
2015-04-29 |
Roche Glycart Ag |
Anticorpos trivalentes, biespecíficos
|
|
AU2010233994A1
(en)
|
2009-04-07 |
2011-09-22 |
Roche Glycart Ag |
Bispecific anti-ErbB-3/anti-c-Met antibodies
|
|
MX2011010169A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-1/anti-c-met.
|
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
|
EP2419446A4
(en)
|
2009-04-17 |
2013-01-23 |
Lpath Inc |
HUMANIZED ANTIBODY COMPOSITIONS AND METHOD FOR BINDING LYSOPHOSPHACIDIC ACID
|
|
SG175305A1
(en)
*
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
|
US9067986B2
(en)
|
2009-04-27 |
2015-06-30 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
KR101811886B1
(ko)
|
2009-05-05 |
2017-12-22 |
노비뮨 에스 에이 |
항―ｉｌ―17ｆ 항체 및 이의 사용 방법
|
|
NZ596136A
(en)
|
2009-05-08 |
2013-12-20 |
Vaccinex Inc |
Anti-cd100 antibodies and methods for using the same
|
|
AU2010249787A1
(en)
|
2009-05-20 |
2011-12-22 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
TW201100543A
(en)
*
|
2009-05-27 |
2011-01-01 |
Hoffmann La Roche |
Tri-or tetraspecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
NZ597259A
(en)
|
2009-06-23 |
2014-04-30 |
Alexion Pharma Inc |
Bispecific antibodies that bind to complement proteins
|
|
KR20120027055A
(ko)
|
2009-06-26 |
2012-03-20 |
리제네론 파라마큐티칼스 인코포레이티드 |
천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
|
|
AU2010268690B2
(en)
|
2009-07-03 |
2011-11-10 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
|
WO2011005715A1
(en)
|
2009-07-07 |
2011-01-13 |
Genentech, Inc. |
Diagnosis and treatment of autoimmune demyelinating diseases
|
|
CA2768013C
(en)
|
2009-07-15 |
2018-08-21 |
Prometheus Laboratories Inc. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
|
JP2012533322A
(ja)
|
2009-07-20 |
2012-12-27 |
ジェネンテック， インコーポレイテッド |
クローン病のための遺伝子発現マーカー
|
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
|
BR112012002083A2
(pt)
|
2009-07-31 |
2016-11-08 |
Genentech Inc |
inibição de metaste tumoral
|
|
JP2013500987A
(ja)
|
2009-07-31 |
2013-01-10 |
アムジェン インコーポレイテッド |
３型メタロプロテイナーゼ組織阻害剤（ｔｉｍｐ−３）に結合するポリペプチド、組成物および方法
|
|
KR20180035936A
(ko)
|
2009-08-06 |
2018-04-06 |
제넨테크, 인크. |
단백질 정제 시의 바이러스 제거의 개선방법
|
|
US20110039300A1
(en)
|
2009-08-10 |
2011-02-17 |
Robert Bayer |
Antibodies with enhanced adcc functions
|
|
BR112012002974B1
(pt)
|
2009-08-11 |
2022-06-07 |
Genentech, Inc |
Processo para produzir um anticorpo em uma célula hospedeira de célula ovário de hamster chinês (cho) expressando o referido polipeptídeo
|
|
US20110038871A1
(en)
|
2009-08-11 |
2011-02-17 |
Veena Viswanth |
Ccr2 inhibitors for treating conditions of the eye
|
|
EP2464664B1
(en)
|
2009-08-13 |
2015-09-23 |
Crucell Holland B.V. |
Antibodies against human respiratory syncytial virus (rsv) and methods of use
|
|
US20110053223A1
(en)
|
2009-08-14 |
2011-03-03 |
Robert Bayer |
Cell culture methods to make antibodies with enhanced adcc function
|
|
EP2473521A2
(en)
|
2009-08-31 |
2012-07-11 |
Amplimmune, Inc. |
B7-h4 fusion proteins and methods of use thereof
|
|
JP5787891B2
(ja)
|
2009-09-01 |
2015-09-30 |
ジェネンテック， インコーポレイテッド |
改変されたプロテインａ溶離による向上したタンパク質精製
|
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
SG179196A1
(en)
*
|
2009-09-16 |
2012-04-27 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
|
BR112012005670A2
(pt)
|
2009-09-17 |
2017-01-10 |
Hoffmann La Roche |
''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
|
US9005926B2
(en)
|
2009-10-02 |
2015-04-14 |
Biogen Idec Ma Inc. |
Methods of preventing and removing trisulfide bonds
|
|
WO2011044368A1
(en)
|
2009-10-07 |
2011-04-14 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
|
JP6016636B2
(ja)
|
2009-10-15 |
2016-10-26 |
ジェネンテック， インコーポレイテッド |
改変したレセプター特異性を持つキメラ線維芽細胞増殖因子
|
|
EP2488204B1
(en)
|
2009-10-16 |
2016-04-06 |
Oncomed Pharmaceuticals, Inc. |
Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
|
|
CA2771817A1
(en)
|
2009-10-19 |
2011-04-28 |
Genentech, Inc. |
Modulators of hepatocyte growth factor activator
|
|
KR20120110168A
(ko)
|
2009-10-20 |
2012-10-09 |
프로메테우스 레버러터리스 인코포레이티드 |
종양원성 융합 단백질을 검출하기 위한 근접-매개 검정법
|
|
CA2778442A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
|
JP2013508401A
(ja)
|
2009-10-22 |
2013-03-07 |
ジェネンテック， インコーポレイテッド |
軸索変性の調節
|
|
TW201120210A
(en)
|
2009-11-05 |
2011-06-16 |
Hoffmann La Roche |
Glycosylated repeat-motif-molecule conjugates
|
|
MX2012005864A
(es)
|
2009-11-20 |
2012-08-31 |
Amgen Inc |
Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
|
|
AU2010321720B2
(en)
|
2009-11-23 |
2017-03-02 |
Amgen Inc. |
Monomeric antibody Fc
|
|
KR101740171B1
(ko)
|
2009-11-24 |
2017-05-25 |
메디뮨 리미티드 |
Ｂ７―ｈ１에 대한 표적화된 결합 물질
|
|
MX338694B
(es)
|
2009-11-30 |
2016-04-27 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
|
RU2673908C2
(ru)
|
2009-12-02 |
2018-12-03 |
Имэджинэб, Инк. |
Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения
|
|
EP2507381A4
(en)
|
2009-12-04 |
2016-07-20 |
Hoffmann La Roche |
PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS
|
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗－ｖｅｇｆ－ｃ抗體及其使用方法
|
|
RU2017102553A
(ru)
|
2009-12-21 |
2018-12-19 |
Дженентек, Инк. |
Состав, содержащий антитело
|
|
ES2585350T3
(es)
|
2009-12-23 |
2016-10-05 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti Bv8 y usos de los mismos
|
|
WO2011075786A1
(en)
|
2009-12-23 |
2011-06-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them 2
|
|
WO2011080796A1
(en)
|
2009-12-28 |
2011-07-07 |
Oncotherapy Science, Inc. |
Anti-cdh3 antibodies and uses thereof
|
|
JP5851419B2
(ja)
*
|
2009-12-29 |
2016-02-03 |
エマージェント プロダクト デベロップメント シアトル， エルエルシー |
ヘテロダイマー結合タンパク質およびその使用
|
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
BR112012019887B1
(pt)
|
2010-02-08 |
2021-06-08 |
Regeneron Pharmaceuticals, Inc |
método para fabricação de anticorpo e método para selecionar uma sequência de ácido nucleico da região variável da cadeia pesada humana para produzir um anticorpo
|
|
WO2011100403A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
|
CN102844442B
(zh)
|
2010-02-12 |
2016-09-07 |
昂考梅德药品有限公司 |
用于鉴定和分离表达多肽的细胞的方法
|
|
PL2536748T3
(pl)
|
2010-02-18 |
2015-01-30 |
Genentech Inc |
Antagoniści neureguliny i ich zastosowanie w leczeniu nowotworu
|
|
EP2539370B1
(en)
|
2010-02-23 |
2019-05-15 |
Sanofi |
Anti-alpha2 integrin antibodies and their uses
|
|
TWI429453B
(zh)
|
2010-02-23 |
2014-03-11 |
Genentech Inc |
抗tat419抗體及其用途
|
|
IL303569A
(en)
|
2010-02-24 |
2023-08-01 |
Immunogen Inc |
Folate receptor 1 antibodies and immunoconjugates and uses thereof
|
|
US20110212088A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Sabbadini Roger A |
Anti-paf antibodies
|
|
EP2542577A1
(en)
*
|
2010-03-01 |
2013-01-09 |
Lostam Biopharmaceuticals Ltd |
Improved therapeutic antibodies against flagellated pseudomonas aeruginosa
|
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
|
PT2542256T
(pt)
|
2010-03-04 |
2019-09-05 |
Macrogenics Inc |
Anticorpos reativos com b7-h3, fragmentos imunologicamente ativos dos mesmos e sua utilização
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
CN106046159B
(zh)
|
2010-03-12 |
2020-06-16 |
德彪发姆国际有限公司 |
Cd37结合分子及其免疫缀合物
|
|
SG184033A1
(en)
|
2010-03-24 |
2012-10-30 |
Genentech Inc |
Anti-lrp6 antibodies
|
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
|
EP3153521B1
(en)
|
2010-03-26 |
2019-09-04 |
Trustees of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
AR080794A1
(es)
|
2010-03-26 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
|
|
SG184195A1
(en)
|
2010-03-30 |
2012-11-29 |
Janssen Biotech Inc |
Humanized il-25 antibodies
|
|
US8481687B2
(en)
|
2010-04-09 |
2013-07-09 |
Aveo Pharmaceuticals, Inc. |
Anti-ErbB3 antibodies
|
|
JP2013528360A
(ja)
|
2010-04-09 |
2013-07-11 |
アムジェン インコーポレイテッド |
Ｂｔｎｌ９タンパク質、核酸および抗体ならびにそれらの使用
|
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
|
DK2560993T3
(da)
|
2010-04-20 |
2024-10-14 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
JP2019048814A
(ja)
*
|
2010-04-20 |
2019-03-28 |
ゲンマブ エー／エス |
ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
|
|
AU2013203221B2
(en)
*
|
2010-04-20 |
2016-06-02 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
|
CA2796633C
(en)
*
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
PL2563813T3
(pl)
|
2010-04-30 |
2016-01-29 |
Alexion Pharma Inc |
Przeciwciała anty-C5a i sposoby stosowania przeciwciał
|
|
WO2011135040A1
(en)
|
2010-04-30 |
2011-11-03 |
F. Hoffmann-La Roche Ag |
Fluorescent antibody fusion protein, its production and use
|
|
CN107090045A
(zh)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
|
JP2013525484A
(ja)
|
2010-05-03 |
2013-06-20 |
ジェネンテック， インコーポレイテッド |
タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
|
|
SG185415A1
(en)
|
2010-05-06 |
2012-12-28 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
KR20130066632A
(ko)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
치료적 저밀도 지단백질-관련 단백질 ６ （ｌｒｐ６） 항체에 대한 조성물 및 사용 방법
|
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
|
BR112012028977B1
(pt)
|
2010-05-17 |
2020-05-05 |
Emd Millipore Corp |
método de purificação de biomolécula por meio de polímeros estímulo-responsivos
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
AU2011258254B2
(en)
|
2010-05-25 |
2016-01-07 |
Genentech, Inc. |
Methods of purifying polypeptides
|
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
CA2800728C
(en)
|
2010-05-28 |
2020-10-27 |
Genentech, Inc. |
Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
|
|
WO2011153346A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
|
CN103080136B
(zh)
|
2010-06-18 |
2015-08-12 |
霍夫曼-拉罗奇有限公司 |
抗Axl抗体及使用方法
|
|
NZ603581A
(en)
|
2010-06-19 |
2015-05-29 |
Sloan Kettering Inst Cancer |
Anti-gd2 antibodies
|
|
CA2803588A1
(en)
|
2010-06-22 |
2011-12-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the c3d fragment of complement component 3
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
|
EP3202415B1
(en)
|
2010-06-30 |
2021-12-08 |
Compugen Ltd. |
Fusion protein comprising a c1orf32 polypeptide and one or more domains of an immunoglobulin heavy chain constant region for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders.
|
|
WO2012012141A1
(en)
|
2010-06-30 |
2012-01-26 |
Amgen Inc. |
Scnn1a/tnfrsf1a fusion proteins in cancer
|
|
CA3062786C
(en)
|
2010-07-09 |
2022-04-19 |
Janssen Vaccines & Prevention B.V. |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
|
KR20130120439A
(ko)
|
2010-07-09 |
2013-11-04 |
제넨테크, 인크. |
항-뉴로필린 항체 및 사용 방법
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
JP2013536175A
(ja)
|
2010-07-16 |
2013-09-19 |
アブリンクス エン．ヴェー． |
修飾された単一ドメイン抗原結合分子及びその使用
|
|
JP2013534307A
(ja)
|
2010-07-19 |
2013-09-02 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
抗癌治療への応答可能性の増大した患者を同定する方法
|
|
MX2013000667A
(es)
|
2010-07-19 |
2013-02-27 |
Hoffmann La Roche |
Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
|
|
JP5972871B2
(ja)
|
2010-07-20 |
2016-08-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗ｉｌ−２３ヘテロ二量体特異的抗体
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
|
JP2013541937A
(ja)
|
2010-08-05 |
2013-11-21 |
エフ．ホフマン−ラ ロシュ アーゲー |
抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質
|
|
JP2013540701A
(ja)
|
2010-08-12 |
2013-11-07 |
セラクローン サイエンシーズ， インコーポレイテッド |
抗赤血球凝集素抗体組成物およびその使用方法
|
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
|
RS56702B1
(sr)
|
2010-08-13 |
2018-03-30 |
Roche Glycart Ag |
Anti-fap antitela i metode primene
|
|
CA2806640A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
|
WO2012021773A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1beta and il-18, for treatment of disease
|
|
KR20140005864A
(ko)
|
2010-08-16 |
2014-01-15 |
암젠 인코퍼레이티드 |
미오스타틴에 결합하는 항체, 조성물 및 방법
|
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
|
BR112013001847A2
(pt)
*
|
2010-08-24 |
2016-05-31 |
Hoffmann La Roche |
anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
|
|
CA2807269A1
(en)
*
|
2010-08-24 |
2012-03-01 |
Roche Glycart Ag |
Activatable bispecific antibodies
|
|
RU2013110874A
(ru)
|
2010-08-25 |
2014-09-27 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против il-18r1 и их применения
|
|
PE20140190A1
(es)
|
2010-08-27 |
2014-02-10 |
Stem Centrx Inc |
Moduladores de proteinas notum y metodos de uso
|
|
SG187886A1
(en)
|
2010-08-31 |
2013-04-30 |
Genentech Inc |
Biomarkers and methods of treatment
|
|
PL3556396T3
(pl)
|
2010-08-31 |
2022-09-12 |
Theraclone Sciences, Inc. |
Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
|
|
KR101862236B1
(ko)
|
2010-09-02 |
2018-05-29 |
백시넥스 인코포레이티드 |
항-ｃｘｃｌ13 항체 및 이의 이용 방법
|
|
KR20140014064A
(ko)
|
2010-09-03 |
2014-02-05 |
스템 센트알엑스 인코포레이티드 |
신규한 조절 인자 및 사용 방법
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
|
US8993727B2
(en)
|
2010-09-22 |
2015-03-31 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
|
ES2588981T3
(es)
|
2010-10-05 |
2016-11-08 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
|
WO2012061129A1
(en)
|
2010-10-25 |
2012-05-10 |
Genentech, Inc |
Treatment of gastrointestinal inflammation and psoriasis a
|
|
WO2012058592A2
(en)
|
2010-10-29 |
2012-05-03 |
Immunogen, Inc. |
Non-antagonistic egfr-binding molecules and immunoconjugates thereof
|
|
CN103298489A
(zh)
|
2010-10-29 |
2013-09-11 |
伊缪诺金公司 |
新型egfr结合分子及其免疫偶联物
|
|
CA2815266C
(en)
|
2010-11-05 |
2023-09-05 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
SG189475A1
(en)
|
2010-11-05 |
2013-05-31 |
Transbio Ltd |
Markers of endothelial progenitor cells and uses thereof
|
|
CN103328514B
(zh)
|
2010-11-09 |
2015-12-02 |
阿尔蒂单抗治疗公司 |
用于抗原结合的蛋白复合物及其使用方法
|
|
EP2638070B1
(en)
|
2010-11-10 |
2016-10-19 |
F.Hoffmann-La Roche Ag |
Methods and compositions for neural disease immunotherapy
|
|
US9511151B2
(en)
|
2010-11-12 |
2016-12-06 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of cancer
|
|
NO2644698T3
(da)
|
2010-11-17 |
2018-06-02 |
|
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
|
PE20140981A1
(es)
|
2010-11-30 |
2014-08-20 |
Genentech Inc |
Anticuerpo para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
|
|
KR102568454B1
(ko)
|
2010-11-30 |
2023-08-18 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
|
EP4279512A3
(en)
|
2010-11-30 |
2024-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
RU2016123839A
(ru)
|
2010-12-08 |
2018-11-30 |
АббВай Стемсентркс ЭлЭлСи |
Новые модуляторы и способы их применения
|
|
KR101615474B1
(ko)
|
2010-12-16 |
2016-04-25 |
제넨테크, 인크. |
Th2 억제에 관한 진단 및 치료
|
|
NZ610976A
(en)
|
2010-12-20 |
2015-07-31 |
Genentech Inc |
Anti-mesothelin antibodies and immunoconjugates
|
|
CN103261230A
(zh)
|
2010-12-22 |
2013-08-21 |
霍夫曼-拉罗奇有限公司 |
抗pcsk9抗体及使用方法
|
|
JP2014503821A
(ja)
|
2010-12-23 |
2014-02-13 |
ネステク ソシエテ アノニム |
抗体ベースのアレイを用いる悪性がんの療法のための薬剤選択
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
GB2559498B
(en)
|
2011-01-10 |
2018-10-24 |
Univ Michigan Regents |
Stem cell factor inhibitor
|
|
CN103415621A
(zh)
|
2011-01-14 |
2013-11-27 |
雷德伍德生物科技股份有限公司 |
醛标记免疫球蛋白多肽及其使用方法
|
|
CN103649126B
(zh)
|
2011-01-19 |
2016-11-09 |
菲卢马克斯制药公司 |
用于调节铁稳态的组合物及其使用方法
|
|
AU2012212075A1
(en)
|
2011-02-02 |
2013-07-18 |
Amgen Inc. |
Methods and compositons relating to inhibition of IGF-1R
|
|
AR085141A1
(es)
|
2011-02-03 |
2013-09-11 |
Alexion Pharma Inc |
Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
CA2825064C
(en)
|
2011-02-04 |
2022-08-30 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
SG10201604160WA
(en)
|
2011-02-10 |
2016-07-28 |
Roche Glycart Ag |
Mutant Interleukin-2 Polypeptides
|
|
AU2012217867A1
(en)
|
2011-02-14 |
2013-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
RU2013141078A
(ru)
|
2011-02-28 |
2015-04-10 |
Ф. Хоффманн-Ля Рош Аг |
Одновалентные антигенсвязывающие белки
|
|
AR085404A1
(es)
|
2011-02-28 |
2013-09-25 |
Hoffmann La Roche |
Proteinas de union a antigeno
|
|
US9499605B2
(en)
|
2011-03-03 |
2016-11-22 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
|
US20140056897A1
(en)
|
2011-03-10 |
2014-02-27 |
Hco Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
|
US9624294B2
(en)
|
2011-03-14 |
2017-04-18 |
Cellmid Limited |
Antibody recognizing N-domain of midkine
|
|
AU2012229188A1
(en)
|
2011-03-15 |
2013-09-26 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
US20140112926A1
(en)
|
2011-03-16 |
2014-04-24 |
Amgen Inc. |
Fc VARIANTS
|
|
CN103429619B
(zh)
|
2011-03-17 |
2017-07-28 |
雷蒙特亚特特拉维夫大学有限公司 |
双特异性和单特异性、不对称抗体和其制备方法
|
|
CN108285488B
(zh)
|
2011-03-25 |
2023-01-24 |
伊克诺斯科学公司 |
异二聚体免疫球蛋白
|
|
ES2692268T3
(es)
|
2011-03-29 |
2018-12-03 |
Roche Glycart Ag |
Variantes de Fc de anticuerpo
|
|
CN106039306A
(zh)
|
2011-03-30 |
2016-10-26 |
埃博灵克斯股份有限公司 |
使用针对TNFα的单结构域抗体治疗免疫病症的方法
|
|
AU2012233313C1
(en)
|
2011-03-30 |
2017-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for altering plasma retention and immunogenicity of antigen-binding molecule
|
|
BR112013023787A2
(pt)
|
2011-03-31 |
2017-06-13 |
Genentech Inc |
método de tratamento de um distúrbio inflamatório gastrointestinal em um paciente, artigo de manufatura e método para induzir a remissão prolongada em um paciente sofrendo de colite ulcerativa
|
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
WO2012142515A2
(en)
|
2011-04-13 |
2012-10-18 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
KR20140029446A
(ko)
|
2011-04-15 |
2014-03-10 |
컴퓨젠 엘티디. |
면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
|
|
BR112013026306A2
(pt)
|
2011-04-20 |
2017-09-05 |
Roche Glycart Ag |
MÉTODO E CONSTRUTOS PARA A PASSAGEM DE PENDENTE DO pH DA BARREIRA SANGUE-CÉREBRO
|
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
|
EP3103810A3
(en)
|
2011-04-21 |
2017-03-08 |
Garvan Institute of Medical Research |
Modified variable domain molecules and methods for producing and using them
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
CN103608684B
(zh)
|
2011-05-12 |
2016-05-04 |
基因泰克公司 |
利用框架签名肽检测动物样品中的治疗性抗体的多重反应监测lc-ms/ms方法
|
|
EP2707383B1
(en)
|
2011-05-13 |
2018-04-18 |
Biogen MA Inc. |
Methods of preventing and removing trisulfide bonds
|
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
EP2710035B1
(en)
|
2011-05-16 |
2017-04-12 |
F. Hoffmann-La Roche AG |
Fgfr1 agonists and methods of use
|
|
AU2012258637B2
(en)
|
2011-05-24 |
2017-07-20 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
CN108424451B
(zh)
|
2011-06-03 |
2022-09-09 |
佐马技术有限公司 |
对TGF-β具有特异性的抗体
|
|
US9193793B2
(en)
|
2011-06-13 |
2015-11-24 |
Csl Limited |
Antibodies against G-CSFR and uses thereof
|
|
AR086924A1
(es)
|
2011-06-15 |
2014-01-29 |
Hoffmann La Roche |
Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
|
|
WO2013001517A1
(en)
|
2011-06-30 |
2013-01-03 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
|
BR112013032630B1
(pt)
|
2011-06-30 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Polipeptídeo heterodimerizado compreendendo região fc de igg
|
|
SG194932A1
(en)
|
2011-06-30 |
2013-12-30 |
Genentech Inc |
Anti-c-met antibody formulations
|
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
|
|
EP2543680A1
(en)
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
|
CA2841745A1
(en)
|
2011-07-15 |
2013-01-24 |
Oncomed Pharmaceuticals, Inc. |
Rspo binding agents and uses thereof
|
|
KR20140053991A
(ko)
|
2011-07-18 |
2014-05-08 |
아츠 바이올로직스 에이/에스 |
장기간 작용하는 황체 형성 호르몬 (ｌｈ) 화합물
|
|
LT3572517T
(lt)
|
2011-08-05 |
2021-04-26 |
Regeneron Pharmaceuticals, Inc. |
Humanizuotos universalios lengvosios grandinės pelės
|
|
EP2744825A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Inhibition of angiogenesis in refractory tumors
|
|
JP2014526891A
(ja)
|
2011-08-17 |
2014-10-09 |
ジェネンテック， インコーポレイテッド |
ニューレグリン抗体とその使用
|
|
LT2748202T
(lt)
|
2011-08-23 |
2018-09-25 |
Roche Glycart Ag |
Bispecifinės antigeną surišančios molekulės
|
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
|
AU2012298537B2
(en)
|
2011-08-23 |
2017-08-10 |
Roche Glycart Ag |
Bispecific T cell activating antigen binding molecules
|
|
US20130058936A1
(en)
|
2011-08-23 |
2013-03-07 |
Peter Bruenker |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
KR20140048292A
(ko)
|
2011-08-23 |
2014-04-23 |
로슈 글리카트 아게 |
항-mcsp 항체
|
|
WO2013033008A2
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
WO2013033623A1
(en)
|
2011-09-02 |
2013-03-07 |
Nestec S.A. |
Profiling of signal pathway proteins to determine therapeutic efficacy
|
|
WO2013040433A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
MX2014002990A
(es)
|
2011-09-19 |
2014-05-21 |
Genentech Inc |
Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
|
|
CA2845147A1
(en)
|
2011-09-23 |
2013-03-28 |
Roche Glycart Ag |
Bispecific anti-egfr/anti igf-1r antibodies
|
|
DK2758073T3
(da)
|
2011-09-23 |
2019-01-14 |
Oncomed Pharm Inc |
Vegf/dll4-bindende midler og anvendelser deraf
|
|
EP2760889A4
(en)
|
2011-09-30 |
2015-04-15 |
Teva Pharmaceuticals Australia Pty Ltd |
ANTIBODIES AGAINST TL1A AND USES THEREOF
|
|
US9663573B2
(en)
|
2011-10-05 |
2017-05-30 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
RU2654567C2
(ru)
|
2011-10-11 |
2018-05-21 |
Дженентек, Инк. |
Улучшенная сборка биспецифических антител
|
|
AR088322A1
(es)
|
2011-10-14 |
2014-05-28 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso
|
|
BR112014008590A2
(pt)
|
2011-10-15 |
2017-10-24 |
Genentech Inc |
métodos de uso de antagonistas de scd1
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
AU2012328880B2
(en)
|
2011-10-24 |
2017-02-23 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
|
KR102049803B1
(ko)
*
|
2011-10-27 |
2019-11-29 |
젠맵 에이/에스 |
이종이량체 단백질의 생산
|
|
US9265817B2
(en)
|
2011-10-28 |
2016-02-23 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
|
EP2776051A4
(en)
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
|
|
CA2853230C
(en)
|
2011-10-31 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
|
|
LT3257564T
(lt)
|
2011-11-02 |
2019-04-10 |
F. Hoffmann-La Roche Ag |
Perkrovos ir eliuentinė chromatografija
|
|
ES2666856T3
(es)
|
2011-11-04 |
2018-05-08 |
Novartis Ag |
Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
|
|
BR112014010580B1
(pt)
|
2011-11-04 |
2021-01-12 |
Zymeworks, Inc. |
constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
|
|
EP2794010A4
(en)
|
2011-11-21 |
2015-10-21 |
Immunogen Inc |
METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE
|
|
BR112014012005A2
(pt)
|
2011-11-21 |
2017-12-19 |
Genentech Inc |
composições, métodos, formulação farmacêutica e artigo
|
|
WO2013078378A1
(en)
|
2011-11-23 |
2013-05-30 |
Amgen Inc. |
Methods of treatment using an antibody against interferon gamma
|
|
KR20210074395A
(ko)
|
2011-11-30 |
2021-06-21 |
추가이 세이야쿠 가부시키가이샤 |
면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
|
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
|
US9688756B2
(en)
|
2011-12-21 |
2017-06-27 |
Amgen Inc. |
Variant Fc-polypeptides with enhanced binding to the neonatal Fc receptor
|
|
CN113881702A
(zh)
|
2011-12-22 |
2022-01-04 |
弗·哈夫曼-拉罗切有限公司 |
表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
|
JP2015503907A
(ja)
*
|
2011-12-22 |
2015-02-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
真核細胞のための全長抗体提示システムおよびその使用
|
|
SG10201601882PA
(en)
|
2011-12-22 |
2016-04-28 |
Hoffmann La Roche |
Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
|
|
WO2013096812A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
AU2013209707A1
(en)
|
2012-01-18 |
2014-07-24 |
Genentech, Inc. |
Anti-LRP5 antibodies and methods of use
|
|
EP2804630B1
(en)
|
2012-01-18 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Methods of using fgf19 modulators
|
|
EP2809684A1
(en)
|
2012-01-31 |
2014-12-10 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
|
WO2013113615A1
(en)
|
2012-02-03 |
2013-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
|
|
NZ628314A
(en)
|
2012-02-06 |
2017-01-27 |
Inhibrx Lp |
Cd47 antibodies and methods of use thereof
|
|
EP2812357B1
(en)
|
2012-02-10 |
2020-11-04 |
F.Hoffmann-La Roche Ag |
Single-chain antibodies and other heteromultimers
|
|
WO2013120056A1
(en)
|
2012-02-11 |
2013-08-15 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
|
US20150018241A1
(en)
|
2012-02-15 |
2015-01-15 |
Hoffmann-La Roche Inc. |
Fc-receptor based affinity chromatography
|
|
EP2817338B1
(en)
|
2012-02-24 |
2017-07-26 |
AbbVie Stemcentrx LLC |
Dll3 modulators and methods of use
|
|
TWI682939B
(zh)
|
2012-02-24 |
2020-01-21 |
日商中外製藥股份有限公司 |
經ＦｃγＲＩＩＢ促進抗原消失之抗原結合分子
|
|
JP6193275B2
(ja)
|
2012-03-02 |
2017-09-06 |
ヴァクシネックス， インコーポレイテッド |
Ｂ細胞媒介炎症性疾患を治療するための方法
|
|
WO2013134414A1
(en)
*
|
2012-03-06 |
2013-09-12 |
Galaxy Biotech, Llc |
Bispecific antibodies with an fgf2 binding domain
|
|
US10988516B2
(en)
|
2012-03-26 |
2021-04-27 |
Uti Limited Partnership |
Methods and compositions for treating inflammation
|
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
|
EP2830646B1
(en)
|
2012-03-27 |
2018-03-07 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
|
EP2831117B1
(en)
|
2012-03-29 |
2017-11-01 |
NovImmune SA |
Anti-tlr4 antibodies and uses thereof
|
|
CN104411332B
(zh)
|
2012-03-30 |
2018-11-23 |
索伦托治疗有限公司 |
与vegfr2结合的全人抗体
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
AU2013244999A1
(en)
|
2012-04-05 |
2014-09-25 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies against human TWEAK and human IL17 and uses thereof
|
|
KR102318623B1
(ko)
|
2012-04-06 |
2021-11-02 |
오메로스 코포레이션 |
발작성 야간혈색뇨증의 치료를 위해 masp-1, masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
|
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
|
UA119227C2
(uk)
|
2012-04-20 |
2019-05-27 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептид, що зв'язується з cd3
|
|
NZ799532A
(en)
|
2012-04-20 |
2023-07-28 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
|
US9212227B2
(en)
|
2012-04-30 |
2015-12-15 |
Janssen Biotech, Inc. |
ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
|
|
RU2014148162A
(ru)
|
2012-05-01 |
2016-06-20 |
Дженентек, Инк. |
Анти-pmel17 антитела и их иммуноконъюгаты
|
|
WO2013164325A1
(en)
*
|
2012-05-02 |
2013-11-07 |
F. Hoffmann-La Roche Ag |
Multispecific antigen binding proteins
|
|
JP6267689B2
(ja)
|
2012-05-10 |
2018-01-24 |
バイオアトラ、エルエルシー |
多重特異性モノクローナル抗体
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
CA2873929C
(en)
|
2012-05-21 |
2019-08-13 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
MX2014014086A
(es)
|
2012-05-23 |
2015-01-26 |
Genentech Inc |
Metodo de seleccion para agentes terapeuticos.
|
|
CA2869529A1
(en)
|
2012-05-24 |
2013-11-28 |
Raffaella CASTOLDI |
Multispecific antibodies
|
|
TWI617578B
(zh)
|
2012-05-30 |
2018-03-11 |
Chugai Pharmaceutical Co Ltd |
標的組織專一的抗原結合分子
|
|
EP2854843A4
(en)
|
2012-05-31 |
2016-06-01 |
Sorrento Therapeutics Inc |
ANTIGEN BINDING PROTEINS THAT BIND PD-L1
|
|
JP2015520192A
(ja)
|
2012-06-06 |
2015-07-16 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Ｈｉｐｐｏ経路を調節する結合剤およびその使用
|
|
US11142563B2
(en)
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
|
CN104364266A
(zh)
|
2012-06-15 |
2015-02-18 |
霍夫曼-拉罗奇有限公司 |
抗-pcsk9抗体,制剂,剂量给药,和使用方法
|
|
PL2861246T3
(pl)
|
2012-06-18 |
2021-10-25 |
Omeros Corporation |
Kompozycje i sposoby hamowania MASP-1 i/lub MASP-2 i/lub MASP-3 w leczeniu różnych chorób i zaburzeń
|
|
CA2877573A1
(en)
|
2012-06-21 |
2013-12-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind c-met
|
|
CA2877814A1
(en)
|
2012-06-22 |
2013-12-27 |
Dingqiu HUANG |
Antigen binding proteins that bind ccr2
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
KR20150030744A
(ko)
|
2012-06-27 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
|
|
WO2014001324A1
(en)
|
2012-06-27 |
2014-01-03 |
Hoffmann-La Roche Ag |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
|
DK2869837T3
(da)
|
2012-07-04 |
2016-09-26 |
Hoffmann La Roche |
Anti-theophyllin-antistoffer og fremgangsmåder til anvendelse
|
|
BR112014030844A2
(pt)
|
2012-07-04 |
2019-10-15 |
Hoffmann La Roche |
anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo
|
|
CN107973856B
(zh)
|
2012-07-04 |
2021-11-23 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原-抗体缀合物
|
|
EP2870247B1
(en)
|
2012-07-05 |
2019-06-26 |
F.Hoffmann-La Roche Ag |
Expression and secretion system
|
|
US11180572B2
(en)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Dimeric protein with triple mutations
|
|
AU2013288931A1
(en)
|
2012-07-09 |
2014-12-11 |
Genentech, Inc. |
Immunoconjugates comprising anti-CD22 antibodies
|
|
MX2015000359A
(es)
|
2012-07-09 |
2015-04-14 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd79b.
|
|
EP2684896A1
(en)
|
2012-07-09 |
2014-01-15 |
International-Drug-Development-Biotech |
Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
|
|
SG11201500087VA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
|
CN104411337A
(zh)
|
2012-07-09 |
2015-03-11 |
基因泰克公司 |
包含抗cd79b抗体的免疫偶联物
|
|
CN104768571B
(zh)
|
2012-07-13 |
2018-11-09 |
酵活有限公司 |
多价异多聚体支架设计和构建体
|
|
LT2872534T
(lt)
|
2012-07-13 |
2018-10-25 |
Roche Glycart Ag |
Dvigubai specifiniai anti-vegf/anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
|
|
MX2015000426A
(es)
|
2012-07-13 |
2015-07-14 |
Univ Pennsylvania |
Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
|
|
EP2875046B1
(en)
|
2012-07-19 |
2020-02-26 |
Amgen Inc. |
Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
|
|
EP2882777B1
(en)
|
2012-08-07 |
2018-10-10 |
Roche Glycart AG |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
US9346872B2
(en)
|
2012-08-08 |
2016-05-24 |
Roche Glycart Ag |
Interleukin-10 fusion proteins
|
|
CN104704001B
(zh)
|
2012-08-09 |
2019-02-12 |
罗切格利卡特公司 |
Asgpr抗体及其用途
|
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
JP6302909B2
(ja)
|
2012-08-18 |
2018-03-28 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
シアリダーゼの同定および画像化のための細胞透過性プローブ
|
|
KR102134088B1
(ko)
|
2012-08-24 |
2020-07-14 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
|
|
SG11201500873XA
(en)
|
2012-08-24 |
2015-04-29 |
Chugai Pharmaceutical Co Ltd |
Fcgriib-specific fc region variant
|
|
SG11201500938XA
(en)
|
2012-08-31 |
2015-04-29 |
Immunogen Inc |
Diagnostic assays and kits for detection of folate receptor 1
|
|
EP3552628A1
(en)
|
2012-09-07 |
2019-10-16 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
|
KR101963231B1
(ko)
|
2012-09-11 |
2019-03-28 |
삼성전자주식회사 |
이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
|
|
WO2014047311A1
(en)
|
2012-09-19 |
2014-03-27 |
Genentech, Inc. |
Methods and compositions for preventing norleucine misincorporation into proteins
|
|
EP2898327A1
(en)
|
2012-09-19 |
2015-07-29 |
Dana-Farber Cancer Institute, Inc. |
Dynamic bh3 profiling
|
|
KR20150076172A
(ko)
|
2012-09-25 |
2015-07-06 |
그렌마크 파머수티칼스 에스. 아. |
이질-이합체 면역글로불린의 정제
|
|
MX2015003885A
(es)
|
2012-09-27 |
2015-07-06 |
Merus B V |
Anticuerpos igg biespecificos, acopladores de linfocitos t.
|
|
AU2013326974B2
(en)
|
2012-10-03 |
2019-01-03 |
Zymeworks Bc Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
|
KR101850591B1
(ko)
|
2012-10-05 |
2018-04-19 |
제넨테크, 인크. |
염증성 장 질환의 진단 및 치료 방법
|
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
MX2015003616A
(es)
|
2012-10-08 |
2015-06-05 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso.
|
|
US9603948B2
(en)
|
2012-10-11 |
2017-03-28 |
Uti Limited Partnership |
Methods and compositions for treating multiple sclerosis and related disorders
|
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
|
WO2014071018A1
(en)
|
2012-10-31 |
2014-05-08 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a dll4 antagonist
|
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
CN104755500B
(zh)
|
2012-11-08 |
2020-10-02 |
霍夫曼-拉罗奇有限公司 |
结合HER3 β-发夹的HER3抗原结合蛋白
|
|
AU2013342163B2
(en)
|
2012-11-08 |
2018-08-16 |
F. Hoffmann-La Roche Ltd |
IL-6 antagonists and uses thereof
|
|
EA201892509A1
(ru)
|
2012-11-13 |
2019-04-30 |
Дженентек, Инк. |
Антитела к гемагглютинину и способы применения
|
|
CN105051528A
(zh)
|
2012-11-15 |
2015-11-11 |
弗·哈夫曼-拉罗切有限公司 |
离子强度介导的pH梯度离子交换色谱
|
|
EP2927321B1
(en)
|
2012-11-27 |
2021-02-17 |
Ajou University Industry-Academic Cooperation Foundation |
Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
CA2893562C
(en)
|
2012-11-28 |
2023-09-12 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
|
CN110183534A
(zh)
|
2012-12-03 |
2019-08-30 |
诺夫免疫股份有限公司 |
抗cd47抗体及其使用方法
|
|
EP2928483A4
(en)
|
2012-12-04 |
2016-06-08 |
Oncomed Pharm Inc |
IMMUNOTHERAPY BY LIAISON AGENTS
|
|
DK2928923T3
(da)
|
2012-12-10 |
2020-02-17 |
Biogen Ma Inc |
Antistoffer mod dendritisk celle-antigen 2 fra blod og anvendelser deraf
|
|
CN104995303A
(zh)
|
2012-12-18 |
2015-10-21 |
诺华股份有限公司 |
利用结合乙酰透明质酸的肽标签的组合物和方法
|
|
WO2014104165A1
(ja)
|
2012-12-27 |
2014-07-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
JP6618362B2
(ja)
|
2013-01-14 |
2019-12-11 |
ゼンコア インコーポレイテッド |
新規異種二量体タンパク質
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CA2898326C
(en)
|
2013-01-18 |
2022-05-17 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
US9161966B2
(en)
|
2013-01-30 |
2015-10-20 |
Ngm Biopharmaceuticals, Inc. |
GDF15 mutein polypeptides
|
|
EP3626743A1
(en)
|
2013-02-01 |
2020-03-25 |
Kira Biotech Pty Limited |
Anti-cd83 antibodies and use thereof
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
PL2953972T3
(pl)
|
2013-02-05 |
2021-03-08 |
Engmab Sàrl |
Metoda wyboru przeciwciał przeciwko bcma
|
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
CA2900468C
(en)
|
2013-02-06 |
2024-04-30 |
Inhibrx Llc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
|
CN104995211B
(zh)
|
2013-02-07 |
2019-09-13 |
Csl有限公司 |
Il-11r结合蛋白及其应用
|
|
WO2014124326A1
(en)
|
2013-02-08 |
2014-08-14 |
Stem Centrx, Inc. |
Novel multispecific constructs
|
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
|
ES2870802T3
(es)
|
2013-02-12 |
2021-10-27 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas a elevado pH
|
|
WO2014126871A1
(en)
|
2013-02-12 |
2014-08-21 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
PL2958943T3
(pl)
|
2013-02-20 |
2020-04-30 |
The Trustees Of The University Of Pennsylvania |
Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
|
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
|
EP2958944B1
(en)
|
2013-02-22 |
2019-03-27 |
AbbVie Stemcentrx LLC |
Antidll3-antibody-pbd conjugates and uses thereof
|
|
KR102182488B1
(ko)
|
2013-02-25 |
2020-11-24 |
제넨테크, 인크. |
약물 내성 akt 돌연변이체의 검출 및 치료를 위한 방법 및 조성물
|
|
CN110845618A
(zh)
|
2013-02-26 |
2020-02-28 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
RU2015140921A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Антитела к mcsp
|
|
PT2961771T
(pt)
|
2013-02-26 |
2020-02-28 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas para ativação das células t, específicas para cd3 e cea
|
|
RU2015140917A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
CA2902505A1
(en)
|
2013-03-06 |
2014-09-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-c-met tandem fc bispecific antibodies
|
|
CA2902263A1
(en)
|
2013-03-06 |
2014-09-12 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
WO2014137355A1
(en)
|
2013-03-08 |
2014-09-12 |
Vaccinex, Inc. |
Anti-cxcl13 antibodies and associated epitope sequences
|
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
|
CN105209069B
(zh)
|
2013-03-13 |
2019-08-23 |
豪夫迈·罗氏有限公司 |
抗体配制剂
|
|
CA3113172A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Screen for compound that prevents protein oxidation based on comparison with l-tryptophan
|
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
|
CA3135558A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Prevention of protein oxidation in a composition
|
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
|
EP3839044A1
(en)
|
2013-03-14 |
2021-06-23 |
MacroGenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
|
JP2016516046A
(ja)
|
2013-03-14 |
2016-06-02 |
ジェネンテック， インコーポレイテッド |
がんの治療方法及びがん薬物耐性を阻止する方法
|
|
CN105189552B
(zh)
|
2013-03-14 |
2019-08-02 |
基因泰克公司 |
抗b7-h4抗体和免疫缀合物
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
KR20150127203A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
|
|
KR20150131177A
(ko)
|
2013-03-15 |
2015-11-24 |
제넨테크, 인크. |
항-CRTh2 항체 및 그의 용도
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10588949B2
(en)
|
2013-03-15 |
2020-03-17 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
|
WO2014145016A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2968545B1
(en)
|
2013-03-15 |
2019-03-06 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-gd2 antibodies
|
|
CN105246510A
(zh)
|
2013-03-15 |
2016-01-13 |
豪夫迈·罗氏有限公司 |
细胞培养培养基和抗体生产方法
|
|
KR102235452B1
(ko)
|
2013-03-15 |
2021-04-02 |
제넨테크, 인크. |
항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
|
|
CN110079599B
(zh)
|
2013-03-15 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
治疗pd-1和pd-l1相关疾患的生物标志物和方法
|
|
EP3623380A1
(en)
|
2013-03-15 |
2020-03-18 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
KR102218494B1
(ko)
|
2013-03-15 |
2021-02-19 |
인트린식 라이프사이언시스, 엘엘씨 |
항-헵시딘 항체 및 그의 용도
|
|
AU2014235003A1
(en)
|
2013-03-15 |
2015-09-17 |
Janssen Biotech, Inc. |
Interferon alpha and omega antibody antagonists
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
CA2902739C
(en)
*
|
2013-03-15 |
2022-11-22 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014151910A1
(en)
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
|
CA2902910A1
(en)
|
2013-03-15 |
2014-09-25 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
|
WO2014144466A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
JP6469644B2
(ja)
|
2013-03-15 |
2019-02-13 |
アムジエン・インコーポレーテツド |
抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
|
|
JP2016515120A
(ja)
|
2013-03-15 |
2016-05-26 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
|
|
CA2907181C
(en)
|
2013-03-15 |
2023-10-17 |
Viktor Roschke |
Multivalent and monovalent multispecific complexes and their uses
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
MD20180107A2
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
|
CA2904095A1
(en)
|
2013-03-27 |
2014-10-02 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
|
MX2015014017A
(es)
|
2013-04-02 |
2016-02-10 |
Chugai Pharmaceutical Co Ltd |
Variante de la region fc.
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
EP2983710B1
(en)
|
2013-04-09 |
2019-07-31 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
|
SG10201708547YA
(en)
|
2013-04-17 |
2017-11-29 |
Genzyme Corp |
Compositions and methods for treating and preventing macular degeneration
|
|
KR102282134B1
(ko)
|
2013-04-29 |
2021-07-27 |
에프. 호프만-라 로슈 아게 |
인간 fcrn-결합 변형된 항체 및 사용 방법
|
|
KR20160003803A
(ko)
|
2013-04-29 |
2016-01-11 |
에프. 호프만-라 로슈 아게 |
FcRn 결합이 제거된 항-IGF-1R 항체 및 혈관 눈 질환의 치료에 있어서 이의 용도
|
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
CA2910945A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
|
WO2014186798A1
(en)
|
2013-05-17 |
2014-11-20 |
Amplimmune, Inc. |
Receptors for b7-h4
|
|
EA038367B1
(ru)
|
2013-05-20 |
2021-08-16 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
|
AU2014268316B2
(en)
|
2013-05-23 |
2019-10-10 |
Takeda Pharmaceutical Company Limited |
Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
|
|
WO2014188377A2
(en)
|
2013-05-24 |
2014-11-27 |
Nestec S.A. |
Pathway specific assays for predicting irritable bowel syndrome diagnosis
|
|
CN105683217B
(zh)
|
2013-05-31 |
2019-12-10 |
索伦托治疗有限公司 |
与pd-1结合的抗原结合蛋白
|
|
CA2913370C
(en)
|
2013-05-31 |
2022-12-13 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
|
DK3019240T3
(da)
|
2013-07-09 |
2024-06-03 |
Annexon Inc |
Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
|
|
WO2015006554A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
|
CN105377873B
(zh)
|
2013-07-12 |
2021-03-30 |
豪夫迈·罗氏有限公司 |
阐明离子交换层析输入优化
|
|
AU2014290069B2
(en)
|
2013-07-16 |
2019-01-03 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
|
|
WO2015023596A1
(en)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
Compositions and method for treating complement-associated conditions
|
|
AU2014306564B2
(en)
|
2013-08-14 |
2019-10-17 |
Antlera Therapeutics Inc. |
Antibodies against frizzled proteins and methods of use thereof
|
|
RU2016111139A
(ru)
|
2013-08-28 |
2017-10-03 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые модуляторы sez6 и способы их применения
|
|
BR112016004242A8
(pt)
|
2013-08-28 |
2018-06-12 |
Stemcentrx Inc |
Métodos para conjugação sítio-específica de anticorpos e composições
|
|
EP3041865A2
(en)
|
2013-09-03 |
2016-07-13 |
NovImmune S.A. |
Readily isolated bispecific binding molecules with native format having mutated constant regions
|
|
AU2014332458B2
(en)
*
|
2013-09-05 |
2020-03-12 |
Igm Biosciences, Inc. |
Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
|
|
CN105848746B
(zh)
|
2013-09-05 |
2019-07-09 |
豪夫迈·罗氏有限公司 |
用于层析重复利用的方法
|
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
|
|
EP3046940B1
(en)
|
2013-09-17 |
2019-07-03 |
F.Hoffmann-La Roche Ag |
Methods of using anti-lgr5 antibodies
|
|
CA2922503C
(en)
|
2013-09-19 |
2021-10-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of bh3 profiling
|
|
WO2015048272A1
(en)
|
2013-09-25 |
2015-04-02 |
Amgen Inc. |
V-c-fc-v-c antibody
|
|
DK3050896T3
(da)
|
2013-09-27 |
2021-07-19 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
|
|
BR112016006397B1
(pt)
|
2013-09-27 |
2024-01-16 |
Genentech, Inc |
Formulações de anticorpo de anti-pdl1, seu uso, artigo de fabricação e composição
|
|
EA201600303A1
(ru)
|
2013-09-30 |
2016-11-30 |
Чугаи Сеияку Кабушики Каиша |
Способ получения антигенсвязывающей молекулы с использованием модифицированного хелперного фага
|
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
|
RU2016117978A
(ru)
|
2013-10-11 |
2017-11-17 |
Дженентек, Инк. |
Ингибиторы nsp4 и способы их применения
|
|
KR20160070136A
(ko)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
|
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
|
SG11201603127WA
(en)
|
2013-10-23 |
2016-05-30 |
Genentech Inc |
Methods of diagnosing and treating eosinophilic disorders
|
|
US9493563B2
(en)
|
2013-11-04 |
2016-11-15 |
Glenmark Pharmaceuticals S.A. |
Production of T cell retargeting hetero-dimeric immunoglobulins
|
|
KR20160077202A
(ko)
|
2013-11-04 |
2016-07-01 |
유티아이 리미티드 파트너쉽 |
지속적 면역요법을 위한 방법 및 조성물
|
|
HUE058272T2
(hu)
|
2013-11-06 |
2022-07-28 |
Janssen Biotech Inc |
Anti-CCL17 antitestek
|
|
JPWO2015068847A1
(ja)
|
2013-11-11 |
2017-03-09 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子
|
|
CN105940113A
(zh)
|
2013-11-13 |
2016-09-14 |
酵活有限公司 |
靶向egfr和/或her2的单价抗原结合构建体及其用途
|
|
KR102399292B1
(ko)
|
2013-11-21 |
2022-05-17 |
에프. 호프만-라 로슈 아게 |
항-알파-시누클레인 항체 및 사용 방법
|
|
CA2931356A1
(en)
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
|
CN105980557B
(zh)
|
2013-12-04 |
2020-04-07 |
中外制药株式会社 |
抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
|
|
JP6502942B2
(ja)
|
2013-12-13 |
2019-04-17 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ３３抗体とイムノコンジュゲート
|
|
MX2016007887A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2.
|
|
MX2016007885A
(es)
|
2013-12-17 |
2017-01-11 |
Genentech Inc |
Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
|
|
SI3192812T1
(sl)
|
2013-12-17 |
2020-10-30 |
Genentech, Inc. |
Anti-CD3 protitelesa in načini uporabe
|
|
MX2016007965A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
|
|
KR102466794B1
(ko)
|
2013-12-18 |
2022-11-11 |
씨에스엘 리미티드 |
상처 치료 방법
|
|
JP6779785B2
(ja)
|
2013-12-19 |
2020-11-04 |
ノバルティス アーゲー |
ヒトメソテリンキメラ抗原受容体およびその使用
|
|
PT3083680T
(pt)
|
2013-12-20 |
2020-03-17 |
Hoffmann La Roche |
Anticorpos humanizados anti-tau(ps422) e métodos de utilização
|
|
EP4420663A3
(en)
|
2013-12-20 |
2024-10-30 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
|
SG11201605200XA
(en)
|
2013-12-24 |
2016-07-28 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
|
PL3087095T3
(pl)
|
2013-12-24 |
2020-03-31 |
Argenx Bvba |
Antagoniści fcrn i sposoby stosowania
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
PL3089996T3
(pl)
|
2014-01-03 |
2021-12-13 |
F. Hoffmann-La Roche Ag |
Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
|
|
JP6602304B2
(ja)
|
2014-01-03 |
2019-11-06 |
エフ．ホフマン−ラ ロシュ アーゲー |
共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
|
|
WO2015103026A2
(en)
|
2014-01-03 |
2015-07-09 |
The Regents Of The University Of Michigan |
Treatment of neurological disorders
|
|
MX2016008191A
(es)
|
2014-01-03 |
2017-11-16 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
|
MX2016008631A
(es)
|
2014-01-08 |
2016-12-20 |
Shanghai hengrui pharmaceutical co ltd |
Proteina heterodimérica il-5 y usos de la misma.
|
|
CA2931986A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
CN105916880B
(zh)
|
2014-01-15 |
2020-01-17 |
豪夫迈·罗氏有限公司 |
具有改善的蛋白A结合作用的Fc区变体
|
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
TW201620939A
(zh)
|
2014-01-16 |
2016-06-16 |
中央研究院 |
治療及檢測癌症之組合物及方法
|
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
MX2016009515A
(es)
|
2014-01-24 |
2016-10-26 |
Genentech Inc |
Metodos para utilizar anticuerpos anti-steap1 e inmunoconjugados.
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
KR102489452B1
(ko)
|
2014-02-02 |
2023-01-16 |
메디뮨 리미티드 |
Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질
|
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
ES2704731T3
(es)
|
2014-02-06 |
2019-03-19 |
Hoffmann La Roche |
Proteínas de fusión de interleucina 2 y usos de las mismas
|
|
RU2703145C2
(ru)
|
2014-02-06 |
2019-10-15 |
Джензим Корпорейшн |
Композиции и способы лечения и предотвращения дегенерации желтого пятна
|
|
TWI785472B
(zh)
|
2014-02-08 |
2022-12-01 |
美商建南德克公司 |
治療阿茲海默症之方法
|
|
CN106163548A
(zh)
|
2014-02-08 |
2016-11-23 |
健泰科生物技术公司 |
治疗阿尔茨海默氏病的方法
|
|
WO2015120474A1
(en)
|
2014-02-10 |
2015-08-13 |
Igm Biosciences, Inc. |
Iga multi-specific binding molecules
|
|
TWI631135B
(zh)
|
2014-02-12 |
2018-08-01 |
建南德克公司 |
抗ｊａｇｇｅｄ１抗體及使用方法
|
|
AU2015218633A1
(en)
|
2014-02-21 |
2016-09-01 |
Abbvie Stemcentrx Llc |
Anti-DLL3 antibodies and drug conjugates for use in melanoma
|
|
JP2017507939A
(ja)
|
2014-02-21 |
2017-03-23 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
ES2816624T3
(es)
|
2014-02-28 |
2021-04-05 |
Merus Nv |
Anticuerpos que se unen a EGFR y ERBB3
|
|
SI3110849T1
(sl)
|
2014-02-28 |
2021-01-29 |
Merus N.V. |
Protitelo, ki veže ERBB-2 in ERBB-3
|
|
ES2897765T3
(es)
|
2014-03-14 |
2022-03-02 |
Hoffmann La Roche |
Procedimientos y composiciones para la secreción de polipéptidos heterólogos
|
|
UY36032A
(es)
|
2014-03-14 |
2015-10-30 |
Novartis Ag |
Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
AU2015230938C1
(en)
|
2014-03-21 |
2021-10-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック， インコーポレイテッド |
ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
|
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
|
MA39804A
(fr)
|
2014-03-27 |
2017-02-01 |
Hoffmann La Roche |
Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
|
|
EP3122781B1
(en)
|
2014-03-28 |
2020-01-01 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
SG11201608106PA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
DK3126394T3
(da)
|
2014-03-31 |
2020-01-13 |
Hoffmann La Roche |
Anti-OX40-antistoffer og fremgangsmåder til anvendelse
|
|
EP3825326A1
(en)
|
2014-04-01 |
2021-05-26 |
Adimab, LLC |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
|
SG10202107077QA
(en)
|
2014-04-02 |
2021-07-29 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
WO2015152908A1
(en)
|
2014-04-02 |
2015-10-08 |
U.S. Army Medical Research Institute Of Infectious Diseases |
Rapid dual direct fluorescent antibody assay for the identification of bacillus anthracis
|
|
WO2015156268A1
(ja)
|
2014-04-07 |
2015-10-15 |
中外製薬株式会社 |
免疫活性化抗原結合分子
|
|
KR102487608B1
(ko)
|
2014-04-07 |
2023-01-12 |
노파르티스 아게 |
항-cd19 키메라 항원 수용체를 사용한 암의 치료
|
|
BR112016024088A2
(pt)
|
2014-04-16 |
2018-06-19 |
Biocon Ltd. |
formulações de proteína estáveis que compreendem um excesso molar de sorbitol
|
|
US10040862B2
(en)
|
2014-04-18 |
2018-08-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to CD99
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
SG10201913507SA
(en)
|
2014-05-02 |
2020-02-27 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
WO2015171822A1
(en)
|
2014-05-06 |
2015-11-12 |
Genentech, Inc. |
Production of heteromultimeric proteins using mammalian cells
|
|
US11505605B2
(en)
|
2014-05-13 |
2022-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
DK3143138T3
(da)
|
2014-05-13 |
2022-04-25 |
Bioatla Inc |
Betinget aktive biologiske proteiner
|
|
ES2936810T3
(es)
|
2014-05-16 |
2023-03-22 |
Pfizer |
Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
|
|
WO2015179658A2
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
|
CN106661622B
(zh)
|
2014-05-23 |
2020-08-21 |
豪夫迈·罗氏有限公司 |
Mit生物标志物和使用它们的方法
|
|
EP3149036A4
(en)
|
2014-05-27 |
2017-12-27 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
|
EP3904388A1
(en)
|
2014-05-27 |
2021-11-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
|
KR102512592B1
(ko)
|
2014-05-27 |
2023-03-21 |
아카데미아 시니카 |
항-ｈｅｒ2 글리코항체 및 이의 용도
|
|
KR102493430B1
(ko)
|
2014-05-28 |
2023-01-31 |
자임워크스 비씨 인코포레이티드 |
변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
|
|
US11332523B2
(en)
|
2014-05-28 |
2022-05-17 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
|
EP3152235B1
(en)
|
2014-05-29 |
2021-08-25 |
MacroGenics, Inc. |
Tri-specific binding molecules and methods of use thereof
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
CA2949982A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
|
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック， インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗ｈｅｒ２表位之單株抗體及其使用之方法
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
EP3160991A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
|
US20170290876A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
BR112016029935A2
(pt)
|
2014-06-26 |
2017-10-31 |
Hoffmann La Roche |
?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo?
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
US9884921B2
(en)
|
2014-07-01 |
2018-02-06 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
US10406197B2
(en)
|
2014-07-10 |
2019-09-10 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in Huntington's disease
|
|
JP2017526641A
(ja)
|
2014-07-11 |
2017-09-14 |
ジェネンテック， インコーポレイテッド |
Ｎｏｔｃｈ経路阻害
|
|
SG11201700207WA
(en)
|
2014-07-11 |
2017-02-27 |
Genentech Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
EP3722316A1
(en)
|
2014-07-21 |
2020-10-14 |
Novartis AG |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
|
UA123432C2
(uk)
|
2014-07-30 |
2021-04-07 |
Нджм Біофармасьютікалз, Інк. |
Димер та спосіб його застосування для лікування метаболічних розладів
|
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
JP6464255B2
(ja)
|
2014-08-04 |
2019-02-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｔ細胞活性化抗原結合分子
|
|
EA201790342A1
(ru)
|
2014-08-08 |
2017-07-31 |
ЭЛЕКТОР ЭлЭлСи |
Антитела к trem2 и способы их применения
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
|
EP3485910A2
(en)
|
2014-08-22 |
2019-05-22 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind cxcr3
|
|
EP3185885B1
(en)
|
2014-08-26 |
2020-08-19 |
Compugen Ltd. |
Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
|
|
KR102615681B1
(ko)
|
2014-08-28 |
2023-12-18 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗ｍｆｉ２抗體及使用方法
|
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
|
ES2890669T3
(es)
|
2014-09-09 |
2022-01-21 |
Janssen Biotech Inc |
Terapias de combinación con anticuerpos anti-CD38
|
|
WO2016040723A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-her2 antibodies and immunoconjugates
|
|
AR101848A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos de anti-b7-h4 e inmunoconjugados
|
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
|
UY36302A
(es)
|
2014-09-15 |
2016-04-29 |
Amgen Inc |
Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
|
|
BR112017004393A2
(pt)
|
2014-09-15 |
2018-02-27 |
Genentech Inc |
formulações de anticorpo
|
|
CN107580628B
(zh)
|
2014-09-17 |
2022-01-07 |
诺华股份有限公司 |
用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
|
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
MX2017003640A
(es)
|
2014-09-19 |
2017-10-31 |
Regeneron Pharma |
Receptores antigenicos quimericos.
|
|
WO2016049036A1
(en)
|
2014-09-22 |
2016-03-31 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
|
CA3069221C
(en)
|
2014-09-23 |
2023-04-04 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
US20170247476A1
(en)
|
2014-09-25 |
2017-08-31 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
AU2015323860B2
(en)
|
2014-09-29 |
2021-05-27 |
Duke University |
Bispecific molecules comprising an HIV-1 envelope targeting arm
|
|
US20170304460A1
(en)
|
2014-10-01 |
2017-10-26 |
Medimmune, Llc |
Method of conjugating a polypeptide
|
|
ES2850325T3
(es)
|
2014-10-09 |
2021-08-27 |
Engmab Sarl |
Anticuerpos biespecíficos contra CD3epsilon y ROR1
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
CA2964317C
(en)
|
2014-10-14 |
2021-10-05 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
CN107074938A
(zh)
|
2014-10-16 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
抗‑α‑突触核蛋白抗体和使用方法
|
|
AU2015336931B2
(en)
|
2014-10-23 |
2021-04-29 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
|
WO2016061632A1
(en)
|
2014-10-23 |
2016-04-28 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
|
PT3212233T
(pt)
|
2014-10-31 |
2020-07-16 |
Oncomed Pharm Inc |
Terapia combinada para o tratamento de doenças
|
|
EP3212226B1
(en)
|
2014-10-31 |
2020-03-18 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
|
EP3215850B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
JP2017536842A
(ja)
|
2014-11-03 |
2017-12-14 |
ジェネンテック， インコーポレイテッド |
Ｏｘ４０アゴニスト治療薬の有効性及び評価を予測するための方法及びバイオマーカー
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
RU2739500C2
(ru)
|
2014-11-05 |
2020-12-25 |
Дженентек, Инк. |
Способы получения двуцепочечных белков в бактериях
|
|
BR112017009297B1
(pt)
|
2014-11-05 |
2024-02-15 |
Annexon, Inc |
Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
|
|
CA2966558C
(en)
|
2014-11-05 |
2024-03-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
CA2960797A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
|
BR112017006591A2
(pt)
|
2014-11-06 |
2018-01-16 |
Hoffmann La Roche |
polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
|
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
|
IL251858B
(en)
|
2014-11-07 |
2022-09-01 |
Eleven Biotherapeutics Inc |
Improved il–6 antagonists
|
|
WO2016077381A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
EP3552488A1
(en)
|
2014-11-10 |
2019-10-16 |
F. Hoffmann-La Roche AG |
Animal model for nephropathy and agents for treating the same
|
|
MX2017006250A
(es)
|
2014-11-14 |
2017-11-17 |
Hoffmann La Roche |
Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf.
|
|
JP2017537090A
(ja)
|
2014-11-17 |
2017-12-14 |
ジェネンテック， インコーポレイテッド |
Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
|
|
EP3845565A3
(en)
|
2014-11-19 |
2021-09-08 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
CN107001473B
(zh)
|
2014-11-19 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
抗-运铁蛋白受体抗体及使用方法
|
|
CA2968338A1
(en)
|
2014-11-19 |
2016-05-26 |
Nestec S.A. |
Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
|
|
CN107250158B
(zh)
|
2014-11-19 |
2022-03-25 |
基因泰克公司 |
抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
|
|
PT3221357T
(pt)
|
2014-11-20 |
2020-07-28 |
Hoffmann La Roche |
Cadeias leves comuns e métodos de utilização
|
|
HUE059632T2
(hu)
|
2014-11-20 |
2022-12-28 |
Hoffmann La Roche |
T-sejteket aktiváló bispecifikus antigénkötõ molekulák és PD-1 tengelyt célzó antagonisták kombinációs terápiája
|
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
US11033637B2
(en)
|
2014-11-21 |
2021-06-15 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
|
NZ732144A
(en)
|
2014-11-26 |
2020-04-24 |
Xencor Inc |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3223848A4
(en)
|
2014-11-27 |
2018-07-18 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
|
WO2016087514A1
(en)
|
2014-12-02 |
2016-06-09 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
多重特異性抗体
|
|
EP3227336B1
(en)
|
2014-12-05 |
2019-07-03 |
F.Hoffmann-La Roche Ag |
Anti-cd79b antibodies and methods of use
|
|
JP2018505911A
(ja)
|
2014-12-05 |
2018-03-01 |
イミュネクスト，インコーポレーテッド |
推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
|
|
US11001625B2
(en)
|
2014-12-10 |
2021-05-11 |
Tufts University |
VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
|
BR112017011234A2
(pt)
|
2014-12-10 |
2018-03-27 |
Genentech Inc |
anticorpos contra receptor da barreira hematoencefálica e métodos de uso
|
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
|
WO2016096788A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Assay and method for determining cdc eliciting antibodies
|
|
MY183415A
(en)
|
2014-12-19 |
2021-02-18 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
|
AR103161A1
(es)
|
2014-12-19 |
2017-04-19 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
|
|
EP3233907B1
(en)
|
2014-12-19 |
2021-03-03 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
WO2016109410A2
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN107530421B
(zh)
|
2014-12-30 |
2021-07-20 |
细胞基因公司 |
抗cd47抗体及其用途
|
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
|
EP3247723A1
(en)
|
2015-01-22 |
2017-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
|
TN2018000324A1
(en)
|
2015-01-23 |
2020-01-16 |
Sanofi Sa |
ANTl-CD3 ANTIBODIES, ANTl-CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO CD3 AND/OR CD123
|
|
KR102691114B1
(ko)
|
2015-01-24 |
2024-08-01 |
아카데미아 시니카 |
신규한 글리칸 콘주게이트 및 이를 사용하는 방법
|
|
JP2018510844A
(ja)
|
2015-01-24 |
2018-04-19 |
アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ |
がんマーカーおよびその使用方法
|
|
JP2018504143A
(ja)
|
2015-01-26 |
2018-02-15 |
セレクティスＣｅｌｌｅｃｔｉｓ |
がん免疫治療のための抗ｈｓｐ７０特異的キメラ抗原受容体（ｃａｒ）
|
|
EP3250927B1
(en)
|
2015-01-28 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Gene expression markers and treatment of multiple sclerosis
|
|
EP4223873A3
(en)
|
2015-01-31 |
2023-09-06 |
The Trustees of the University of Pennsylvania |
Compositions and methods for t cell delivery of therapeutic molecules
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016126972A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
CA2974547A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses thereof
|
|
CA2976446A1
(en)
|
2015-02-13 |
2016-08-18 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind ctla4
|
|
AU2016222683A1
(en)
|
2015-02-26 |
2017-07-13 |
Genentech, Inc. |
Integrin beta7 antagonists and methods of treating crohn's disease
|
|
KR101892883B1
(ko)
|
2015-02-27 |
2018-10-05 |
추가이 세이야쿠 가부시키가이샤 |
Il-6 관련 질환 치료용 조성물
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
SG11201707186YA
(en)
|
2015-03-06 |
2017-10-30 |
Genentech Inc |
Ultrapurified dsba and dsbc and methods of making and using the same
|
|
KR102720769B1
(ko)
|
2015-03-09 |
2024-10-22 |
아르제넥스 비브이 |
FcRn 길항제를 사용하여 Fc-함유된 제제의 혈청 수준을 감소시키는 방법
|
|
AR104484A1
(es)
|
2015-03-10 |
2017-07-26 |
Sorrento Therapeutics Inc |
Anticuerpos anti-psma como agentes terapéuticos
|
|
JP6394444B2
(ja)
*
|
2015-03-10 |
2018-09-26 |
株式会社デンソー |
ブラシレスモータ
|
|
KR20170127011A
(ko)
|
2015-03-16 |
2017-11-20 |
제넨테크, 인크. |
Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
EP3277717B1
(en)
|
2015-03-31 |
2020-11-18 |
Medimmune Limited |
A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
|
|
WO2016156291A1
(en)
|
2015-03-31 |
2016-10-06 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a trimeric tnf family ligand
|
|
EP3279216A4
(en)
|
2015-04-01 |
2019-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
|
|
CN116327915A
(zh)
|
2015-04-03 |
2023-06-27 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
|
MX2017012352A
(es)
|
2015-04-03 |
2018-01-26 |
Eureka Therapeutics Inc |
Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
EP3828199A1
(en)
|
2015-04-06 |
2021-06-02 |
Acceleron Pharma Inc. |
Alk7: actriib heteromultimers and uses thereof
|
|
IL287952B2
(en)
|
2015-04-06 |
2024-11-01 |
President And Fellows Of Harvard College |
Compositions and methods for non-myeloablative training
|
|
JP6810702B2
(ja)
|
2015-04-06 |
2021-01-06 |
アクセルロン ファーマ インコーポレイテッド |
シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
|
|
EP3280441B1
(en)
|
2015-04-07 |
2021-09-29 |
Alector LLC |
Anti-sortilin antibodies and methods of use thereof
|
|
AU2016246695A1
(en)
|
2015-04-07 |
2017-10-26 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
|
WO2016164656A1
(en)
|
2015-04-08 |
2016-10-13 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind cd38
|
|
SI3280729T1
(sl)
|
2015-04-08 |
2022-09-30 |
Novartis Ag |
Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
|
|
AU2016245887B2
(en)
|
2015-04-10 |
2021-09-23 |
Adimab, Llc. |
Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
|
|
EP3283523A1
(en)
|
2015-04-17 |
2018-02-21 |
Elsalys Biotech |
Anti-tyro3 antibodies and uses thereof
|
|
EP3283619B1
(en)
|
2015-04-17 |
2023-04-05 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
CN107995863A
(zh)
|
2015-04-20 |
2018-05-04 |
特雷罗药物股份有限公司 |
通过线粒体分析预测对阿伏西地的应答
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2016172551A2
(en)
|
2015-04-24 |
2016-10-27 |
Genentech, Inc. |
Methods of identifying bacteria comprising binding polypeptides
|
|
CN116063543A
(zh)
|
2015-04-24 |
2023-05-05 |
豪夫迈·罗氏有限公司 |
多特异性抗原结合蛋白
|
|
EP3288964B1
(en)
|
2015-04-27 |
2024-02-21 |
Dana-Farber Cancer Institute, Inc. |
High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
|
|
EP3291832A4
(en)
|
2015-05-06 |
2018-09-12 |
UTI Limited Partnership |
Nanoparticle compositions for sustained therapy
|
|
KR20180018525A
(ko)
|
2015-05-08 |
2018-02-21 |
젠코어 인코포레이티드 |
Cd3 및 종양 항원과 결합하는 이종이량체 항체
|
|
EP4450524A2
(en)
|
2015-05-11 |
2024-10-23 |
F. Hoffmann-La Roche AG |
Compositions and methods of treating lupus nephritis
|
|
AU2016262074A1
(en)
|
2015-05-12 |
2017-11-09 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
AU2016263198C1
(en)
|
2015-05-15 |
2023-10-05 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
|
BR112017024933A8
(pt)
|
2015-05-18 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Alvocidib produce com a bioavailabilidade aumentada
|
|
FI3298033T4
(fi)
|
2015-05-18 |
2023-09-22 |
Tcr2 Therapeutics Inc |
Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
|
|
JP6827426B2
(ja)
|
2015-05-20 |
2021-02-10 |
ヤンセン バイオテツク，インコーポレーテツド |
軽鎖アミロイドーシス及びその他のｃｄ３８陽性血液悪性疾患の治療のための抗ｃｄ３８抗体
|
|
IL293719B2
(en)
|
2015-05-21 |
2023-07-01 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
|
KR102583058B1
(ko)
|
2015-05-28 |
2023-09-25 |
제넨테크, 인크. |
항-cd3 동종이량체를 검출하기 위한 세포 기반 검정
|
|
IL294138A
(en)
|
2015-05-29 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
|
ES2810700T3
(es)
|
2015-05-29 |
2021-03-09 |
Hoffmann La Roche |
Metilación del promotor de PD-L1 en cáncer
|
|
CN107810012A
(zh)
|
2015-06-02 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗il‑34抗体治疗神经疾病的组合物和方法
|
|
JP6793134B2
(ja)
|
2015-06-05 |
2020-12-02 |
ジェネンテック， インコーポレイテッド |
抗ｔａｕ抗体及び使用方法
|
|
KR20180025888A
(ko)
|
2015-06-08 |
2018-03-09 |
제넨테크, 인크. |
항-ox40 항체 및 pd-1 축 결합 길항제를 사용하여 암을 치료하는 방법
|
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
|
WO2016201388A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
|
EP3307779A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
|
JP2018524295A
(ja)
|
2015-06-15 |
2018-08-30 |
ジェネンテック， インコーポレイテッド |
抗体及び免疫複合体
|
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
|
CN107849145B
(zh)
|
2015-06-16 |
2021-10-26 |
基因泰克公司 |
抗cd3抗体及其使用方法
|
|
US10323094B2
(en)
|
2015-06-16 |
2019-06-18 |
Genentech, Inc. |
Humanized and affinity matured antibodies to FcRH5 and methods of use
|
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
|
CA2986592A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
|
EP3310386B1
(en)
|
2015-06-22 |
2021-07-21 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
|
|
LT3313441T
(lt)
|
2015-06-24 |
2024-05-27 |
Janssen Biotech, Inc. |
Imuniteto moduliavimas ir solidinių navikų gydymas antikūnais, kurie specifiškai suriša cd38
|
|
EP3744732A1
(en)
|
2015-06-24 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Humanized anti-tau(ps422) antibodies and methods of use
|
|
DK3313882T3
(da)
|
2015-06-24 |
2020-05-11 |
Janssen Pharmaceutica Nv |
Anti-VISTA antistoffer og fragmenter
|
|
EP3314255B1
(en)
|
2015-06-25 |
2019-07-31 |
H. Hoffnabb-La Roche Ag |
Cell based assay for determining antibody or ligand binding and function
|
|
AU2016288461B2
(en)
|
2015-06-29 |
2021-10-07 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
|
NZ737726A
(en)
|
2015-07-06 |
2023-03-31 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
|
US20180201693A1
(en)
|
2015-07-09 |
2018-07-19 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
|
WO2017010874A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
|
CA2991980A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
|
EP3322735A4
(en)
|
2015-07-15 |
2019-03-13 |
Zymeworks Inc. |
BISPECIFIC ANTIGEN-BINDING CONSTRUCTS CONJUGATED TO A MEDICINAL PRODUCT
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
US10829735B2
(en)
|
2015-07-21 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods for improving the efficacy and expansion of immune cells
|
|
PL3317301T3
(pl)
|
2015-07-29 |
2021-11-15 |
Novartis Ag |
Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
US10568887B2
(en)
|
2015-08-03 |
2020-02-25 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
|
DK3331910T3
(da)
|
2015-08-03 |
2020-03-16 |
Engmab Sarl |
Monoklonale antistoffer mod humant b-cellemodningsantigen (bcma)
|
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
CN107921128B
(zh)
|
2015-08-05 |
2022-04-26 |
詹森生物科技公司 |
抗cd154抗体及其使用方法
|
|
WO2017027325A1
(en)
|
2015-08-07 |
2017-02-16 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
|
EA034582B1
(ru)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Конструкции варианта sirp-альфа и их применение
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
EP3331902B1
(en)
|
2015-08-07 |
2021-04-28 |
ALX Oncology Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
BR112017026543A2
(pt)
|
2015-08-26 |
2018-08-14 |
Bison Therapeutics Inc |
plataforma de anticorpo multiespecífico e métodos relacionados
|
|
AU2016316768A1
(en)
|
2015-08-28 |
2018-03-29 |
Alector Llc |
Anti-Siglec-7 antibodies and methods of use thereof
|
|
US11890301B2
(en)
|
2015-08-28 |
2024-02-06 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
|
CN108348551A
(zh)
|
2015-08-28 |
2018-07-31 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
|
WO2017044811A1
(en)
|
2015-09-11 |
2017-03-16 |
Bruce Andrien |
Recombinant glycosylated eculizumab and eculizumab variants
|
|
AU2016323153B2
(en)
|
2015-09-15 |
2021-04-22 |
Board Of Regents, The University Of Texas System |
T-cell receptor (TCR)-binding antibodies and uses thereof
|
|
CA2998174A1
(en)
|
2015-09-15 |
2017-03-23 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
|
CA2993423C
(en)
|
2015-09-18 |
2024-03-12 |
Chugai Seiyaku Kabushiki Kaisha |
Il-8-binding antibodies and uses thereof
|
|
UA126278C2
(uk)
|
2015-09-21 |
2022-09-14 |
Аптево Рісьорч Енд Девелопмент Ллс |
Поліпептиди, які зв'язують cd3
|
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ｏｘ４０抗体及びその診断用途
|
|
WO2017053705A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
|
BR112018005737A2
(pt)
|
2015-09-23 |
2018-10-09 |
Genentech Inc |
anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína
|
|
MX2018003533A
(es)
|
2015-09-24 |
2019-04-25 |
Abvitro Llc |
Composiciones de anticuerpo de virus de inmunodeficiencia humana (vih) y metodos de uso.
|
|
EP3353210B1
(en)
|
2015-09-25 |
2024-11-06 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
|
KR102431342B1
(ko)
|
2015-10-02 |
2022-08-10 |
에프. 호프만-라 로슈 아게 |
Pd1 및 tim3에 특이적인 이중특이성 항체
|
|
AR106199A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas activadoras de células t
|
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
|
HUE056033T2
(hu)
|
2015-10-02 |
2022-01-28 |
Hoffmann La Roche |
Anti-pd1 antitestek és felhasználási módszerek
|
|
JP6734919B2
(ja)
|
2015-10-02 |
2020-08-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
同時結合を測定するための細胞ベースのｆｒｅｔアッセイ法
|
|
EP3356420B1
(en)
*
|
2015-10-02 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
US10526413B2
(en)
|
2015-10-02 |
2020-01-07 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specific for OX40
|
|
AU2016329111A1
(en)
|
2015-10-02 |
2018-02-08 |
F. Hoffmann-La Roche Ag |
Bispecific anti-CEAXCD3 T cell activating antigen binding molecules
|
|
WO2017055391A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules binding mesothelin and cd3
|
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
|
WO2017055314A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
|
US20190330335A1
(en)
|
2015-10-06 |
2019-10-31 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
|
WO2017062682A2
(en)
|
2015-10-06 |
2017-04-13 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
|
WO2017062649A1
(en)
|
2015-10-07 |
2017-04-13 |
Alexion Pharmaceuticals, Inc. |
A method for treating age-related macular degeneration in a patient
|
|
MX2018004157A
(es)
|
2015-10-07 |
2019-04-01 |
F Hoffmann La Roche Ag |
Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador.
|
|
BR112018007152A2
(pt)
|
2015-10-08 |
2018-11-06 |
Zymeworks Inc |
construtos de polipeptídeo de ligação a antígeno compreendendo cadeias leves kappa e lambda e usos dos mesmos
|
|
MX2018004177A
(es)
|
2015-10-08 |
2018-09-11 |
Macrogenics Inc |
Terapia de combinacion para el tratamiento de cancer.
|
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
JP7296728B2
(ja)
|
2015-10-23 |
2023-06-23 |
メルス ナムローゼ フェンノートシャップ |
癌の成長を抑制する結合分子
|
|
SI3365366T1
(sl)
|
2015-10-25 |
2022-02-28 |
Sanofi |
Trispecifični in/ali trivalentni vezavni proteini za preprečevanje ali zdravljenje okužbe s HIV
|
|
EP3368575A2
(en)
|
2015-10-29 |
2018-09-05 |
Alector LLC |
Anti-siglec-9 antibodies and methods of use thereof
|
|
CA3000048A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
CN108289951A
(zh)
|
2015-10-30 |
2018-07-17 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体和缀合物
|
|
RU2021117293A
(ru)
|
2015-10-30 |
2021-06-23 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
JP6869553B2
(ja)
|
2015-10-30 |
2021-05-12 |
ギャラクシー バイオテック， エルエルシーＧａｌａｘｙ Ｂｉｏｔｅｃｈ， Ｌｌｃ |
デスレセプター４及びデスレセプター５に結合する非常に強力な抗体
|
|
PT3827845T
(pt)
|
2015-11-03 |
2022-07-08 |
Janssen Biotech Inc |
Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações
|
|
JP6998869B2
(ja)
|
2015-11-08 |
2022-02-04 |
ジェネンテック， インコーポレイテッド |
多重特異性抗体のスクリーニング方法
|
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
|
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
|
US10711282B2
(en)
|
2015-11-23 |
2020-07-14 |
Novartis Ag |
Optimized lentiviral transfer vectors and uses thereof
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2017100372A1
(en)
|
2015-12-07 |
2017-06-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
|
PL3387015T3
(pl)
|
2015-12-09 |
2022-02-14 |
F. Hoffmann-La Roche Ag |
Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
EA201891178A1
(ru)
|
2015-12-14 |
2019-01-31 |
Макродженикс, Инк. |
Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
|
|
CN106883297B
(zh)
*
|
2015-12-16 |
2019-12-13 |
苏州康宁杰瑞生物科技有限公司 |
基于ch3结构域的异二聚体分子、其制备方法及用途
|
|
JP2019502695A
(ja)
|
2015-12-17 |
2019-01-31 |
ノバルティス アーゲー |
ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用
|
|
WO2017106684A2
(en)
|
2015-12-17 |
2017-06-22 |
Janssen Biotech, Inc. |
Antibodies specifically binding hla-dr and their uses
|
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Ｐｄ−１に対する抗体分子およびその使用
|
|
DK3390442T5
(da)
|
2015-12-18 |
2024-09-23 |
Chugai Pharmaceutical Co Ltd |
Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf
|
|
KR20180091918A
(ko)
|
2015-12-28 |
2018-08-16 |
추가이 세이야쿠 가부시키가이샤 |
Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법
|
|
CA3007491A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
|
EP3397287A1
(en)
|
2015-12-30 |
2018-11-07 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
|
BR112018013074A2
(pt)
|
2015-12-30 |
2018-12-11 |
Novartis Ag |
terapias de célula efetora imune com eficácia real-çada
|
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
|
EA201891601A1
(ru)
|
2016-01-10 |
2019-03-29 |
Неоткс Терапьютикс Лтд. |
Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
|
|
EP3405489A1
(en)
|
2016-01-20 |
2018-11-28 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
|
EP3405492B1
(en)
|
2016-01-21 |
2020-10-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
WO2017132279A1
(en)
|
2016-01-25 |
2017-08-03 |
Genentech, Inc. |
Methods for assaying t-cell dependent bispecific antibodies
|
|
AU2017212484C1
(en)
|
2016-01-27 |
2020-11-05 |
Medimmune, Llc |
Methods for preparing antibodies with a defined glycosylation pattern
|
|
US10118963B2
(en)
|
2016-01-29 |
2018-11-06 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
|
CA3014013A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
|
EP3419599A4
(en)
|
2016-02-23 |
2019-09-11 |
Sesen Bio, Inc. |
IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
|
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2017152102A2
(en)
|
2016-03-04 |
2017-09-08 |
Alector Llc |
Anti-trem1 antibodies and methods of use thereof
|
|
AU2017225733A1
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
|
|
EP3426693A4
(en)
|
2016-03-08 |
2019-11-13 |
Academia Sinica |
PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
MX2018010988A
(es)
|
2016-03-14 |
2019-01-21 |
Chugai Pharmaceutical Co Ltd |
Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
|
|
JP7034489B2
(ja)
|
2016-03-15 |
2022-03-14 |
アイタブメッド （エイチケイ） リミテッド |
多重特異性Ｆａｂ融合タンパクおよびその使用
|
|
CN109153728A
(zh)
|
2016-03-21 |
2019-01-04 |
埃尔斯塔治疗公司 |
多特异性和多功能分子及其用途
|
|
CA3012422A1
(en)
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
FI3433280T3
(fi)
|
2016-03-22 |
2023-06-06 |
Hoffmann La Roche |
Proteaasin aktivoimia t-solubispesifisiä molekyylejä
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
WO2017165734A1
(en)
|
2016-03-25 |
2017-09-28 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
UA123785C2
(uk)
|
2016-03-28 |
2021-06-02 |
Інсайт Корпорейшн |
Сполуки піролотриазину як інгібітори tam
|
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
EP3436477A2
(en)
|
2016-03-29 |
2019-02-06 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
|
|
EP3436070A4
(en)
|
2016-03-29 |
2019-11-27 |
University of Southern California |
CHIMERIC ANTIGENIC RECEPTORS TARGETING CANCER
|
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
DK3443006T5
(da)
|
2016-04-13 |
2024-09-16 |
Sanofi Sa |
Trispecifikke og/eller trivalente bindingsproteiner
|
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
MX2018012433A
(es)
|
2016-04-15 |
2019-03-01 |
Macrogenics Inc |
Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos.
|
|
RU2746994C2
(ru)
|
2016-04-15 |
2021-04-23 |
Иммьюнекст Инк. |
Антитела против человеческого vista и их применение
|
|
KR20190006495A
(ko)
|
2016-04-15 |
2019-01-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd80 변이체 면역조절 단백질 및 그의 용도
|
|
BR112018070934A2
(pt)
|
2016-04-15 |
2019-02-26 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras variantes ligantes de icos e usos das mesmas
|
|
KR20190003957A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암 모니터링 및 치료 방법
|
|
PT3443096T
(pt)
|
2016-04-15 |
2023-05-30 |
Novartis Ag |
Composições e métodos para expressão seletiva de recetores de antigénios quiméricos
|
|
ES2850428T3
(es)
|
2016-04-15 |
2021-08-30 |
Hoffmann La Roche |
Procedimientos de monitorización y tratamiento del cáncer
|
|
CA3021086C
(en)
|
2016-04-15 |
2023-10-17 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
|
JP2019515677A
(ja)
|
2016-04-26 |
2019-06-13 |
アール．ピー．シェーラー テクノロジーズ エルエルシー |
抗体複合体ならびにそれを作製および使用する方法
|
|
WO2017190079A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
|
JP6675017B2
(ja)
|
2016-05-02 |
2020-04-01 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
コントースボディ−単鎖標的結合物質
|
|
JP7181091B2
(ja)
|
2016-05-10 |
2022-11-30 |
ジェネンテック， インコーポレイテッド |
ポリペプチドの組み換え産生中にトリスルフィド結合を減少させる方法
|
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
|
JP7089483B2
(ja)
|
2016-05-11 |
2022-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
修飾された抗テネイシン抗体及び使用方法
|
|
JP7285076B2
(ja)
|
2016-05-11 |
2023-06-01 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｔｎｆファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
|
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
|
WO2017197234A1
(en)
|
2016-05-13 |
2017-11-16 |
Bioatla, Llc |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
KR20190007026A
(ko)
|
2016-05-17 |
2019-01-21 |
제넨테크, 인크. |
면역요법에서의 진단 및 사용을 위한 기질 유전자 특질
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
WO2017201488A1
(en)
|
2016-05-20 |
2017-11-23 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
|
EP3458101B1
(en)
|
2016-05-20 |
2020-12-30 |
H. Hoffnabb-La Roche Ag |
Protac antibody conjugates and methods of use
|
|
SG10202011624SA
(en)
|
2016-05-23 |
2021-01-28 |
Momenta Pharmaceuticals Inc |
Compositions and methods related to engineered fc constructs
|
|
CA3025162A1
(en)
|
2016-05-26 |
2017-11-30 |
Qilu Puget Sound Biotherapeutics Corporation |
Mixtures of antibodies
|
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック， インコーポレイテッド |
部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
CN113907043B
(zh)
|
2016-06-03 |
2023-08-01 |
瑞泽恩制药公司 |
表达外源末端脱氧核苷酸转移酶的非人动物
|
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
|
RU2022104399A
(ru)
|
2016-06-14 |
2022-05-05 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
|
CN109563124A
(zh)
|
2016-06-17 |
2019-04-02 |
豪夫迈·罗氏有限公司 |
多特异性抗体的纯化
|
|
JP7133477B2
(ja)
|
2016-06-24 |
2022-09-08 |
ジェネンテック， インコーポレイテッド |
抗ポリユビキチン多重特異性抗体
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
RU2019102008A
(ru)
|
2016-06-28 |
2020-07-28 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают рецептор соматостатина 2-го типа
|
|
JP7175769B2
(ja)
|
2016-06-30 |
2022-11-21 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
改善された養子ｔ細胞療法
|
|
AU2017290389B2
(en)
|
2016-07-01 |
2024-09-26 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
CN109415435B
(zh)
|
2016-07-04 |
2024-01-16 |
豪夫迈·罗氏有限公司 |
新型抗体形式
|
|
WO2018011691A1
(en)
|
2016-07-12 |
2018-01-18 |
Nestec S.A. |
Competitive immunoassay methods
|
|
JP7138630B2
(ja)
|
2016-07-14 |
2022-09-16 |
ゲンマブ エー／エス |
Ｃｄ４０およびｃｄ１３７に対する多重特異性抗体
|
|
PT3496739T
(pt)
|
2016-07-15 |
2021-06-21 |
Acceleron Pharma Inc |
Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
|
|
CA3030837A1
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
TWI790206B
(zh)
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
CN115925780A
(zh)
|
2016-07-22 |
2023-04-07 |
美国安进公司 |
含有Fc的蛋白的纯化方法
|
|
EP3487880A1
(en)
|
2016-07-25 |
2019-05-29 |
Biogen MA Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
|
FI3490582T3
(fi)
|
2016-07-27 |
2024-08-01 |
Acceleron Pharma Inc |
Koostumuksia käytettäväksi myelofibroosin hoitamisessa
|
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
CN117986372A
(zh)
|
2016-07-29 |
2024-05-07 |
中外制药株式会社 |
显示增加的备选fviii辅因子功能活性的双特异性抗体
|
|
CN110267677A
(zh)
|
2016-08-01 |
2019-09-20 |
诺华股份有限公司 |
使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
|
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
EP3496748A4
(en)
|
2016-08-05 |
2020-01-15 |
Medimmune, LLC |
ANTI-O2 ANTIBODIES AND USES THEREOF
|
|
TWI831965B
(zh)
|
2016-08-05 |
2024-02-11 |
日商中外製藥股份有限公司 |
Il-8相關疾病之治療用或預防用組成物
|
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック， インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
|
WO2018030806A1
(ko)
|
2016-08-10 |
2018-02-15 |
아주대학교산학협력단 |
항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
|
|
BR112019002394B1
(pt)
|
2016-08-10 |
2021-12-21 |
Ajou University Industry-Academic Cooperation Foundation |
Proteína heterodimérica fundida com fc e seu uso
|
|
JP7093767B2
(ja)
|
2016-08-11 |
2022-06-30 |
ジェネンテック， インコーポレイテッド |
ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
|
|
MX2019001572A
(es)
|
2016-08-15 |
2019-08-29 |
Genentech Inc |
Método de cromatografía para cuantificar un tensioactivo no iónico en una composición que comprende el tensioactivo no iónico y un polipéptido.
|
|
EP3502250B1
(en)
|
2016-08-22 |
2024-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Gene-modified rodent expressing human gpc3 polypeptide
|
|
EP3500594A4
(en)
|
2016-08-22 |
2020-03-11 |
Cho Pharma Inc. |
ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
|
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
US10870694B2
(en)
|
2016-09-02 |
2020-12-22 |
Dana Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
|
KR101928981B1
(ko)
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
|
|
TW201825511A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現免疫檢查點調節子的溶瘤病毒
|
|
IL313895A
(en)
|
2016-09-14 |
2024-08-01 |
Teneoone Inc |
CD3 binding antibodies
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
CN109689682B
(zh)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
|
US11242400B2
(en)
|
2016-09-21 |
2022-02-08 |
Aptevo Research And Development Llc |
CD123 binding proteins and related compositions and methods
|
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
|
CA3034105A1
(en)
|
2016-09-23 |
2018-03-29 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
SG11201900845YA
(en)
|
2016-09-23 |
2019-02-27 |
Genentech Inc |
Uses of il-13 antagonists for treating atopic dermatitis
|
|
MY194994A
(en)
*
|
2016-09-29 |
2022-12-30 |
Beijing Hanmi Pharmaceutical Co Ltd |
Heterodimeric immunoglobulin constructs and preparation methods thereof
|
|
US20180094052A1
(en)
|
2016-09-30 |
2018-04-05 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody
|
|
EP3519437B1
(en)
|
2016-09-30 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Bispecific antibodies against p95her2
|
|
EP3519820B1
(en)
|
2016-09-30 |
2020-12-09 |
H. Hoffnabb-La Roche Ag |
Spr-based dual-binding assay for the functional analysis of multispecific molecules
|
|
CA3039074A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma Inc. |
Compositions and method for treating kidney disease
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
KR20190075078A
(ko)
|
2016-10-05 |
2019-06-28 |
악셀레론 파마 인코포레이티드 |
ALK4:ActRIIB 이형다량체 및 이의 용도
|
|
WO2018067874A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma Inc. |
Variant actriib proteins and uses thereof
|
|
MX2019003934A
(es)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
|
AU2017341048A1
(en)
|
2016-10-07 |
2019-05-23 |
TCR2 Therapeutics Inc. |
Compositions and methods for T-cell receptors reprogramming using fusion proteins
|
|
AU2017341047B2
(en)
|
2016-10-07 |
2024-10-10 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
CR20190227A
(es)
|
2016-10-14 |
2019-08-29 |
Xencor Inc |
Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15ra y fragmentos de anticuerpo pd-1
|
|
EP3529619B1
(en)
|
2016-10-19 |
2021-06-30 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5a in a sample
|
|
JP7096240B2
(ja)
|
2016-10-19 |
2022-07-05 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
試料中の非結合ｃ５の定量化方法
|
|
JP7160484B2
(ja)
|
2016-10-19 |
2022-10-25 |
メディミューン，エルエルシー |
抗ｏ１抗体およびその使用
|
|
EP3529269A2
(en)
|
2016-10-19 |
2019-08-28 |
Invenra, Inc. |
Antibody constructs
|
|
WO2018081648A2
(en)
|
2016-10-29 |
2018-05-03 |
Genentech, Inc. |
Anti-mic antibidies and methods of use
|
|
BR112019008426A2
(pt)
|
2016-11-02 |
2019-09-03 |
Engmab Sarl |
anticorpo biespecífico contra bcma e cd3 e um fármaco imunológico para uso combinado no tratamento de mieloma múltiplo
|
|
WO2018144097A1
(en)
|
2016-11-04 |
2018-08-09 |
Akeagen Llc |
Genetically modified non-human animals and methods for producing heavy chain-only antibodies
|
|
EP3535299A1
(en)
|
2016-11-04 |
2019-09-11 |
Novimmune S.A. |
Anti-cd19 antibodies and methods of use thereof
|
|
WO2018089293A2
(en)
|
2016-11-08 |
2018-05-17 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-pd1 and anti-ctla4 antibodies
|
|
MX2019005497A
(es)
|
2016-11-09 |
2019-11-18 |
Uti Lp |
Moleculas de pmhc de clase ii recombinantes.
|
|
CA3043179A1
(en)
|
2016-11-10 |
2018-05-17 |
Keros Therapeutics, Inc. |
Gdnf fusion polypeptides and methods of use thereof
|
|
MA46753A
(fr)
|
2016-11-14 |
2019-09-18 |
Amgen Inc |
Protéines de liaison à l'antigène bispécifiques ou biparatopiques et utilisations de celles-ci
|
|
CN109923128A
(zh)
|
2016-11-15 |
2019-06-21 |
基因泰克公司 |
用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
|
|
JP2020502261A
(ja)
|
2016-11-16 |
2020-01-23 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ２３特異的抗体で乾癬を治療する方法
|
|
CA3043652A1
(en)
|
2016-11-18 |
2018-05-24 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
MX2019006045A
(es)
|
2016-11-23 |
2019-11-11 |
Harpoon Therapeutics Inc |
Proteinas triespecificas dirigidas a psma y metodos de uso.
|
|
AU2017363300A1
(en)
|
2016-11-23 |
2019-06-20 |
Harpoon Therapeutics, Inc. |
Prostate specific membrane antigen binding protein
|
|
TN2019000164A1
(en)
|
2016-11-23 |
2020-10-05 |
Bioverativ Therapeutics Inc |
Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
|
CA3045323A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
|
US20180193003A1
(en)
|
2016-12-07 |
2018-07-12 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
|
AU2017373945A1
(en)
|
2016-12-07 |
2019-06-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
CA3044679A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
WO2018106776A2
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
CN110114674B
(zh)
|
2016-12-13 |
2023-05-09 |
豪夫迈·罗氏有限公司 |
确定肿瘤样品中存在靶抗原的方法
|
|
CA3044416A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Delinia, Inc. |
Multivalent regulatory t cell modulators
|
|
CA3046023A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
|
WO2018112264A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
|
WO2018112223A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
|
CA3046093A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
|
TW201834710A
(zh)
|
2016-12-14 |
2018-10-01 |
美商寶珍那提公司 |
以整合素抑制劑治療胃腸道疾病
|
|
EP4410832A2
(en)
|
2016-12-14 |
2024-08-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
AU2017378398B2
(en)
|
2016-12-14 |
2023-02-02 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
|
|
EP3554345A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
|
EP3554540B1
(en)
|
2016-12-14 |
2023-08-02 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
AU2017380981A1
(en)
|
2016-12-19 |
2019-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1BB (CD137) agonists
|
|
US20200157190A1
(en)
|
2016-12-19 |
2020-05-21 |
Abcam Plc |
Monovalent and divalent binding proteins
|
|
CA3047557A1
(en)
|
2016-12-19 |
2018-06-28 |
Tolero Pharmaceuticals, Inc. |
Profiling peptides and methods for sensitivity profiling
|
|
EP3559034B1
(en)
|
2016-12-20 |
2020-12-02 |
H. Hoffnabb-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
|
AU2017384276B9
(en)
|
2016-12-21 |
2020-11-26 |
F. Hoffmann-La Roche Ag |
In vitro glycoengineering of antibodies
|
|
MX2019006123A
(es)
|
2016-12-21 |
2019-08-12 |
Hoffmann La Roche |
Metodo para glicomanipulacion in vitro de anticuerpos.
|
|
WO2018114772A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Assay for determining antibody or ligand binding and function
|
|
AU2017382251A1
(en)
|
2016-12-21 |
2019-07-11 |
Teneobio, Inc. |
Anti-BCMA heavy chain-only antibodies
|
|
JP6931058B2
(ja)
|
2016-12-21 |
2021-09-01 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
抗体のインビトロ糖鎖工学における酵素の再使用
|
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
|
WO2018122053A1
(en)
|
2016-12-29 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Anti-angiopoietin-2 antibody formulation
|
|
EP3565843A1
(en)
|
2017-01-03 |
2019-11-13 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Ｍｅｔ抗體以及其免疫結合物及用途
|
|
DK3565828T3
(da)
|
2017-01-05 |
2022-02-21 |
Kahr Medical Ltd |
Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
|
|
WO2018127918A1
(en)
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A sirp alpha-cd70 fusion protein and methods of use thereof
|
|
WO2018127916A1
(en)
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A pd1-cd70 fusion protein and methods of use thereof
|
|
WO2018127917A1
(en)
|
2017-01-05 |
2018-07-12 |
Kahr Medical Ltd. |
A pd1-41bbl fusion protein and methods of use thereof
|
|
CN110650748B
(zh)
|
2017-01-06 |
2024-01-02 |
动量制药公司 |
与经工程改造的Fc构建体相关的组合物和方法
|
|
US11390685B2
(en)
|
2017-01-06 |
2022-07-19 |
Biosion, Inc. |
ErbB2 antibodies and uses therefore
|
|
US11111305B2
(en)
|
2017-01-09 |
2021-09-07 |
Torch Therapeutics |
Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
|
|
TW201831517A
(zh)
|
2017-01-12 |
2018-09-01 |
美商優瑞科生物技術公司 |
靶向組織蛋白h3肽/mhc複合體之構築體及其用途
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3573658A4
(en)
|
2017-01-30 |
2021-07-21 |
Janssen Biotech, Inc. |
ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
|
|
WO2018144535A1
(en)
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
EP3576789A4
(en)
|
2017-02-01 |
2020-11-25 |
Centrymed Pharmaceuticals Inc. |
MONOMER HUMAN IGG1-FC AND BISPECIFIC ANTIBODIES
|
|
KR20240038148A
(ko)
|
2017-02-07 |
2024-03-22 |
얀센 바이오테크 인코포레이티드 |
활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
|
KR20190133160A
(ko)
|
2017-02-07 |
2019-12-02 |
다이이찌 산쿄 가부시키가이샤 |
항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
WO2018148445A1
(en)
|
2017-02-08 |
2018-08-16 |
Adimab, Llc |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
US10738131B2
(en)
|
2017-02-10 |
2020-08-11 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
|
WO2018151820A1
(en)
|
2017-02-16 |
2018-08-23 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
|
KR20240049621A
(ko)
|
2017-02-17 |
2024-04-16 |
사노피 |
디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
|
|
NZ756763A
(en)
|
2017-02-17 |
2023-04-28 |
Denali Therapeutics Inc |
Engineered transferrin receptor binding polypeptides
|
|
US10626169B2
(en)
|
2017-02-17 |
2020-04-21 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
|
BR112019017197A2
(pt)
|
2017-02-20 |
2020-04-14 |
Dragonfly Therapeutics Inc |
proteínas que se ligam a her2, nkg2d e cd16
|
|
WO2018155611A1
(ja)
|
2017-02-24 |
2018-08-30 |
中外製薬株式会社 |
薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
|
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
|
|
CN110546277B
(zh)
|
2017-03-01 |
2024-06-11 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
EP3589650A1
(en)
|
2017-03-02 |
2020-01-08 |
Novartis AG |
Engineered heterodimeric proteins
|
|
FI3592769T3
(fi)
|
2017-03-09 |
2024-07-30 |
Genmab As |
Vasta-aineita PD-L1:tä vastaan
|
|
NZ756132A
(en)
|
2017-03-10 |
2022-02-25 |
Hoffmann La Roche |
Method for producing multispecific antibodies
|
|
KR20190141146A
(ko)
|
2017-03-16 |
2019-12-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l2 변이체 면역조절 단백질 및 그의 용도
|
|
EP3596114A2
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
EP4306537A3
(en)
|
2017-03-16 |
2024-03-06 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
PT3443006T
(pt)
|
2017-03-17 |
2023-10-26 |
Sanofi Sa |
Proteínas de ligação triespecíficas e/ou trivalentes
|
|
CA3056248A1
(en)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Optimized antibody compositions for treatment of ocular disorders
|
|
CA3055985A1
(en)
|
2017-03-22 |
2018-09-27 |
Genentech, Inc. |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
|
US11492399B2
(en)
|
2017-03-24 |
2022-11-08 |
Zenyaku Kogyo Co., Ltd. |
Anti-IgM/B cell surface antigen bispecific antibody
|
|
AU2018241881B2
(en)
|
2017-03-27 |
2024-10-10 |
Biomunex Pharmaceuticals |
Stable multispecific antibodies
|
|
KR20190133198A
(ko)
|
2017-03-27 |
2019-12-02 |
셀진 코포레이션 |
면역원성의 감소를 위한 방법 및 조성물
|
|
SG10201911225WA
(en)
|
2017-03-28 |
2020-01-30 |
Genentech Inc |
Methods of treating neurodegenerative diseases
|
|
JP7205995B2
(ja)
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性ｔｎｆ受容体に対する二重特異性抗原結合分子
|
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
|
JP7196094B2
(ja)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激ｔｎｆ受容体のための二重特異性抗原結合分子
|
|
WO2018183941A2
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
|
US11596670B2
(en)
|
2017-03-30 |
2023-03-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
|
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
|
WO2018183934A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
|
CA3054632A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
|
UA127586C2
(uk)
|
2017-03-31 |
2023-10-25 |
Ґенмаб Холдінґ Б.В. |
Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування
|
|
BR112019020508A2
(pt)
|
2017-03-31 |
2020-08-04 |
Merus N.V. |
anticorpos biespecíficos de ligação a erbb-2 e erbb3 para utilização no tratamento de células que possuem um gene de fusão nrg1
|
|
JP7579703B2
(ja)
|
2017-04-01 |
2024-11-08 |
北京韓美薬品有限公司 |
抗ｐｄ－ｌ１／抗ｐｄ－１天然抗体構造様ヘテロダイマー二重特異性抗体およびその調製方法
|
|
KR102667951B1
(ko)
|
2017-04-03 |
2024-05-22 |
에프. 호프만-라 로슈 아게 |
Steap-1에 결합하는 항체
|
|
CA3055769A1
(en)
|
2017-04-03 |
2018-10-11 |
Oncologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
MY201482A
(en)
|
2017-04-03 |
2024-02-26 |
Hoffmann La Roche |
Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
|
|
WO2018187385A1
(en)
|
2017-04-03 |
2018-10-11 |
The Regents Of The University Of California |
Compositions and methods of diagnosing pancreatic cancer
|
|
AU2018247796A1
(en)
|
2017-04-04 |
2019-08-29 |
F. Hoffmann-La Roche Ag |
Novel bispecific antigen binding molecules capable of specific binding to CD40 and to FAP
|
|
HRP20221141T1
(hr)
|
2017-04-05 |
2022-11-25 |
F. Hoffmann - La Roche Ag |
Anti-lag3 protutijela
|
|
JP6997212B2
(ja)
|
2017-04-05 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ１及びｌａｇ３に特異的に結合する二重特異性抗体
|
|
AU2018250641A1
(en)
|
2017-04-11 |
2019-10-31 |
Inhibrx Biosciences, Inc. |
Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
|
|
CN110505883A
(zh)
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
|
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
|
JP2020517262A
(ja)
|
2017-04-21 |
2020-06-18 |
キンドレッド バイオサイエンシズ インコーポレイテッド |
獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
|
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
|
PE20200150A1
(es)
|
2017-04-21 |
2020-01-17 |
Genentech Inc |
Uso de antagonistas de klk5 para el tratamiento de una enfermedad
|
|
EP4230649A3
(en)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
|
SG11201909728XA
(en)
|
2017-04-26 |
2019-11-28 |
Eureka Therapeutics Inc |
Constructs specifically recognizing glypican 3 and uses thereof
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
CN110573626B
(zh)
|
2017-04-28 |
2024-05-03 |
豪夫迈·罗氏有限公司 |
抗体选择方法
|
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
CN110913908B
(zh)
|
2017-05-12 |
2022-05-27 |
哈普恩治疗公司 |
靶向msln的三特异性蛋白质及使用方法
|
|
CN113896792A
(zh)
|
2017-05-12 |
2022-01-07 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
|
WO2018213316A1
(en)
|
2017-05-16 |
2018-11-22 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
|
EP3630830A1
(en)
|
2017-05-23 |
2020-04-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
|
JP7220161B2
(ja)
|
2017-05-26 |
2023-02-09 |
ノビミューン エスアー |
抗ＣＤ４７ｘ抗メソテリン抗体およびそれを使用する方法
|
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
|
WO2018222901A1
(en)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
|
MX2019014274A
(es)
|
2017-06-02 |
2020-01-23 |
Hoffmann La Roche |
Metodo de tratamiento.
|
|
KR102661320B1
(ko)
|
2017-06-05 |
2024-05-03 |
얀센 바이오테크 인코포레이티드 |
이중특이성 항체 생성을 위한 표면 전하 조작 방법
|
|
NZ760232A
(en)
|
2017-06-07 |
2023-05-26 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
|
WO2018237037A2
(en)
|
2017-06-20 |
2018-12-27 |
Teneobio, Inc. |
HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
|
|
WO2018237006A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS
|
|
CN110831965B
(zh)
|
2017-06-21 |
2023-03-07 |
吉利德科学公司 |
靶向hiv gp120和cd3的多特异性抗体
|
|
CA3066774A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
|
MX2019015738A
(es)
|
2017-06-27 |
2020-02-20 |
Novartis Ag |
Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
|
|
MA49517A
(fr)
|
2017-06-30 |
2020-05-06 |
Xencor Inc |
Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
|
|
KR102611853B1
(ko)
|
2017-06-30 |
2023-12-08 |
자임워크스 비씨 인코포레이티드 |
안정화된 키메라 fabs
|
|
GB201710984D0
(en)
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
CN111316099A
(zh)
|
2017-07-12 |
2020-06-19 |
约翰霍普金斯大学 |
用于1型糖尿病诊断的基于脂蛋白体的znt8自身抗原
|
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
|
MX2020000604A
(es)
|
2017-07-21 |
2020-09-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
|
US10961318B2
(en)
|
2017-07-26 |
2021-03-30 |
Forty Seven, Inc. |
Anti-SIRP-α antibodies and related methods
|
|
CN110869050B
(zh)
|
2017-07-28 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
双特异性抗体配制剂
|
|
CN113896797B
(zh)
|
2017-08-01 |
2023-05-09 |
Ab工作室有限公司 |
双特异性抗体及其用途
|
|
JP2020529605A
(ja)
|
2017-08-01 |
2020-10-08 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
濾過およびクロマトグラフィ用ポッドならびにその使用方法
|
|
MY201526A
(en)
|
2017-08-03 |
2024-02-27 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
|
CR20190486A
(es)
|
2017-08-03 |
2020-02-10 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
|
AU2018309339A1
(en)
|
2017-08-04 |
2020-02-20 |
BioNTech SE |
Binding agents binding to PD-L1 and CD137 and use thereof
|
|
EA202090215A1
(ru)
|
2017-08-09 |
2020-07-01 |
Мерус Н.В. |
АНТИТЕЛА, СВЯЗЫВАЮЩИЕ EGFR И cMET
|
|
MX2020000903A
(es)
|
2017-08-11 |
2020-07-22 |
Genentech Inc |
Anticuerpos anti-cd8 y usos de los mismos.
|
|
WO2019036363A1
(en)
|
2017-08-14 |
2019-02-21 |
Progenity Inc. |
TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
US11485781B2
(en)
|
2017-08-17 |
2022-11-01 |
Massachusetts Institute Of Technology |
Multiple specificity binders of CXC chemokines
|
|
WO2019036856A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
DYNAMIC BANKS OF LIGHT CHAIN OF HUMAN ANTIBODY
|
|
US11578426B2
(en)
|
2017-08-21 |
2023-02-14 |
Adagene Inc. |
Dynamic human heavy chain antibody libraries
|
|
WO2019040674A1
(en)
|
2017-08-22 |
2019-02-28 |
Sanabio, Llc |
SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
|
|
CN111315773A
(zh)
|
2017-09-08 |
2020-06-19 |
马弗里克治疗公司 |
含有Fc区的条件性活化的结合部分
|
|
PE20212205A1
(es)
|
2017-09-08 |
2021-11-18 |
Maverick Therapeutics Inc |
Proteinas de union condicionalmente activadas restringidas
|
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
|
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
|
EP3688036A4
(en)
|
2017-09-25 |
2021-06-23 |
Dingfu Biotarget Co., Ltd |
PROTEINOUS HETERODIMER AND USE OF IT
|
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
|
SG10202007194PA
(en)
|
2017-09-29 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Multispecific antigen-binding molecules having blood coagulation factor viii (fviii) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ing
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
|
CA3078800A1
(en)
|
2017-10-10 |
2019-04-18 |
Sanofi |
Anti-cd38 antibodies and methods of use
|
|
EP4219540A3
(en)
|
2017-10-10 |
2023-12-06 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
CN111372950B
(zh)
|
2017-10-12 |
2024-11-05 |
免疫苏醒公司 |
Vegfr-抗体轻链融合蛋白
|
|
JP7256796B2
(ja)
|
2017-10-13 |
2023-04-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｔｈｏｍｓｅｎ－ｎｏｕｖｅｌｌｅ（ｔｎ）抗原に対するヒト抗体
|
|
EP3694871A4
(en)
|
2017-10-13 |
2021-11-10 |
Harpoon Therapeutics, Inc. |
B-CELL MATURATION ANTIG-BINDING PROTEINS
|
|
BR112020007196A2
(pt)
|
2017-10-13 |
2020-12-01 |
Harpoon Therapeutics, Inc. |
proteínas triespecíficas e métodos de uso
|
|
BR112020007576A2
(pt)
|
2017-10-18 |
2020-09-24 |
Novartis Ag |
composições e métodos para degradação de proteína seletiva
|
|
CA3078517A1
(en)
|
2017-10-18 |
2019-04-25 |
Alpine Immune Sciences, Inc. |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
|
AU2018350370B2
(en)
|
2017-10-18 |
2023-05-04 |
Csl Limited |
Human serum albumin variants and uses thereof
|
|
CA3078157A1
(en)
|
2017-10-20 |
2019-04-25 |
F.Hoffmann-La Roche Ag |
Method for generating multispecific antibodies from monospecific antibodies
|
|
MX2020004229A
(es)
|
2017-10-25 |
2020-07-22 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
|
|
EP3704145A1
(en)
|
2017-10-30 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Method for in vivo generation of multispecific antibodies from monospecific antibodies
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
CN111278856A
(zh)
|
2017-11-01 |
2020-06-12 |
豪夫迈·罗氏有限公司 |
三Fab-康特斯体
|
|
US11339221B2
(en)
|
2017-11-01 |
2022-05-24 |
Tufts Medical Center, Inc. |
Bispecific antibody constructs and methods of use
|
|
WO2019086499A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Novel tnf family ligand trimer-containing antigen binding molecules
|
|
CN111182944B
(zh)
|
2017-11-01 |
2022-11-22 |
豪夫迈·罗氏有限公司 |
双特异性2+1 Contorsbody
|
|
EP3704150A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
The compbody - a multivalent target binder
|
|
EP3704155A2
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Combination therapy with targeted ox40 agonists
|
|
JP7433224B2
(ja)
|
2017-11-02 |
2024-02-19 |
バイエル・アクチエンゲゼルシヤフト |
Ａｌｋ－１およびｂｍｐｒ－２に結合する二重特異性抗体
|
|
US20190160102A1
(en)
|
2017-11-03 |
2019-05-30 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems for tumor growth inhibition
|
|
EP3707510B1
(en)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
EP4428147A3
(en)
|
2017-11-09 |
2024-10-30 |
Keros Therapeutics, Inc. |
Activin receptor type iia variants and methods of use thereof
|
|
WO2019092181A1
(en)
|
2017-11-10 |
2019-05-16 |
Agency For Science, Technology And Research |
Il2rbeta/common gamma chain antibodies
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
KR20240023192A
(ko)
|
2017-11-24 |
2024-02-20 |
유큐(베이징) 바이오파마 코., 엘티디 |
항―ｏｘ４０ 항체 및 그의 용도
|
|
BR112020010514A2
(pt)
|
2017-11-29 |
2020-11-24 |
Csl Limited |
método para tratar ou prevenir lesão por isquemia-reperfusão
|
|
SG11202003944WA
(en)
|
2017-12-08 |
2020-06-29 |
Argenx Bvba |
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
CA3079039A1
(en)
|
2017-12-14 |
2019-06-20 |
F. Hoffmann-La Roche Ag |
Use of a cea cd3 bispecific antibody and a pd-1 axis binding antagonist in a dosage regime to treat cancer
|
|
CA3085782A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Wnt surrogate molecules and uses thereof
|
|
CA3086199A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
JP7418332B2
(ja)
|
2017-12-19 |
2024-01-19 |
スロゼン オペレーティング， インコーポレイテッド |
抗フリズルド抗体及び使用方法
|
|
CA3085785A1
(en)
|
2017-12-19 |
2019-06-27 |
Surrozen, Inc. |
Anti-lrp5/6 antibodies and methods of use
|
|
WO2019126536A1
(en)
|
2017-12-20 |
2019-06-27 |
Alexion Pharmaceuticals Inc. |
Humanized anti-cd200 antibodies and uses thereof
|
|
AU2018390881A1
(en)
|
2017-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to HLA-A2/WT1
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
US11945839B2
(en)
|
2017-12-22 |
2024-04-02 |
Hoffmann-La Roche Inc. |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
|
CN111448217A
(zh)
|
2017-12-22 |
2020-07-24 |
阿根思公司 |
双特异性抗原结合构建体
|
|
TW201929907A
(zh)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Pilra結合劑用於治療疾病之用途
|
|
MX2020006715A
(es)
|
2017-12-27 |
2020-08-20 |
Teneobio Inc |
Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
|
|
AU2018396964C1
(en)
|
2017-12-28 |
2024-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against PD-L1
|
|
TWI817974B
(zh)
|
2017-12-28 |
2023-10-11 |
日商中外製藥股份有限公司 |
細胞毒性誘導治療劑
|
|
CN117050184A
(zh)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
针对tigit的单域抗体和其变体
|
|
CN111479588A
(zh)
|
2017-12-29 |
2020-07-31 |
豪夫迈·罗氏有限公司 |
用于改善抗vegf抗体的vegf受体阻断选择性的方法
|
|
US11440957B2
(en)
|
2017-12-29 |
2022-09-13 |
Alector Llc |
Anti-TMEM106B antibodies and methods of use thereof
|
|
WO2019136179A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
WO2019140116A2
(en)
|
2018-01-10 |
2019-07-18 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
|
SG11202006410WA
(en)
|
2018-01-12 |
2020-08-28 |
Genzyme Corp |
Methods for the quantitation of polypeptides
|
|
JP7366908B2
(ja)
|
2018-01-15 |
2023-10-23 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
Ｐｄ－１に対する単一ドメイン抗体及びその変異体
|
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
BR112020013405A2
(pt)
|
2018-01-25 |
2020-12-01 |
Acm Biolabs Pte Ltd. |
polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso
|
|
RU2020127792A
(ru)
|
2018-01-26 |
2022-02-28 |
Дженентек, Инк. |
СЛИТЫЕ БЕЛКИ IL-22- Fc И СПОСОБЫ ПРИМЕНЕНИЯ
|
|
PL3743088T3
(pl)
|
2018-01-26 |
2023-03-20 |
F. Hoffmann-La Roche Ag |
Kompozycje i sposoby stosowania il-22 fc
|
|
WO2019152660A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3746476A1
(en)
|
2018-01-31 |
2020-12-09 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
|
JP2021511793A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
|
|
EP3746470A1
(en)
|
2018-01-31 |
2020-12-09 |
F. Hoffmann-La Roche AG |
Stabilized immunoglobulin domains
|
|
FR3077296A1
(fr)
|
2018-02-01 |
2019-08-02 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Dimeres de variants du facteur x
|
|
WO2019148410A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1 antibodies
|
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
|
EP3749359A1
(en)
|
2018-02-06 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Treatment of ophthalmologic diseases
|
|
KR20200118065A
(ko)
|
2018-02-08 |
2020-10-14 |
제넨테크, 인크. |
이중특이적 항원-결합 분자 및 이의 사용 방법
|
|
US20210047407A1
(en)
|
2018-02-08 |
2021-02-18 |
Amgen Inc. |
Low ph pharmaceutical antibody formulation
|
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
|
US11884733B2
(en)
|
2018-02-08 |
2024-01-30 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the NKG2D receptor
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
CR20200394A
(es)
|
2018-02-09 |
2020-11-05 |
Genentech Inc |
Métodos terapéuticos y diagnósticos para enfermedades inflrmatorias mediadas por mostocitos
|
|
JP2021512624A
(ja)
|
2018-02-11 |
2021-05-20 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
抗ｐｄ−１／抗ｖｅｇｆ天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造
|
|
US20200399373A1
(en)
|
2018-02-14 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule and combination
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
MX2020008502A
(es)
|
2018-02-21 |
2020-09-25 |
Genentech Inc |
Dosis para el tratamiento con proteinas de fusion il-22 fc.
|
|
WO2019161536A1
(en)
|
2018-02-23 |
2019-08-29 |
Eucure (Beijing) Biopharma Co. , Ltd |
Anti-pd-1 antibodies and uses thereof
|
|
JP7474709B2
(ja)
|
2018-02-27 |
2024-04-25 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
|
|
MX2020009265A
(es)
|
2018-03-05 |
2020-10-01 |
Janssen Biotech Inc |
Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
|
|
KR20200132913A
(ko)
|
2018-03-13 |
2020-11-25 |
에프. 호프만-라 로슈 아게 |
4-1bb 작용제와 항-cd20 항체의 치료 조합
|
|
SG11202008770QA
(en)
|
2018-03-13 |
2020-10-29 |
Zymeworks Inc |
Anti-her2 biparatopic antibody-drug conjugates and methods of use
|
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
JP7037218B2
(ja)
|
2018-03-14 |
2022-03-16 |
サーフィス オンコロジー インコーポレイテッド |
Ｃｄ３９と結合する抗体及びその使用
|
|
BR112020014591A2
(pt)
|
2018-03-14 |
2020-12-01 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
anticorpos anticlaudina 18.2
|
|
WO2019178364A2
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
CN112334484A
(zh)
|
2018-03-14 |
2021-02-05 |
诺维莫尼公司 |
抗-CD3ε抗体及其应用方法
|
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|
|
WO2019175380A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
EP3765064A1
(en)
|
2018-03-16 |
2021-01-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
WO2019175384A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
|
EP3768720A4
(en)
|
2018-03-20 |
2022-01-05 |
Wuxi Biologics Ireland Limited |
NEW ANTI-LAG-3 ANTIBODY POLYPEPTIDE
|
|
MX2020009774A
(es)
|
2018-03-21 |
2020-10-08 |
Alx Oncology Inc |
Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
|
|
CN112512571A
(zh)
|
2018-03-22 |
2021-03-16 |
表面肿瘤学公司 |
抗il-27抗体及其用途
|
|
GB201804701D0
(en)
|
2018-03-23 |
2018-05-09 |
Gammadelta Therapeutics Ltd |
Lymphocytes expressing heterologous targeting constructs
|
|
CN112040769B
(zh)
|
2018-03-24 |
2023-05-16 |
瑞泽恩制药公司 |
用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途
|
|
SG11202008620VA
(en)
|
2018-03-26 |
2020-10-29 |
Regeneron Pharma |
Humanized rodents for testing therapeutic agents
|
|
US20190300610A1
(en)
|
2018-03-29 |
2019-10-03 |
Hummingbird Bioscience Pte. Ltd. |
Vista antigen-binding molecules
|
|
KR20200135510A
(ko)
|
2018-03-29 |
2020-12-02 |
제넨테크, 인크. |
포유류 세포들에서 젖분비자극 활성의 조절
|
|
FR3079430A1
(fr)
|
2018-03-29 |
2019-10-04 |
Primequal Sa |
Dispositif et embout d'application et d'etalement d'un produit de type liquide, gel ou pate
|
|
WO2019185163A1
(en)
|
2018-03-29 |
2019-10-03 |
Hummingbird Bioscience Holdings Pte. Ltd. |
Vista antigen-binding molecules
|
|
WO2019185164A1
(en)
|
2018-03-29 |
2019-10-03 |
Hummingbird Bioscience Holdings Pte. Ltd. |
Her3 antigen-binding molecules
|
|
TW202003567A
(zh)
|
2018-03-30 |
2020-01-16 |
大陸商南京傳奇生物科技有限公司 |
針對lag-3之單一結構域抗體及其用途
|
|
WO2019195623A2
(en)
|
2018-04-04 |
2019-10-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
US10870691B2
(en)
|
2018-04-05 |
2020-12-22 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis B virus protein X
|
|
WO2019195561A2
(en)
|
2018-04-06 |
2019-10-10 |
BioLegend, Inc. |
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
|
|
US10654944B2
(en)
|
2018-04-10 |
2020-05-19 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
|
CN112218686A
(zh)
|
2018-04-11 |
2021-01-12 |
印希比股份有限公司 |
具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
|
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
CA3094235A1
(en)
|
2018-04-13 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
IL278090B2
(en)
|
2018-04-18 |
2024-07-01 |
Xencor Inc |
Proteins from heterodimeric il-15/il-15rα Ochi-fc and their uses
|
|
WO2019204646A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
EP3781599A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
CN112074538B
(zh)
|
2018-04-30 |
2024-10-18 |
瑞泽恩制药公司 |
结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途
|
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
|
MA52590A
(fr)
|
2018-05-11 |
2021-03-17 |
Janssen Biotech Inc |
Méthodes de traitement de la dépression à l'aide d'anticorps il-23
|
|
KR20210021468A
(ko)
|
2018-05-14 |
2021-02-26 |
웨어울프 세라퓨틱스, 인크. |
활성화가능한 사이토카인 폴리펩타이드 및 이의 사용 방법
|
|
FI3794024T3
(fi)
|
2018-05-14 |
2023-08-10 |
Werewolf Therapeutics Inc |
Aktivoitavia interleukiini-2-polypeptidejä ja niiden käyttömenetelmiä
|
|
AU2019268410A1
(en)
|
2018-05-16 |
2020-12-17 |
Csl Limited |
Soluble complement receptor type 1 variants and uses thereof
|
|
SG11202011306TA
(en)
|
2018-05-16 |
2020-12-30 |
Janssen Biotech Inc |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
|
WO2019222663A1
(en)
|
2018-05-17 |
2019-11-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-cd63 antibodies, conjugates, and uses thereof
|
|
MA52940A
(fr)
|
2018-05-18 |
2021-04-28 |
Incyte Corp |
Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
|
|
JP7206297B2
(ja)
|
2018-05-18 |
2023-01-17 |
エフ．ホフマン－ラ ロシュ アーゲー |
大核酸の細胞内標的指向送達
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
SG11202011082UA
(en)
|
2018-05-25 |
2020-12-30 |
Alector Llc |
Anti-sirpa antibodies and methods of use thereof
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
MX2020012797A
(es)
|
2018-06-01 |
2021-03-25 |
Compugen Ltd |
Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
|
|
CN112533952B
(zh)
|
2018-06-01 |
2023-03-07 |
大有华夏生物医药集团有限公司 |
治疗疾病或病况的组合物及其用途
|
|
CR20200571A
(es)
|
2018-06-01 |
2021-01-18 |
Novartis Ag |
Moléculas de únion contra bcma y usos de las mismas
|
|
EP3801767A1
(en)
|
2018-06-08 |
2021-04-14 |
Alector LLC |
Anti-siglec-7 antibodies and methods of use thereof
|
|
EP3802825A1
(en)
|
2018-06-08 |
2021-04-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
TWI848953B
(zh)
|
2018-06-09 |
2024-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
|
KR20210020932A
(ko)
|
2018-06-13 |
2021-02-24 |
노파르티스 아게 |
Bcma 키메라 항원 수용체 및 이의 용도
|
|
MX2020013652A
(es)
|
2018-06-14 |
2022-04-21 |
Regeneron Pharma |
Animales no humanos con capacidad de reordenamiento dh-dh en las secuencias codificantes de la cadena pesada de inmunoglobulina.
|
|
FR3082427B1
(fr)
|
2018-06-14 |
2020-09-25 |
Lab Francais Du Fractionnement |
Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
CA3101642A1
(en)
|
2018-06-18 |
2019-12-26 |
Anwita Biosciences, Inc. |
Anti-mesothelin constructs and uses thereof
|
|
EP3806904A4
(en)
|
2018-06-18 |
2022-04-27 |
Eureka Therapeutics, Inc. |
PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED CONSTRUCTS AND USES THEREOF
|
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
CA3104467A1
(en)
|
2018-06-20 |
2019-12-26 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
|
EP3812399A4
(en)
|
2018-06-20 |
2022-03-23 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR ACTIVATING THE IMMUNE RESPONSE OF A TARGET CELL AND ASSOCIATED COMPOSITION
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
|
MX2020014203A
(es)
|
2018-06-21 |
2021-05-27 |
Yumanity Therapeutics Inc |
Composiciones y métodos para el tratamiento y la prevención de trastornos neurológicos.
|
|
US12129298B2
(en)
|
2018-06-21 |
2024-10-29 |
Daiichi Sankyo Company, Limited |
Compositions including CD3 antigen binding fragments and uses thereof
|
|
EP3810624A4
(en)
|
2018-06-22 |
2022-07-06 |
Cugene Inc. |
CYTOKINE-BASED BIOACTIVABLE MEDICATIONS AND METHODS OF USE THEREOF
|
|
MA52968A
(fr)
|
2018-06-23 |
2021-04-28 |
Hoffmann La Roche |
Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
|
|
SG11202013163TA
(en)
|
2018-06-29 |
2021-01-28 |
Incyte Corp |
Formulations of an axl/mer inhibitor
|
|
WO2020006374A2
(en)
|
2018-06-29 |
2020-01-02 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
|
CR20210047A
(es)
|
2018-07-02 |
2021-05-21 |
Amgen Inc |
Proteína de unión al antígeno anti-steap1
|
|
KR102579246B1
(ko)
|
2018-07-03 |
2023-09-19 |
길리애드 사이언시즈, 인코포레이티드 |
HIV gp120을 표적화하는 항체 및 사용 방법
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
|
AU2019297361B2
(en)
|
2018-07-05 |
2024-06-27 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020012486A1
(en)
|
2018-07-11 |
2020-01-16 |
Kahr Medical Ltd. |
SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
|
|
TWI809147B
(zh)
|
2018-07-13 |
2023-07-21 |
美商阿列克特有限責任公司 |
抗分揀蛋白抗體及其使用方法
|
|
TW202019965A
(zh)
|
2018-07-16 |
2020-06-01 |
美商安進公司 |
治療多發性骨髓瘤之方法
|
|
EP3824295A4
(en)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY
|
|
CN112839644A
(zh)
|
2018-07-18 |
2021-05-25 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂、抗代谢物和铂剂治疗肺癌的方法
|
|
AU2018432434A1
(en)
|
2018-07-20 |
2021-01-28 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-CD40 antibodies and uses thereof
|
|
BR112021000727A2
(pt)
|
2018-07-20 |
2021-04-13 |
Surface Oncology, Inc. |
Composições anti-cd112r e métodos
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
CN112752768A
(zh)
|
2018-07-27 |
2021-05-04 |
艾利妥 |
抗siglec-5抗体及其使用方法
|
|
CA3106829A1
(en)
|
2018-08-03 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
|
TW202019478A
(zh)
|
2018-08-08 |
2020-06-01 |
美商建南德克公司 |
色胺酸衍生物及ｌ－甲硫胺酸用於蛋白質調配之用途
|
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
CA3051549A1
(en)
|
2018-08-09 |
2020-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
|
EP3833443A1
(en)
|
2018-08-09 |
2021-06-16 |
Compass Therapeutics LLC |
Antigen binding agents that bind cd277 and uses thereof
|
|
AU2019318031A1
(en)
|
2018-08-10 |
2021-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-CD137 antigen-binding molecule and utilization thereof
|
|
EP3837286A4
(en)
|
2018-08-16 |
2022-08-10 |
The Johns Hopkins University |
ANTIBODIES TO HUMAN ZNT8
|
|
US20220267454A1
(en)
|
2018-08-16 |
2022-08-25 |
Cantargia Ab |
Anti-IL1RAP Antibody Compositions
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
US20210188957A1
(en)
|
2018-08-29 |
2021-06-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule
|
|
CN113039209A
(zh)
|
2018-08-30 |
2021-06-25 |
T细胞受体治疗公司 |
用于使用融合蛋白进行tcr重编程的组合物和方法
|
|
CA3109959A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
PE20211096A1
(es)
|
2018-08-31 |
2021-06-14 |
Alector Llc |
Anticuerpos anti-cd33 y metodos para usarlos
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
AU2019337759A1
(en)
|
2018-09-10 |
2021-03-11 |
Legend Biotech Ireland Limited |
Single-domain antibodies against CD33 and constructs thereof
|
|
US20220105176A1
(en)
|
2018-09-12 |
2022-04-07 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
|
JP7387743B2
(ja)
|
2018-09-12 |
2023-11-28 |
ユーカー（ベンジン） バイオファーマ カンパニー，リミテッド |
抗ｔｎｆｒｓｆ９抗体及びその使用
|
|
EP3849565A4
(en)
|
2018-09-12 |
2022-12-28 |
Fred Hutchinson Cancer Research Center |
REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS
|
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
AU2019345151A1
(en)
|
2018-09-19 |
2021-04-29 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant CD80 fusion proteins and related constructs
|
|
AU2019342133A1
(en)
|
2018-09-21 |
2021-04-22 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
CA3155293A1
(en)
|
2018-09-24 |
2020-04-02 |
The Medical College Of Wisconsin, Inc. |
System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
|
|
KR20210086623A
(ko)
|
2018-09-25 |
2021-07-08 |
하푼 테라퓨틱스, 인크. |
Ddl3 결합 단백질 및 사용 방법
|
|
EP3856343A1
(en)
|
2018-09-25 |
2021-08-04 |
Biolegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
|
BR112021005907A2
(pt)
|
2018-09-27 |
2021-08-10 |
Xilio Development, Inc. |
citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
|
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
PE20211863A1
(es)
|
2018-10-01 |
2021-09-21 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
|
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
CA3115163A1
(en)
|
2018-10-04 |
2020-04-09 |
Genmab Holding B.V. |
Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
|
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
|
AU2019357467A1
(en)
|
2018-10-09 |
2021-05-27 |
Sanofi |
Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
|
|
JP2022504822A
(ja)
|
2018-10-11 |
2022-01-13 |
インヒブルクス インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
CN113166261A
(zh)
|
2018-10-11 |
2021-07-23 |
印希比股份有限公司 |
B7h3单域抗体及其治疗性组合物
|
|
WO2020076992A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
AU2019356573A1
(en)
|
2018-10-11 |
2021-05-27 |
Inhibrx Biosciences, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
|
CA3116188A1
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
CA3117212A1
(en)
|
2018-10-23 |
2020-04-30 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|
|
CA3115110A1
(en)
|
2018-10-24 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
JP2022512798A
(ja)
|
2018-10-25 |
2022-02-07 |
エフ．ホフマン－ラ ロシュ アーゲー |
抗体ＦｃＲｎ結合の改変
|
|
GB201817354D0
(en)
|
2018-10-25 |
2018-12-12 |
Hummingbird Bioscience Pte Ltd |
Engineered FC
|
|
SG11202103334YA
(en)
|
2018-10-26 |
2021-05-28 |
Hoffmann La Roche |
Multispecific antibody screening method using recombinase mediated cassette exchange
|
|
CA3117409A1
(en)
|
2018-10-29 |
2020-05-07 |
Biogen Ma Inc. |
Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
|
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
|
BR112021007946A2
(pt)
|
2018-10-29 |
2021-08-03 |
F. Hoffmann-La Roche Ag |
formulação de anticorpo
|
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
|
AU2019375413A1
(en)
|
2018-11-05 |
2021-05-27 |
Genentech, Inc. |
Methods of producing two chain proteins in prokaryotic host cells
|
|
AU2019375014A1
(en)
|
2018-11-06 |
2021-05-27 |
BioNTech SE |
Antibody formulation
|
|
WO2020094836A1
(en)
|
2018-11-09 |
2020-05-14 |
Euchloe Bio Pte. Ltd. |
Il2rbeta/common gamma chain antibodies
|
|
TW202031683A
(zh)
|
2018-11-09 |
2020-09-01 |
新加坡商優其洛伊生物私人有限公司 |
介白素2受體β(IL2Rβ)/共同γ鏈抗體
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
JP7469305B2
(ja)
|
2018-11-19 |
2024-04-16 |
バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド |
抗ｐｄ－１抗体およびその使用
|
|
EP3883607A4
(en)
|
2018-11-20 |
2022-08-17 |
Janssen Biotech, Inc. |
SAFE AND EFFECTIVE PROCESS FOR TREATING PSORIASIS WITH A SPECIFIC ANTI-IL-23 ANTIBODY
|
|
WO2020104496A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
JP2022510276A
(ja)
|
2018-11-30 |
2022-01-26 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｃｄ８６バリアント免疫調節タンパク質およびその使用
|
|
CN113490499A
(zh)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
|
|
EP3891186A1
(en)
|
2018-12-05 |
2021-10-13 |
MorphoSys AG |
Multispecific antigen-binding molecules
|
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
KR20210106491A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
약제학적 조합물
|
|
JP2022514290A
(ja)
|
2018-12-20 |
2022-02-10 |
ジェネンテック， インコーポレイテッド |
改変抗体ｆｃおよび使用方法
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
EA202191656A1
(ru)
|
2018-12-21 |
2021-10-26 |
23Эндми, Инк. |
Анти-il-36 антитела и способы их применения
|
|
US20220064327A1
(en)
|
2018-12-21 |
2022-03-03 |
Kymab Limited |
Fixaxfx bispecific antibody with common light chain
|
|
CA3121804A1
(en)
|
2018-12-21 |
2020-06-25 |
Genentech, Inc. |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
|
AU2019410075B2
(en)
|
2018-12-21 |
2022-08-25 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3
|
|
WO2020127628A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted superagonistic cd28 antigen binding molecules
|
|
CR20210326A
(es)
|
2018-12-21 |
2021-09-10 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
|
|
KR20210108421A
(ko)
|
2018-12-24 |
2021-09-02 |
사노피 |
돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질
|
|
JP2024504880A
(ja)
|
2018-12-24 |
2024-02-02 |
サノフイ |
疑似ｆａｂベースの多重特異性結合タンパク質
|
|
EP3674319A1
(en)
|
2018-12-24 |
2020-07-01 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
|
EP3674316A1
(en)
|
2018-12-24 |
2020-07-01 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
|
CN111378045B
(zh)
|
2018-12-28 |
2022-08-02 |
长春金赛药业有限责任公司 |
二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
|
|
EP3902560A1
(en)
|
2018-12-28 |
2021-11-03 |
F. Hoffmann-La Roche AG |
A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
JP7241888B2
(ja)
|
2018-12-30 |
2023-03-17 |
エフ． ホフマン－ラ ロシュ アーゲー |
ｐＨ勾配ＳＰＲに基づく結合アッセイ
|
|
CN113597319A
(zh)
|
2019-01-04 |
2021-11-02 |
分解治疗有限责任公司 |
用核酸酶融合蛋白治疗干燥症
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
CN113474371A
(zh)
|
2019-01-16 |
2021-10-01 |
指南针制药有限责任公司 |
与人cd137结合的抗体的制剂及其用途
|
|
EP3911677A1
(en)
|
2019-01-18 |
2021-11-24 |
Janssen Biotech, Inc. |
Gprc5d chimeric antigen receptors and cells expressing the same
|
|
BR112021014481A2
(pt)
|
2019-01-23 |
2021-10-13 |
Genentech, Inc. |
Método para produzir um polipeptídeo multimérico, método para produzir um anticorpo biespecífico, pluralidade de polipeptídeos multiméricos, células hospedeiras eucarióticas recombinantes, método para identificar uma combinação de sequências e kit de polinucleotídeos
|
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
|
KR20210121137A
(ko)
|
2019-01-29 |
2021-10-07 |
샤이어-엔피에스 파마슈티칼즈, 인크. |
부갑상선 호르몬 변이체
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
US20220144798A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
JP7483732B2
(ja)
|
2019-02-15 |
2024-05-15 |
ノバルティス アーゲー |
３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
JP2022521358A
(ja)
|
2019-02-18 |
2022-04-06 |
バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド |
ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
|
|
EP3927744A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
SG11202109122SA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Anti-tcr antibody molecules and uses thereof
|
|
GB2599227B
(en)
|
2019-02-21 |
2024-05-01 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
|
|
EP3927747A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
WO2020169698A1
(en)
|
2019-02-21 |
2020-08-27 |
F. Hoffmann-La Roche Ag |
Sensitization of cancer cells to tnf by bet inhibition
|
|
CA3131016A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US12006345B2
(en)
|
2019-02-21 |
2024-06-11 |
Xencor, Inc. |
Untargeted and targeted IL-10 Fc-fusion proteins
|
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
US11639388B2
(en)
*
|
2019-02-22 |
2023-05-02 |
Wuhan Yzy Biopharma Co., Ltd. |
CD3 antigen binding fragment and application thereof
|
|
JP2022523204A
(ja)
|
2019-02-25 |
2022-04-21 |
ノバルティス アーゲー |
ウイルス送達のためのメソポーラスシリカ粒子組成物
|
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
US20220235144A1
(en)
|
2019-03-04 |
2022-07-28 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-sirp-alpha antibodies
|
|
US20220144949A1
(en)
|
2019-03-05 |
2022-05-12 |
Takeda Pharmaceutical Limited Company |
CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS
|
|
WO2020181140A1
(en)
|
2019-03-05 |
2020-09-10 |
Maverick Therapeutics, Inc. |
Constrained conditionally activated binding proteins
|
|
AU2020238811A1
(en)
|
2019-03-08 |
2021-07-22 |
Genentech, Inc. |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
|
KR20210141555A
(ko)
|
2019-03-14 |
2021-11-23 |
제넨테크, 인크. |
Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
|
|
CN113631575A
(zh)
|
2019-03-15 |
2021-11-09 |
笛卡尔疗法股份有限公司 |
抗bcma嵌合抗原受体
|
|
US20220153875A1
(en)
|
2019-03-19 |
2022-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
US20230051872A1
(en)
|
2019-03-22 |
2023-02-16 |
Reflexion Pharmaceuticals, Inc. |
Multivalent D-Peptidic Compounds for Target Proteins
|
|
EP3941580A1
(en)
|
2019-03-22 |
2022-01-26 |
Reflexion Pharmaceuticals, Inc. |
D-peptidic compounds for vegf
|
|
MX2021011830A
(es)
|
2019-03-29 |
2022-01-24 |
Atarga Llc |
Anticuerpo anti fgf23.
|
|
EP3947440A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Method for generating avid-binding multispecific antibodies
|
|
JP7249432B2
(ja)
|
2019-03-29 |
2023-03-30 |
エフ． ホフマン－ラ ロシュ アーゲー |
多価分子の機能分析のための、ｓｐｒをベースとする結合アッセイ
|
|
KR20220005471A
(ko)
|
2019-04-08 |
2022-01-13 |
바이오젠 엠에이 인코포레이티드 |
항-인테그린 항체 및 이의 용도
|
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
|
WO2020208124A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using a cea cd3 bispecific antibody and a wnt signaling inhibitor
|
|
EP3953455A1
(en)
|
2019-04-12 |
2022-02-16 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
JP7301155B2
(ja)
|
2019-04-12 |
2023-06-30 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
リポカリンムテインを含む二重特異性抗原結合分子
|
|
WO2020214867A1
(en)
|
2019-04-17 |
2020-10-22 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant icos ligand (icosl) fusion proteins
|
|
JP2022528804A
(ja)
|
2019-04-18 |
2022-06-15 |
ジェネンテック， インコーポレイテッド |
抗体力価試験
|
|
JP2022529154A
(ja)
|
2019-04-19 |
2022-06-17 |
ジェネンテック， インコーポレイテッド |
抗ｍｅｒｔｋ抗体及びその使用方法
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
EP3959237A1
(en)
|
2019-04-25 |
2022-03-02 |
F. Hoffmann-La Roche AG |
Therapeutic multispecific polypeptides activated by polypeptide chain exchange
|
|
TW202106714A
(zh)
|
2019-04-25 |
2021-02-16 |
瑞士商赫孚孟拉羅股份公司 |
藉由多肽鏈交換製造抗體衍生之多肽
|
|
EP3959238A1
(en)
|
2019-04-25 |
2022-03-02 |
F. Hoffmann-La Roche AG |
Activatable therapeutic multispecific polypeptides with extended half-life
|
|
CN113795514A
(zh)
|
2019-05-09 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
制备抗体的方法
|
|
WO2020229378A1
(en)
|
2019-05-13 |
2020-11-19 |
F. Hoffmann-La Roche Ag |
Interference-suppressed pharmacokinetic immunoassay
|
|
JP7550794B2
(ja)
|
2019-05-14 |
2024-09-13 |
ジェネンテック， インコーポレイテッド |
濾胞性リンパ腫を処置するための抗ｃｄ７９ｂ免疫複合体の使用方法
|
|
CN114450022A
(zh)
|
2019-05-14 |
2022-05-06 |
狼人治疗公司 |
分离部分及其使用方法
|
|
WO2020230142A1
(en)
|
2019-05-15 |
2020-11-19 |
Neotx Therapeutics Ltd. |
Cancer treatment
|
|
WO2020232295A1
(en)
|
2019-05-16 |
2020-11-19 |
Procisedx Inc. |
An assay method for the detection of vcam-1 and alpha-2-macroglobulin in blood
|
|
EP3969906A1
(en)
|
2019-05-16 |
2022-03-23 |
ProciseDx Inc. |
Assay detection methods for vcam-1 and calprotectin
|
|
EP3969119A1
(en)
|
2019-05-17 |
2022-03-23 |
Xencor, Inc. |
Il-7-fc-fusi0n proteins
|
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
|
CA3138360A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
CN114173810B
(zh)
|
2019-05-21 |
2024-09-06 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
WO2020236528A1
(en)
|
2019-05-23 |
2020-11-26 |
Procisedx Inc. |
Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibody
|
|
CA3138241A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
|
CA3141690A1
(en)
|
2019-05-30 |
2020-12-03 |
Amgen Inc. |
Engineering the hinge region to drive antibody dimerization
|
|
CN114126648A
(zh)
|
2019-05-31 |
2022-03-01 |
Alx肿瘤生物技术公司 |
用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法
|
|
BR112021024401A2
(pt)
|
2019-06-03 |
2022-04-19 |
Janssen Biotech Inc |
Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa
|
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
|
EP4023230A4
(en)
|
2019-06-05 |
2023-11-15 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIBODY CLEAVAGE SITE BINDING MOLECULE
|
|
JP2022535125A
(ja)
|
2019-06-06 |
2022-08-04 |
プロサイセデクス インコーポレイティド |
血中ヘモグロビンＡ１Ｃ（ＨｂＡ１ｃ）の検出
|
|
US11591388B2
(en)
|
2019-06-07 |
2023-02-28 |
argenx BV |
Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration
|
|
TW202112395A
(zh)
|
2019-06-10 |
2021-04-01 |
日商中外製藥股份有限公司 |
用於與細胞激素抑制劑組合使用之抗t細胞抗原結合分子
|
|
BR112021025077A2
(pt)
|
2019-06-11 |
2022-05-03 |
Alector Llc |
Anticorpos anti-sortilina para uso em terapia
|
|
MX2021015337A
(es)
|
2019-06-14 |
2022-01-18 |
Teneobio Inc |
Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
|
|
BR112021025462A2
(pt)
|
2019-06-19 |
2022-02-01 |
Hoffmann La Roche |
Métodos para produzir um anticorpo bivalente biespecífico e uma célula de mamífero recombinante, ácido desoxirribonucleico, uso de um ácido desoxirribonucleico, célula de mamífero recombinante e composição
|
|
KR20220024637A
(ko)
|
2019-06-19 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법
|
|
JP2022537202A
(ja)
|
2019-06-19 |
2022-08-24 |
エフ．ホフマン－ラ ロシュ アーゲー |
所定の構成の複数の発現カセットの標的指向性組込みによって多価二重特異性抗体発現細胞を作製するための方法
|
|
AU2020294880B2
(en)
|
2019-06-19 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Method for the generation of a protein expressing cell by targeted integration using Cre mRNA
|
|
CA3140192A1
(en)
|
2019-06-19 |
2020-12-24 |
Johannes Auer |
Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
CN116987197A
(zh)
|
2019-06-20 |
2023-11-03 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
|
AU2020307471A1
(en)
|
2019-06-24 |
2022-01-27 |
Novartis Ag |
Dosing regimen and combination therapies for multispecific antibodies targeting B-cell maturation antigen
|
|
JP2022540764A
(ja)
|
2019-06-25 |
2022-09-20 |
プロサイセデクス インコーポレイティド |
抗ＴＮＦα生物製剤および抗薬剤抗体の検出
|
|
MX2021015888A
(es)
|
2019-06-26 |
2022-03-22 |
Hoffmann La Roche |
Fusión de un anticuerpo que se une a cea y 4-1bbl.
|
|
WO2020260327A1
(en)
|
2019-06-26 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Mammalian cell lines with sirt-1 gene knockout
|
|
CN114531878A
(zh)
|
2019-06-27 |
2022-05-24 |
豪夫迈·罗氏有限公司 |
新颖icos抗体及包含它们的肿瘤靶向抗原结合分子
|
|
JP2022538232A
(ja)
|
2019-06-28 |
2022-09-01 |
アムジエン・インコーポレーテツド |
抗ｃｇｒｐ受容体／抗ｐａｃ１受容体二重特異性抗原結合タンパク質
|
|
BR112021026492A2
(pt)
|
2019-06-28 |
2022-02-08 |
Genentech Inc |
Formulações líquidas, formulação liofilizada, artigos de fabricação e método para preparar uma formulação líquida
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
EP3994270A1
(en)
|
2019-07-02 |
2022-05-11 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
|
US20230057904A1
(en)
|
2019-07-10 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Claudin-6 binding molecules and uses thereof
|
|
KR20220044284A
(ko)
|
2019-07-11 |
2022-04-07 |
카 메디컬 리미티드 |
이종이량체 및 이의 사용방법
|
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
EP3999532A2
(en)
|
2019-07-16 |
2022-05-25 |
Sanofi |
Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease
|
|
JP2022540806A
(ja)
|
2019-07-19 |
2022-09-20 |
オンコレスポンス，インク． |
免疫調節抗体およびその使用方法
|
|
CA3147735A1
(en)
|
2019-07-26 |
2021-02-04 |
Janssen Biotech, Inc. |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
|
CN114206373A
(zh)
|
2019-07-26 |
2022-03-18 |
豪夫迈·罗氏有限公司 |
用于以IL-22 Fc融合蛋白预防或治疗移植物抗宿主病(GVHD)的给药
|
|
JP2022541652A
(ja)
|
2019-07-26 |
2022-09-26 |
ヴァンダービルト ユニバーシティ |
エンテロウイルスｄ６８に対するヒトモノクローナル抗体
|
|
JP2022542431A
(ja)
|
2019-07-30 |
2022-10-03 |
キューエルエスエフ バイオセラピューティクス， インコーポレイテッド |
二重特異性抗ｌｒｒｃ１５及びｃｄ３イプシロン抗体
|
|
US11667699B2
(en)
|
2019-07-31 |
2023-06-06 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
|
MX2022001156A
(es)
|
2019-07-31 |
2022-02-22 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d.
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
MX2022001133A
(es)
|
2019-08-01 |
2022-04-25 |
Incyte Corp |
Regimen de dosificacion para un inhibidor de indolamina 2,3-dioxigenasa (ido).
|
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
|
US20210032370A1
(en)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Recruiting agent further binding an mhc molecule
|
|
US20210102002A1
(en)
|
2019-08-06 |
2021-04-08 |
Xencor, Inc. |
HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
|
|
JP7181438B2
(ja)
|
2019-08-06 |
2022-11-30 |
アプリノイア セラピューティクス リミテッド |
病理学的タウ種に結合する抗体及びその使用
|
|
MX2022001682A
(es)
|
2019-08-08 |
2022-05-13 |
Regeneron Pharma |
Nuevos formatos de moleculas de union a antigenos.
|
|
US12098212B2
(en)
|
2019-08-12 |
2024-09-24 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
|
AU2020329217A1
(en)
|
2019-08-12 |
2022-07-28 |
Aptevo Research And Development Llc |
4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
|
|
BR112022002540A2
(pt)
|
2019-08-15 |
2022-06-14 |
Janssen Biotech Inc |
Materiais e métodos para fragmentos variáveis de cadeia única aprimorados
|
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN114650867A
(zh)
|
2019-08-30 |
2022-06-21 |
齐鲁普吉湾生物治疗公司 |
抗cd20抗体、抗cd37抗体及它们的混合物
|
|
GB201913079D0
(en)
|
2019-09-11 |
2019-10-23 |
Hummingbird Bioscience Holdings Pte Ltd |
Treatment and prevention of cancer using her3 antigen-binding molecules
|
|
JP2022547577A
(ja)
|
2019-09-12 |
2022-11-14 |
ジェネンテック， インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
|
WO2021055329A1
(en)
|
2019-09-16 |
2021-03-25 |
Surface Oncology, Inc. |
Anti-cd39 antibody compositions and methods
|
|
US20210130492A1
(en)
|
2019-09-18 |
2021-05-06 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
RU2753282C2
(ru)
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
JP2022549218A
(ja)
|
2019-09-20 |
2022-11-24 |
ジェネンテック， インコーポレイテッド |
抗トリプターゼ抗体の投薬
|
|
WO2021058807A1
(en)
|
2019-09-25 |
2021-04-01 |
Universität Stuttgart |
Trivalent binding molecules
|
|
CN115087671A
(zh)
|
2019-09-25 |
2022-09-20 |
表面肿瘤学公司 |
抗il-27抗体及其用途
|
|
MX2022003507A
(es)
|
2019-09-25 |
2022-04-25 |
Univ Stuttgart |
Modulos de union que comprenden dominios ehd2 modificados.
|
|
US20220281997A1
(en)
|
2019-09-27 |
2022-09-08 |
Nanjing GenScript Biotech Co., Ltd. |
Anti-VHH Domain Antibodies and Use Thereof
|
|
BR112022005909A2
(pt)
|
2019-09-29 |
2022-10-11 |
Jacobio Pharmaceuticals Co Ltd |
anticorpos isolados ou fragmento de ligação ao antígeno dos mesmos, método de preparação e usos dos mesmos, composição nucleotídica, vetor, célula hospedeira, composição farmacêutica, reagente para detecção de lif em amostras biológicas, e método exvivo para detectar o lif em amostras biológicas
|
|
CN115916233A
(zh)
|
2019-10-03 |
2023-04-04 |
Xencor股份有限公司 |
靶向IL-12异源二聚体Fc融合蛋白
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
CN114599971A
(zh)
*
|
2019-10-14 |
2022-06-07 |
皮尔斯生物科技有限公司 |
肽纯化配制物和方法
|
|
KR20220086618A
(ko)
|
2019-10-18 |
2022-06-23 |
제넨테크, 인크. |
미만성 거대 B-세포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
EP4048285A1
(en)
|
2019-10-21 |
2022-08-31 |
Novartis AG |
Tim-3 inhibitors and uses thereof
|
|
WO2021084104A1
(en)
|
2019-10-30 |
2021-05-06 |
Bioinvent International Ab |
Tetravalent antibody molecules
|
|
BR112022008552A2
(pt)
|
2019-11-05 |
2022-08-09 |
Regeneron Pharma |
Moléculas de ligação multiespecíficas de scfv de terminal-n
|
|
AU2020381349A1
(en)
|
2019-11-05 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and lenalidomide
|
|
US20220389119A1
(en)
|
2019-11-08 |
2022-12-08 |
Amgen Inc. |
ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES
|
|
KR20220101147A
(ko)
|
2019-11-14 |
2022-07-19 |
웨어울프 세라퓨틱스, 인크. |
활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
|
|
CN114641270A
(zh)
|
2019-11-15 |
2022-06-17 |
豪夫迈·罗氏有限公司 |
防止水性蛋白质溶液中可见颗粒的形成
|
|
AU2020384305A1
(en)
|
2019-11-15 |
2022-06-30 |
Genzyme Corporation |
Biparatopic CD73 antibodies
|
|
PE20221273A1
(es)
|
2019-11-18 |
2022-09-01 |
Janssen Biotech Inc |
Receptores del antigeno quimerico anti-cd79, celulas car-t, y usos de estos
|
|
US20230047631A1
(en)
|
2019-11-19 |
2023-02-16 |
Amgen Inc. |
Novel multispecific antibody format
|
|
TW202134264A
(zh)
|
2019-11-26 |
2021-09-16 |
瑞士商諾華公司 |
嵌合抗原受體及其用途
|
|
IL293519A
(en)
|
2019-12-06 |
2022-08-01 |
CSL Behring Lengnau AG |
Stable compositions of fc multimers
|
|
CN115066437A
(zh)
|
2019-12-12 |
2022-09-16 |
艾利妥 |
使用抗cd33抗体的方法
|
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
|
AU2020406083A1
(en)
|
2019-12-17 |
2022-06-16 |
Boehringer Ingelheim International Gmbh |
Bifunctional molecules comprising an IL-7 variant
|
|
CN115397853A
(zh)
|
2019-12-17 |
2022-11-25 |
辉瑞大药厂 |
对cd47、pd-l1具特异性的抗体及其用途
|
|
IL293310A
(en)
|
2019-12-18 |
2022-07-01 |
Hoffmann La Roche |
Bispecific anti-ccl2 antibodies
|
|
WO2021122875A1
(en)
|
2019-12-18 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a2/mage-a4
|
|
JP2023506956A
(ja)
|
2019-12-20 |
2023-02-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｉｌ－３７融合タンパク質及びその使用
|
|
WO2021127495A1
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
|
EP4077389A1
(en)
|
2019-12-20 |
2022-10-26 |
Novartis AG |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
CR20220334A
(es)
|
2019-12-23 |
2022-08-26 |
Genentech Inc |
Anticuerpos específicos de apolipoproteína l1 y métodos de uso
|
|
EP4081543A1
(en)
|
2019-12-23 |
2022-11-02 |
Soteria Biotherapeutics, Inc. |
Chemically induced association and dissociation of therapeutic fc compositions and chemically induced dimerization of t cell engager with human serum albumin
|
|
EP4082570A4
(en)
|
2019-12-27 |
2023-09-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-CTLA-4 ANTIBODY AND ITS USE
|
|
TWI766512B
(zh)
|
2020-01-02 |
2022-06-01 |
瑞士商赫孚孟拉羅股份公司 |
用於判定腦中的治療性抗體量之方法
|
|
CA3166549A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
|
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
WO2021138498A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
|
|
EP4084825A1
(en)
|
2020-01-03 |
2022-11-09 |
Incyte Corporation |
Anti-cd73 antibodies and uses thereof
|
|
TWI845803B
(zh)
|
2020-01-06 |
2024-06-21 |
美商法西尼克斯股份有限公司 |
抗ｃｃｒ８抗體及其用途
|
|
LT4087875T
(lt)
|
2020-01-08 |
2024-10-25 |
argenx BV |
Žmogaus neonatalinių fc receptorių (fcrn) antagonistai, skirti pūslinių ligų gydymui
|
|
WO2021139758A1
(zh)
|
2020-01-09 |
2021-07-15 |
江苏恒瑞医药股份有限公司 |
新型多肽复合物
|
|
EP4087866A1
(en)
|
2020-01-09 |
2022-11-16 |
F. Hoffmann-La Roche AG |
New 4-1bbl trimer-containing antigen binding molecules
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
US20230076768A1
(en)
|
2020-01-14 |
2023-03-09 |
Synthekine, Inc. |
IL2 Orthologs and Methods of Use
|
|
WO2021144020A1
(en)
|
2020-01-15 |
2021-07-22 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding prame
|
|
AU2021208515A1
(en)
|
2020-01-15 |
2022-08-04 |
F. Hoffmann-La Roche Ag |
Methods to decrease impurities from recombinant protein manufacturing processes
|
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
JP2023510393A
(ja)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
|
|
WO2021146383A1
(en)
|
2020-01-17 |
2021-07-22 |
BioLegend, Inc. |
Anti-tlr7 agents and compositions and methods for making and using the same
|
|
JP2023513003A
(ja)
|
2020-01-29 |
2023-03-30 |
インヒブルクス インコーポレイテッド |
Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
|
|
IL295129A
(en)
|
2020-01-30 |
2022-09-01 |
Umoja Biopharma Inc |
Bispecific transduction enhancer
|
|
GB202001447D0
(en)
|
2020-02-03 |
2020-03-18 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
JP2023519105A
(ja)
|
2020-02-11 |
2023-05-10 |
ヴァンダービルト ユニバーシティ |
重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
|
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
US20230111593A1
(en)
|
2020-02-14 |
2023-04-13 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
EP4106806A4
(en)
|
2020-02-21 |
2024-07-24 |
Harpoon Therapeutics Inc |
FLT3 BINDING PROTEINS AND METHODS OF USE
|
|
EP4110377A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN115175695A
(zh)
|
2020-02-27 |
2022-10-11 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
EP4110826A4
(en)
|
2020-02-28 |
2024-08-14 |
Shanghai Henlius Biotech Inc |
ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODIES AND THEIR USES
|
|
CA3169939A1
(en)
|
2020-02-28 |
2021-09-02 |
Jie Xue |
Anti-cd137 construct and use thereof
|
|
CN111269326A
(zh)
|
2020-02-28 |
2020-06-12 |
南京北恒生物科技有限公司 |
新型嵌合抗原受体及其用途
|
|
EP3875478A1
(en)
|
2020-03-05 |
2021-09-08 |
Canvax Biotech, S.L. |
Novel non-immunogenic chimeric antigen receptors and uses thereof
|
|
EP4114860A1
(en)
|
2020-03-06 |
2023-01-11 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
|
TW202140027A
(zh)
|
2020-03-06 |
2021-11-01 |
美商英塞特公司 |
包含ａｘｌ／ｍｅｒ及ｐｄ—１／ｐｄ／ｌ１抑制劑之組合療法
|
|
KR20220167276A
(ko)
|
2020-03-10 |
2022-12-20 |
매사추세츠 인스티튜트 오브 테크놀로지 |
NPM1c-양성 암의 면역치료를 위한 조성물 및 방법
|
|
KR20230051617A
(ko)
|
2020-03-13 |
2023-04-18 |
얀센 바이오테크 인코포레이티드 |
Siglec-3/cd33을 결합시키기 위한 물질 및 방법
|
|
CR20220461A
(es)
|
2020-03-13 |
2022-10-21 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos
|
|
CR20220521A
(es)
|
2020-03-18 |
2023-01-23 |
Genmab As |
Anticuerpos
|
|
JP7572446B2
(ja)
|
2020-03-19 |
2024-10-23 |
ジェネンテック， インコーポレイテッド |
アイソフォーム選択的抗ｔｇｆ－ベータ抗体及び使用方法
|
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
CR20220489A
(es)
|
2020-03-24 |
2022-10-31 |
Genentech Inc |
Agentes de fijación a tie2 y métodos de uso.
|
|
WO2021195464A2
(en)
|
2020-03-26 |
2021-09-30 |
Genentech, Inc. |
Modified mammalian cells
|
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
|
FI4045533T3
(fi)
|
2020-03-26 |
2024-02-02 |
Univ Vanderbilt |
Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
|
|
CN116249549A
(zh)
|
2020-03-27 |
2023-06-09 |
诺华股份有限公司 |
用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
|
|
US20230348616A1
(en)
|
2020-03-30 |
2023-11-02 |
Mie University |
Bispecific antibody
|
|
IL296802A
(en)
|
2020-03-31 |
2022-11-01 |
Chugai Pharmaceutical Co Ltd |
A method for the production of multispecific antigen binding molecules
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
EP4130732A4
(en)
|
2020-04-02 |
2024-06-19 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR ANALYZING IMPURITIES MOLECULES IN A COMPOSITION CONTAINING MULTI-SPECIFIC ANTIGEN BINDING MOLECULES
|
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック， インコーポレイテッド |
がんに対する治療方法及び診断方法
|
|
CA3174786A1
(en)
|
2020-04-10 |
2021-10-14 |
Sayantan Mitra |
Activatable cytokine constructs and related compositions and methods
|
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
|
US20230192795A1
(en)
|
2020-04-15 |
2023-06-22 |
Hoffmann-La Roche Inc. |
Immunoconjugates
|
|
GB202005879D0
(en)
|
2020-04-22 |
2020-06-03 |
Petmedix Ltd |
Heterodimeric proteins
|
|
MX2022013112A
(es)
|
2020-04-22 |
2023-01-16 |
Dragonfly Therapeutics Inc |
Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc.
|
|
KR20230028242A
(ko)
|
2020-04-24 |
2023-02-28 |
마렝고 테라퓨틱스, 인크. |
T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도
|
|
BR112022021441A2
(pt)
|
2020-04-24 |
2022-12-13 |
Genentech Inc |
Métodos para tratar linfoma folicular e linfoma difuso de grandes células b e kits
|
|
PE20230078A1
(es)
|
2020-04-24 |
2023-01-11 |
Hoffmann La Roche |
Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados
|
|
JP2023524669A
(ja)
|
2020-04-26 |
2023-06-13 |
バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド |
改変免疫グロブリン
|
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
|
BR112022021690A2
(pt)
|
2020-04-29 |
2022-12-20 |
Teneobio Inc |
Anticorpos de cadeia pesada multispecíficos com regiões constantes de cadeia pesada modificadas
|
|
TWI838621B
(zh)
|
2020-04-29 |
2024-04-11 |
美商泰尼歐萬公司 |
具有經修飾重鏈恆定區之多特異性重鏈抗體
|
|
KR20230007384A
(ko)
|
2020-04-30 |
2023-01-12 |
브리스톨-마이어스 스큅 컴퍼니 |
치료 방법
|
|
WO2021222533A1
(en)
|
2020-04-30 |
2021-11-04 |
Procisedx Inc. |
Methods of detecting antibodies to sars-cov-2
|
|
WO2021220215A1
(en)
|
2020-05-01 |
2021-11-04 |
Novartis Ag |
Engineered immunoglobulins
|
|
WO2021225892A1
(en)
|
2020-05-03 |
2021-11-11 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
|
TW202208414A
(zh)
|
2020-05-08 |
2022-03-01 |
美商艾爾潘免疫科學有限公司 |
April及baff抑制性免疫調節蛋白及其使用方法
|
|
CN115551540A
(zh)
|
2020-05-11 |
2022-12-30 |
豪夫迈·罗氏有限公司 |
使用经修饰的pbmc和免疫缀合物的组合疗法
|
|
BR112022022899A2
(pt)
|
2020-05-12 |
2022-12-20 |
Regeneron Pharma |
Agonistas de il10 e métodos de uso dos mesmos
|
|
EP4149968A1
(en)
|
2020-05-12 |
2023-03-22 |
Lyell Immunopharma, Inc. |
Chimeric antigen receptor spacers
|
|
WO2021231969A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
CN115605184A
(zh)
|
2020-05-15 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
防止胃肠外蛋白质溶液中的可见颗粒形成
|
|
CN115836084A
(zh)
|
2020-05-15 |
2023-03-21 |
阿珀吉尼科斯股份公司 |
多特异性免疫调节剂
|
|
EP4153130A1
(en)
|
2020-05-19 |
2023-03-29 |
F. Hoffmann-La Roche AG |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
|
MX2022014538A
(es)
|
2020-05-19 |
2022-12-15 |
Boehringer Ingelheim Int |
Moleculas de union para el tratamiento de cancer.
|
|
CN111849910B
(zh)
|
2020-05-27 |
2021-06-15 |
南京北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
|
EP4157459A1
(en)
|
2020-05-27 |
2023-04-05 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
|
CR20220608A
(es)
|
2020-05-29 |
2023-01-26 |
23Andme Inc |
Anticuerpos anti-cd200r1 y métodos de uso de estos
|
|
AU2021282817A1
(en)
|
2020-06-01 |
2022-11-17 |
Mustbio Co., Ltd. |
Bispecific antibody or antigen-binding fragment thereof, and preparation method therefor
|
|
IL298632A
(en)
|
2020-06-02 |
2023-01-01 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Non-human animals genetically modified with a common light chain immunoglobulin locus
|
|
BR112022024996A2
(pt)
|
2020-06-08 |
2022-12-27 |
Hoffmann La Roche |
Anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, agente terapêutico, uso do anticorpo e método para tratar um indivíduo com hepatite b
|
|
WO2021249462A1
(zh)
|
2020-06-11 |
2021-12-16 |
南京北恒生物科技有限公司 |
表达nk抑制性分子的工程化免疫细胞及其用途
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
WO2021252977A1
(en)
|
2020-06-12 |
2021-12-16 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
CR20220629A
(es)
|
2020-06-19 |
2023-02-17 |
Hoffmann La Roche |
Moléculas de unión al dominio fc de activación inmunitaria
|
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
|
JP2023530961A
(ja)
|
2020-06-19 |
2023-07-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｃｄ３に結合する抗体
|
|
CR20220637A
(es)
|
2020-06-19 |
2023-01-31 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19
|
|
JP7250219B2
(ja)
|
2020-06-19 |
2023-03-31 |
中外製薬株式会社 |
血管新生阻害剤と組み合わせて使用するための抗ｔ細胞抗原結合分子
|
|
IL296429A
(en)
|
2020-06-19 |
2022-11-01 |
Hoffmann La Roche |
Protease-activated t-cell bispecific antibodies
|
|
TW202216767A
(zh)
|
2020-06-19 |
2022-05-01 |
瑞士商赫孚孟拉羅股份公司 |
與ＣＤ３及ＦｏｌＲ１結合之抗體
|
|
CA3183475A1
(en)
|
2020-06-22 |
2021-12-30 |
Thomas Huber |
Anti-il-36 antibodies and methods of use thereof
|
|
WO2021259890A1
(en)
|
2020-06-23 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Agonistic cd28 antigen binding molecules targeting her2
|
|
BR112022026202A2
(pt)
|
2020-06-23 |
2023-01-17 |
Novartis Ag |
Regime de dosagem compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona
|
|
IL299161A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Cell lines resistant to apoptosis
|
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ３／抗ｃｄ２８二重特異性抗原結合分子
|
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
|
US12077576B2
(en)
|
2020-07-02 |
2024-09-03 |
Trustees Of Tufts College |
VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
|
|
WO2022008468A1
(en)
|
2020-07-07 |
2022-01-13 |
F. Hoffmann-La Roche Ag |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
|
CN115867583A
(zh)
|
2020-07-10 |
2023-03-28 |
豪夫迈·罗氏有限公司 |
与癌细胞结合并将放射性核素靶向所述细胞的抗体
|
|
AU2021307614B2
(en)
|
2020-07-15 |
2024-10-03 |
Bioheng Therapeutics Limited |
Engineered immune cell for allotransplantation
|
|
CR20230009A
(es)
|
2020-07-16 |
2023-01-25 |
Novartis Ag |
Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
|
|
EP4182337A1
(en)
|
2020-07-17 |
2023-05-24 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
AU2021308653A1
(en)
|
2020-07-17 |
2023-02-16 |
Genentech, Inc. |
Anti-Notch2 antibodies and methods of use
|
|
AU2021312225A1
(en)
|
2020-07-21 |
2023-02-16 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation of BRM and methods thereof
|
|
MX2023000883A
(es)
|
2020-07-24 |
2023-02-22 |
Genentech Inc |
Metodos para la expresion de una fusion anticuerpo-multimero.
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
JP2023536818A
(ja)
|
2020-07-29 |
2023-08-30 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
|
|
CN114057890A
(zh)
|
2020-07-31 |
2022-02-18 |
南京北恒生物科技有限公司 |
新型共刺激结构域及其用途
|
|
CN116194124A
(zh)
|
2020-07-31 |
2023-05-30 |
中外制药株式会社 |
包含表达嵌合受体的细胞的药物组合物
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3190430A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il10rb binding molecules and methods of use
|
|
CA3190459A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Gp130 binding molecules and methods of use
|
|
AU2021320227A1
(en)
|
2020-08-05 |
2023-03-23 |
Synthekine, Inc. |
IL27Rα binding molecules and methods of use
|
|
CN116323669A
(zh)
|
2020-08-05 |
2023-06-23 |
辛德凯因股份有限公司 |
受体配对相关的组合物和方法
|
|
US20230272094A1
(en)
|
2020-08-05 |
2023-08-31 |
Synthekine, Inc. |
Il2rb/il2rg synthetic cytokines
|
|
AU2021321525A1
(en)
|
2020-08-05 |
2023-03-30 |
Synthekine, Inc. |
IL10 receptor binding molecules and methods of use
|
|
AU2021322238A1
(en)
|
2020-08-05 |
2023-03-23 |
Synthekine, Inc. |
Compositions and methods related to IL27 receptor binding
|
|
US20230272090A1
(en)
|
2020-08-05 |
2023-08-31 |
Sandro Vivona |
Il2rb binding molecules and methods of use
|
|
US12077594B2
(en)
|
2020-08-05 |
2024-09-03 |
Synthekine, Inc. |
IL2RG binding molecules and methods of use
|
|
AU2021320233A1
(en)
|
2020-08-05 |
2023-03-23 |
Synthekine, Inc. |
IL10Ra binding molecules and methods of use
|
|
CN116194477A
(zh)
|
2020-08-06 |
2023-05-30 |
生物技术欧洲股份公司 |
冠状病毒s蛋白的结合剂
|
|
CN112063588A
(zh)
|
2020-08-13 |
2020-12-11 |
南京北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
|
AU2021329378A1
(en)
|
2020-08-19 |
2023-03-23 |
Xencor, Inc. |
Anti-CD28 compositions
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CN116917316A
(zh)
|
2020-08-26 |
2023-10-20 |
马伦戈治疗公司 |
与NKp30结合的抗体分子及其用途
|
|
WO2022047046A1
(en)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Methods of detecting trbc1 or trbc2
|
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
|
US20230416371A1
(en)
|
2020-08-28 |
2023-12-28 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimer fc polypeptide
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
US20230340054A1
(en)
|
2020-09-01 |
2023-10-26 |
Takeda Pharmaceutical Company Limited |
Interleukin-2 muteins and uses thereof
|
|
IL301003A
(en)
|
2020-09-01 |
2023-04-01 |
Merck Patent Gmbh |
Compounds based on B7-H6, their preparation and pharmaceutical preparations containing them
|
|
JP2023541860A
(ja)
|
2020-09-10 |
2023-10-04 |
ジェンマブ エー／エス |
びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
KR20230066040A
(ko)
|
2020-09-10 |
2023-05-12 |
젠맵 에이/에스 |
만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체
|
|
CN114163532A
(zh)
|
2020-09-10 |
2022-03-11 |
南京北恒生物科技有限公司 |
包含新型共刺激结构域的嵌合抗原受体及其用途
|
|
KR20230066386A
(ko)
|
2020-09-11 |
2023-05-15 |
리제너론 파마슈티칼스 인코포레이티드 |
항원 특이적 항체의 확인 및 제조
|
|
US20220089690A1
(en)
|
2020-09-14 |
2022-03-24 |
Sutro Biopharma, Inc. |
Method for large scale production of antibodies using a cell-free protein synthesis system
|
|
EP4214244A1
(en)
|
2020-09-21 |
2023-07-26 |
Genentech, Inc. |
Purification of multispecific antibodies
|
|
IL301366A
(en)
|
2020-09-24 |
2023-05-01 |
Hoffmann La Roche |
Mammalian cell lines with genetic knockout
|
|
CN116322691A
(zh)
|
2020-09-24 |
2023-06-23 |
豪夫迈·罗氏有限公司 |
T细胞双特异性抗体相关不良反应的预防或减轻
|
|
CA3196933A1
(en)
|
2020-09-29 |
2022-04-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-cd3 antibody and uses thereof
|
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
KR20230104617A
(ko)
|
2020-10-07 |
2023-07-10 |
드렌 바이오, 인크. |
항-덱틴-1 항체 및 이의 사용 방법
|
|
EP4225792A1
(en)
|
2020-10-08 |
2023-08-16 |
Affimed GmbH |
Trispecific binders
|
|
US12006550B2
(en)
|
2020-10-12 |
2024-06-11 |
University Of South Carolina |
Targeting treatment for ADAM30 in pathological cells
|
|
UY39467A
(es)
|
2020-10-13 |
2022-04-29 |
Janssen Biotech Inc |
Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
|
|
WO2022081886A1
(en)
|
2020-10-14 |
2022-04-21 |
Xencor, Inc. |
Bispecific antibodies that bind pd-l1 and cd28
|
|
EP4228697A1
(en)
|
2020-10-16 |
2023-08-23 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating viral and other microbial infections
|
|
JP2023545447A
(ja)
|
2020-10-16 |
2023-10-30 |
キューエルエスエフ バイオセラピューティクス， インコーポレイテッド |
Ｐｄ－ｌ１に結合する多重特異性結合化合物
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
AU2021363536A1
(en)
|
2020-10-20 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
|
|
US12110335B2
(en)
|
2020-10-21 |
2024-10-08 |
Boehringer Ingelheim International Gmbh |
Bispecific anti-VEGF and anti-TrkB binding molecules for the treatment of eye diseases
|
|
IL302277A
(en)
|
2020-10-22 |
2023-06-01 |
Janssen Biotech Inc |
Proteins containing delta-like ligand antigen binding domains (DLL3) and uses thereof
|
|
US12024559B2
(en)
|
2020-10-23 |
2024-07-02 |
Asher Biotherapeutics, Inc. |
Fusions with CD8 antigen binding molecules for modulating immune cell function
|
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
|
JP2023549062A
(ja)
|
2020-10-30 |
2023-11-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
ＣＥＡ ＣＤ３二重特異性抗体及びＴＧＦβシグナル伝達阻害剤を使用したがんの治療
|
|
TW202233677A
(zh)
|
2020-11-02 |
2022-09-01 |
新加坡商蜂鳥生物科技私人有限公司 |
Bcma/taci抗原結合分子
|
|
CN114525259A
(zh)
|
2020-11-03 |
2022-05-24 |
南京北恒生物科技有限公司 |
靶向cd7的嵌合抗原受体及其用途
|
|
CN112300282A
(zh)
|
2020-11-03 |
2021-02-02 |
南京北恒生物科技有限公司 |
靶向cd7的人源化抗体及其用途
|
|
US11919945B2
(en)
|
2020-11-04 |
2024-03-05 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
|
WO2022097090A1
(en)
|
2020-11-05 |
2022-05-12 |
Novartis Ag |
Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
|
|
US20220144956A1
(en)
|
2020-11-06 |
2022-05-12 |
Xencor, Inc. |
HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
|
|
US20240067728A1
(en)
|
2020-11-06 |
2024-02-29 |
Bio-Thera Solutions, Ltd. |
Bispecific antibody and use thereof
|
|
CA3199095A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
JP2023547506A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
Ｂ細胞悪性腫瘍を治療するための抗ｃｄ１９剤及びｂ細胞標的化剤の組み合わせ療法
|
|
CN116472288A
(zh)
|
2020-11-06 |
2023-07-21 |
诺华股份有限公司 |
抗体Fc变体
|
|
KR20230107305A
(ko)
|
2020-11-10 |
2023-07-14 |
상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 |
클라우딘 18a2 및 cd3에 대한 이중특이성 항체 및 이중특이성 항체의 용도
|
|
IL302570A
(en)
|
2020-11-10 |
2023-07-01 |
Hoffmann La Roche |
Prevention or reduction of adverse effects associated with the T-CELL agent
|
|
EP4243857A1
(en)
|
2020-11-13 |
2023-09-20 |
Novartis AG |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
JP2023549316A
(ja)
|
2020-11-16 |
2023-11-24 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｆａｐを標的としたｃｄ４０アゴニストとの併用療法
|
|
EP4244248A1
(en)
|
2020-11-16 |
2023-09-20 |
F. Hoffmann-La Roche AG |
Fab high mannose glycoforms
|
|
CN114524876A
(zh)
|
2020-11-23 |
2022-05-24 |
南京北恒生物科技有限公司 |
靶向nkg2a的抗体及其用途
|
|
EP4251138A1
(en)
|
2020-11-30 |
2023-10-04 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
|
JP2023551907A
(ja)
|
2020-12-01 |
2023-12-13 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
腫瘍関連抗原及びｃｄ３結合タンパク質、関連する組成物、及び方法
|
|
AU2021392039A1
(en)
|
2020-12-02 |
2023-06-29 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
|
CN116635403A
(zh)
|
2020-12-04 |
2023-08-22 |
豪夫迈·罗氏有限公司 |
pH依赖性突变型白细胞介素-2多肽
|
|
MX2023006650A
(es)
|
2020-12-07 |
2023-06-21 |
UCB Biopharma SRL |
Anticuerpos multiespecificos y combinaciones de anticuerpos.
|
|
IL303294A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
|
AU2021402065A1
(en)
|
2020-12-17 |
2023-06-29 |
Boehringer Ingelheim International Gmbh |
Bifunctional anti-pd1/il-7 molecules
|
|
JP7326584B2
(ja)
|
2020-12-17 |
2023-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｈｌａ－ｇ抗体及びその使用
|
|
CN116601175A
(zh)
|
2020-12-18 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
用于靶向疗法的前体蛋白和试剂盒
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
EP4051700A1
(en)
|
2020-12-23 |
2022-09-07 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
|
US20220227867A1
(en)
|
2020-12-24 |
2022-07-21 |
Xencor, Inc. |
ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
|
|
JP2024502005A
(ja)
|
2020-12-29 |
2024-01-17 |
インサイト・コーポレイション |
Ａ２ａ／ａ２ｂ阻害剤、ｐｄ－１／ｐｄ－ｌ１阻害剤、及び抗ｃｄ７３抗体を含む併用療法
|
|
CN116829598A
(zh)
|
2021-01-06 |
2023-09-29 |
豪夫迈·罗氏有限公司 |
采用pd1-lag3双特异性抗体和cd20 t细胞双特异性抗体的组合疗法
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
EP4274616A2
(en)
|
2021-01-11 |
2023-11-15 |
Synthekine, Inc. |
Compositions and methods related to receptor pairing
|
|
WO2022154472A1
(ko)
|
2021-01-12 |
2022-07-21 |
에스지메디칼 주식회사 |
Cd55에 대한 신규 항체 및 이의 용도
|
|
AU2022207615A1
(en)
|
2021-01-12 |
2023-07-13 |
F. Hoffmann-La Roche Ag |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
|
EP4257610A1
(en)
|
2021-01-12 |
2023-10-11 |
Bioheng Therapeutics Limited |
Ror1-targeting antibody and use thereof
|
|
US20240076346A1
(en)
*
|
2021-01-13 |
2024-03-07 |
Kahr Medical Ltd. |
Type i membrane proteins heterodimers and methods of use thereof
|
|
US20240173442A1
(en)
|
2021-01-13 |
2024-05-30 |
Hoffmann-La Roche Inc. |
Combination therapy
|
|
US12060411B2
(en)
|
2021-01-15 |
2024-08-13 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
|
BR112023014418A2
(pt)
|
2021-01-20 |
2023-10-31 |
Oncoresponse Inc |
Anticorpos imunomoduladores e usos dos mesmos
|
|
CN116917326A
(zh)
|
2021-01-22 |
2023-10-20 |
博泰康医药公司 |
抗her-2/trop-2构建体及其用途
|
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
|
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック， インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
|
KR20230137923A
(ko)
|
2021-02-03 |
2023-10-05 |
바이오헝 테라퓨틱스 리미티드 |
신규한 키메라 항원 수용체 및 이의 용도
|
|
JP2024505600A
(ja)
|
2021-02-03 |
2024-02-06 |
モーツァルト セラピューティクス， インコーポレイテッド |
結合剤およびそれを使用する方法
|
|
MX2023009186A
(es)
|
2021-02-05 |
2023-08-21 |
Salubris Biotherapeutics Inc |
Proteinas de fusion de il-15 y metodos para preparacion y uso de las mismas.
|
|
MX2023009568A
(es)
|
2021-02-16 |
2023-10-24 |
Janssen Biotech Inc |
Materiales y métodos para el direccionamiento mejorado de enlazador.
|
|
JP2024512240A
(ja)
|
2021-02-18 |
2024-03-19 |
エフ． ホフマン－ラ ロシュ アーゲー |
複雑な多段階の抗体相互作用を解明するための方法
|
|
AU2022222994A1
(en)
|
2021-02-19 |
2023-09-28 |
Seoul National University R&Db Foundation |
Single domain antibody against cd47 and use thereof
|
|
MX2023009716A
(es)
|
2021-02-19 |
2024-01-08 |
Shaperon Inc |
Anticuerpo de dominio individual contra ligando de muerte programada 1 (pd-l1) y uso del mismo.
|
|
JP2024510898A
(ja)
|
2021-02-25 |
2024-03-12 |
ライエル・イミュノファーマ・インコーポレイテッド |
Ｒｏｒ１を標的とするキメラ抗原受容体
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
JP2024509169A
(ja)
|
2021-03-03 |
2024-02-29 |
ソレント・セラピューティクス・インコーポレイテッド |
抗ｂｃｍａ抗体を含む抗体－薬物コンジュゲート
|
|
JP2024512324A
(ja)
|
2021-03-05 |
2024-03-19 |
ジーオー セラピューティクス，インコーポレイテッド |
抗グリコｃｄ４４抗体およびその使用
|
|
EP4304724A1
(en)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
|
KR20230156051A
(ko)
|
2021-03-09 |
2023-11-13 |
에프. 호프만-라 로슈 아게 |
Pd-1-표적화 il-2 변이체 면역접합체 및 fap/4-1bb 결합 분자의 병용 요법
|
|
WO2022192259A1
(en)
|
2021-03-09 |
2022-09-15 |
Cureimmune Therapeutics Inc. |
BIFUNCTIONAL HOMODIMERIC ANTI-PD-1 AND IL-15/IL-15Rα FUSION PROTEINS AND USES THEREOF
|
|
US11739144B2
(en)
|
2021-03-09 |
2023-08-29 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and CLDN6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
CN117751138A
(zh)
|
2021-03-12 |
2024-03-22 |
詹森生物科技公司 |
用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法
|
|
CN117062839A
(zh)
|
2021-03-12 |
2023-11-14 |
基因泰克公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
|
|
IL305836A
(en)
|
2021-03-12 |
2023-11-01 |
Janssen Biotech Inc |
A method for treating psoriatic arthritis patients with insufficient response to TNF therapy with a specific anti-IL23 antibody
|
|
EP4308157A1
(en)
|
2021-03-15 |
2024-01-24 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
IL305716A
(en)
|
2021-03-16 |
2023-11-01 |
Cytomx Therapeutics Inc |
Activated garaged cytokine constructs and related compositions and methods
|
|
US20240174746A1
(en)
|
2021-03-18 |
2024-05-30 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
US20220315655A1
(en)
|
2021-03-22 |
2022-10-06 |
Novimmune Sa |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
|
US20220315654A1
(en)
|
2021-03-22 |
2022-10-06 |
Novimmune Sa |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
|
WO2022204274A1
(en)
|
2021-03-23 |
2022-09-29 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
|
AR125212A1
(es)
|
2021-03-24 |
2023-06-28 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de estas
|
|
AR125210A1
(es)
|
2021-03-24 |
2023-06-21 |
Janssen Biotech Inc |
Anticuerpos dirigidos a cd22 y cd79b
|
|
BR112023019205A2
(pt)
|
2021-03-26 |
2023-10-24 |
Janssen Biotech Inc |
Anticorpos humanizados contra tau de filamento helicoidal pareado e usos dos mesmos
|
|
BR112023017510A2
(pt)
|
2021-03-29 |
2023-10-10 |
Daiichi Sankyo Co Ltd |
Molécula multiespecífica estável e uso da mesma
|
|
CN116897159A
(zh)
|
2021-03-31 |
2023-10-17 |
江苏恒瑞医药股份有限公司 |
截短的taci多肽及其融合蛋白和用途
|
|
JP2024514306A
(ja)
|
2021-03-31 |
2024-04-01 |
エフ． ホフマン－ラ ロシュ アーゲー |
混合モードクロマトグラフィーによる抗体の精製
|
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗ｉｌ－２ｒ抗體及使用方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AU2022255506A1
(en)
|
2021-04-08 |
2023-11-09 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
WO2022214565A1
(en)
|
2021-04-09 |
2022-10-13 |
F. Hoffmann-La Roche Ag |
Process for selecting cell clones expressing a heterologous polypeptide
|
|
WO2022214653A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
New scaffold for bifunctional molecules with improved properties
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
CA3214934A1
(en)
|
2021-04-12 |
2022-10-20 |
Madhavan Nallani |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
WO2022219076A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
WO2022225880A1
(en)
|
2021-04-19 |
2022-10-27 |
Genentech, Inc. |
Modified mammalian cells
|
|
EP4328243A1
(en)
|
2021-04-20 |
2024-02-28 |
Korea University Research and Business Foundation |
Asymmetric antibody with improved cytotoxicity against cancer cell
|
|
KR20230160389A
(ko)
|
2021-04-22 |
2023-11-23 |
광동 파폰 바이오파마 인크. |
이중 특이성 다기능 융합 폴리펩티드
|
|
JP2024516631A
(ja)
|
2021-04-23 |
2024-04-16 |
プロファウンドバイオ ユーエス カンパニー |
抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法
|
|
CN118056008A
(zh)
|
2021-04-27 |
2024-05-17 |
诺华股份有限公司 |
病毒载体生产系统
|
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
|
EP4334355A1
(en)
|
2021-05-03 |
2024-03-13 |
UCB Biopharma SRL |
Antibodies
|
|
CA3219609A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
JP2024518378A
(ja)
|
2021-05-05 |
2024-05-01 |
イマティクス バイオテクノロジーズ ゲーエムベーハー |
Ｐｒａｍｅに特異的に結合する抗原結合タンパク質
|
|
MX2023012899A
(es)
|
2021-05-05 |
2023-11-08 |
Immatics Biotechnologies Gmbh |
Polipeptidos de union a antigeno bma031 mejorados.
|
|
US20240218057A1
(en)
|
2021-05-06 |
2024-07-04 |
The Rockefeller University |
Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
|
|
JP2024516970A
(ja)
|
2021-05-07 |
2024-04-18 |
サーフィス オンコロジー， エルエルシー |
抗ｉｌ－２７抗体及びその使用
|
|
US20240279310A1
(en)
|
2021-05-07 |
2024-08-22 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
|
CN117396509A
(zh)
|
2021-05-07 |
2024-01-12 |
健玛保 |
包含结合b7h4和cd3的双特异性抗体的药物组合物
|
|
WO2022238481A1
(en)
|
2021-05-11 |
2022-11-17 |
Modiquest B.V. |
Antibodies
|
|
BR112023022707A2
(pt)
|
2021-05-12 |
2024-01-16 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Molécula de ligação ao antígeno a qual se liga especificamente a rankl e ngf, e seu uso médico
|
|
MX2023013264A
(es)
|
2021-05-12 |
2023-11-30 |
Genentech Inc |
Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
|
|
EP4337190A1
(en)
|
2021-05-13 |
2024-03-20 |
ALX Oncology Inc. |
Combination therapies for treating cancer
|
|
CA3219388A1
(en)
|
2021-05-14 |
2022-11-17 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule
|
|
WO2022241082A1
(en)
|
2021-05-14 |
2022-11-17 |
Genentech, Inc. |
Agonists of trem2
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
|
WO2022245500A1
(en)
|
2021-05-19 |
2022-11-24 |
Asher Biotherapeutics, Inc. |
Il-21 polypeptides and targeted constructs
|
|
EP4341385A1
(en)
|
2021-05-21 |
2024-03-27 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
AU2022289684A1
(en)
|
2021-06-09 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
|
WO2022266219A1
(en)
|
2021-06-15 |
2022-12-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind claudin18.2 and cd3
|
|
WO2022262959A1
(en)
|
2021-06-15 |
2022-12-22 |
Astellas Pharma Europe Bv |
Bispecific binding agents binding to cldn18.2 and cd3
|
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
|
US20240279358A1
(en)
|
2021-06-16 |
2024-08-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
KR20240021859A
(ko)
|
2021-06-18 |
2024-02-19 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ccl2 항체
|
|
AU2022299282A1
(en)
|
2021-06-22 |
2024-02-01 |
Merck Patent Gmbh |
Vhh-based nkp30 binders
|
|
IL308134A
(en)
|
2021-06-22 |
2023-12-01 |
Novartis Ag |
BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA
|
|
CA3220353A1
(en)
|
2021-06-25 |
2022-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
|
JP7472405B2
(ja)
|
2021-06-25 |
2024-04-22 |
中外製薬株式会社 |
抗ｃｔｌａ－４抗体
|
|
JP2024524378A
(ja)
|
2021-06-29 |
2024-07-05 |
山▲東▼先声生物制▲薬▼有限公司 |
Ｃｄ１６抗体及びその応用
|
|
CA3223534A1
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
WO2023283345A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Anti-b7-h4 antibodies and uses thereof
|
|
JP2024529339A
(ja)
|
2021-07-13 |
2024-08-06 |
ジェネンテック， インコーポレイテッド |
サイトカイン放出症候群を予測する多変量モデル
|
|
PE20240638A1
(es)
|
2021-07-14 |
2024-03-27 |
Genentech Inc |
Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso
|
|
WO2023284829A1
(zh)
|
2021-07-14 |
2023-01-19 |
江苏恒瑞医药股份有限公司 |
特异性结合hgfr和egfr的抗原结合分子及其医药用途
|
|
JP2024529340A
(ja)
|
2021-07-14 |
2024-08-06 |
シンセカイン インコーポレイテッド |
新生物疾患の細胞療法に使用するための方法および組成物
|
|
KR20240035845A
(ko)
|
2021-07-19 |
2024-03-18 |
리제너론 파아마슈티컬스, 인크. |
Il12 수용체 효능제 및 그의 사용 방법
|
|
CA3219606A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
|
EP4373576A1
(en)
|
2021-07-22 |
2024-05-29 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
|
US20230146665A1
(en)
|
2021-07-27 |
2023-05-11 |
Xencor, Inc. |
Il-18-fc fusion proteins
|
|
WO2023006809A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
|
KR20240038008A
(ko)
|
2021-07-28 |
2024-03-22 |
에프. 호프만-라 로슈 아게 |
암 치료 방법 및 조성물
|
|
CA3225405A1
(en)
|
2021-07-28 |
2023-02-02 |
Alexander Joachim Paul Ungewickell |
Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
CA3231174A1
(en)
|
2021-08-02 |
2023-02-09 |
Innovent Biologics (Suzhou) Co., Ltd. |
Anti-cd79bxcd3 bispecific antibody and use thereof
|
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
|
AU2022324456A1
(en)
|
2021-08-05 |
2024-02-15 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
|
CN115702931A
(zh)
|
2021-08-06 |
2023-02-17 |
百奥泰生物制药股份有限公司 |
抗pd-l1/cd47双特异抗体在治疗疾病中的应用
|
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
EP4387988A2
(en)
|
2021-08-16 |
2024-06-26 |
Regeneron Pharmaceuticals, Inc. |
Novel il27 receptor agonists and methods of use thereof
|
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
|
EP4388000A1
(en)
|
2021-08-20 |
2024-06-26 |
Novartis AG |
Methods of making chimeric antigen receptor?expressing cells
|
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
|
WO2023028612A2
(en)
|
2021-08-27 |
2023-03-02 |
Board Of Regents, The University Of Texas System |
Anti-tslpr (crlf2) antibodies
|
|
AU2022332303A1
(en)
|
2021-08-27 |
2024-02-01 |
Genentech, Inc. |
Methods of treating tau pathologies
|
|
EP4396223A1
(en)
|
2021-08-30 |
2024-07-10 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
JP2024536719A
(ja)
|
2021-09-03 |
2024-10-08 |
キャンサー・リサーチ・テクノロジー・リミテッド |
Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防
|
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
|
JP2024536722A
(ja)
|
2021-09-03 |
2024-10-08 |
ジーオー セラピューティクス，インコーポレイテッド |
抗グリコｃｍｅｔ抗体およびその使用
|
|
KR20240101546A
(ko)
|
2021-09-03 |
2024-07-02 |
고 테라퓨틱스, 인크. |
항-글리코-lamp1 항체 및 그의 용도
|
|
TW202321312A
(zh)
|
2021-09-08 |
2023-06-01 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
包含基於ｍｈｃ或ｍｈｃ樣蛋白的異源二聚體的二價雙特異性嵌合抗體
|
|
EP4148067A1
(en)
|
2021-09-08 |
2023-03-15 |
F. Hoffmann-La Roche AG |
Method for the expression of an antibody-multimer-fusion
|
|
CA3229822A1
(en)
|
2021-09-13 |
2023-03-16 |
Patrick John DOONAN |
Cd33 x v?2 multispecific antibodies for the treatment of cancer
|
|
KR20240058149A
(ko)
|
2021-09-16 |
2024-05-03 |
허밍버드 바이오사이언스 피티이. 엘티디. |
Vista 항원-결합 분자를 사용한 암의 치료 및 예방
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023046071A1
(zh)
|
2021-09-23 |
2023-03-30 |
江苏恒瑞医药股份有限公司 |
抗klb抗体及用途
|
|
EP4405392A1
(en)
|
2021-09-24 |
2024-07-31 |
Janssen Biotech, Inc. |
Proteins comprising cd20 binding domains, and uses thereof
|
|
JP2024534620A
(ja)
|
2021-09-27 |
2024-09-20 |
ゼンコア インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）結合ドメイン組成物
|
|
WO2023046979A1
(en)
|
2021-09-27 |
2023-03-30 |
Hummingbird Bioscience Pte. Ltd. |
Treatment and prevention of cancer using vista antigen-binding molecules
|
|
JPWO2023053282A1
(da)
|
2021-09-29 |
2023-04-06 |
|
|
|
CA3233261A1
(en)
|
2021-09-30 |
2023-04-06 |
Langyong MAO |
Anti-il23 antibody fusion protein and uses thereof
|
|
MX2024004301A
(es)
|
2021-10-08 |
2024-04-26 |
Cytomx Therapeutics Inc |
Construcciones de citocinas activables y metodos combinados.
|
|
TW202334187A
(zh)
|
2021-10-08 |
2023-09-01 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
可活化細胞激素構築體及相關組成物與方法
|
|
US11814437B2
(en)
|
2021-10-08 |
2023-11-14 |
Genmab A/S |
Antibodies binding to CD30 and CD3
|
|
AU2022361184A1
(en)
|
2021-10-08 |
2024-05-09 |
Chugai Seiyaku Kabushiki Kaisha |
Method for preparing prefilled syringe formulation
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
IL312043A
(en)
|
2021-10-14 |
2024-06-01 |
Teneobio Inc |
Mesothelin binding proteins and their uses
|
|
CA3234731A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
|
IL311963A
(en)
|
2021-10-15 |
2024-06-01 |
Regenxbio Inc |
Antibodies and methods of using them
|
|
IL312221A
(en)
|
2021-10-20 |
2024-06-01 |
Synthekine Inc |
FC heterodimeric cytokines and their uses
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
WO2023072159A1
(en)
|
2021-10-27 |
2023-05-04 |
Virtuoso Binco, Inc. |
Multispecific antibodies for treating cd47-associated diseases
|
|
EP4423123A1
(en)
|
2021-10-28 |
2024-09-04 |
Novartis AG |
Engineered fc variants
|
|
EP4423126A1
(en)
|
2021-10-29 |
2024-09-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
TW202325742A
(zh)
|
2021-11-01 |
2023-07-01 |
瑞士商赫孚孟拉羅股份公司 |
使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
|
|
CA3237357A1
(en)
|
2021-11-03 |
2023-05-11 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
|
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
TW202334223A
(zh)
|
2021-11-11 |
2023-09-01 |
美商再生元醫藥公司 |
Ｃｄ２０－ｐｄ１結合分子及其使用方法
|
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
|
WO2023088876A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
Multi-specific immune modulators
|
|
WO2023088889A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
CD137 ligands
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
AU2022392829A1
(en)
|
2021-11-22 |
2024-07-11 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
|
EP4438629A1
(en)
|
2021-11-24 |
2024-10-02 |
Suzhou Light Ferry Biomed. Co., Ltd |
Multispecific ligand binding molecule and application thereof
|
|
CN118284809A
(zh)
|
2021-11-25 |
2024-07-02 |
豪夫迈·罗氏有限公司 |
少量抗体副产物的定量
|
|
EP4437006A1
(en)
|
2021-11-26 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
|
JPWO2023100829A1
(da)
|
2021-11-30 |
2023-06-08 |
|
|
|
MX2024006387A
(es)
|
2021-12-01 |
2024-06-04 |
Chugai Pharmaceutical Co Ltd |
Metodo para preparar formulacion que contiene anticuerpo.
|
|
EP4428156A1
(en)
|
2021-12-03 |
2024-09-11 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Anti-bcma nanobody and use thereof
|
|
WO2023103788A1
(zh)
|
2021-12-06 |
2023-06-15 |
北京三诺佳邑生物技术有限责任公司 |
特异性结合肺炎克雷伯菌o2抗原和o1抗原的双特异性抗体以及组合物
|
|
KR20240127992A
(ko)
|
2021-12-08 |
2024-08-23 |
인사이트 코포레이션 |
항-돌연변이 칼레티쿨린(calr) 항체 및 이의 용도
|
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
|
KR20240116829A
(ko)
|
2021-12-13 |
2024-07-30 |
윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 |
항-abcb1 항체
|
|
CN118541382A
(zh)
|
2021-12-14 |
2024-08-23 |
豪夫迈·罗氏有限公司 |
使用HLA-A2/MAGE-A4 x CD3双特异性抗体和4-1BB(CD137)激动剂治疗癌症
|
|
KR20240116755A
(ko)
|
2021-12-17 |
2024-07-30 |
상하이 헨리우스 바이오테크, 인크. |
항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
|
|
KR20240122784A
(ko)
|
2021-12-17 |
2024-08-13 |
상하이 헨리우스 바이오테크, 인크. |
항-ox40 항체 및 사용 방법
|
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
|
EP4416301A1
(en)
|
2021-12-21 |
2024-08-21 |
F. Hoffmann-La Roche AG |
Method for the determination of hydrolytic activity
|
|
EP4453033A1
(en)
|
2021-12-22 |
2024-10-30 |
Incyte Corporation |
Treatment paradigm for an anti-cd19 antibody therapy
|
|
AU2022423369A1
(en)
|
2021-12-23 |
2024-07-11 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody
|
|
KR20240128067A
(ko)
|
2021-12-29 |
2024-08-23 |
브리스톨-마이어스 스큅 컴퍼니 |
랜딩 패드 세포주의 생성
|
|
CN118510805A
(zh)
|
2021-12-31 |
2024-08-16 |
山东先声生物制药有限公司 |
一种gprc5d抗体及其应用
|
|
US20230322958A1
(en)
|
2022-01-19 |
2023-10-12 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Conjugates and Methods of Use
|
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
|
WO2023147331A1
(en)
|
2022-01-26 |
2023-08-03 |
Mabswitch Inc. |
Bispecific molecule with tunable affinity to a targetted antigen
|
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
|
WO2023147784A1
(zh)
|
2022-02-07 |
2023-08-10 |
江苏恒瑞医药股份有限公司 |
特异性结合psma和cd3的抗原结合分子及其医药用途
|
|
CN118647633A
(zh)
|
2022-02-07 |
2024-09-13 |
威斯特拉公司 |
抗独特型抗体分子及其用途
|
|
JPWO2023153442A1
(da)
|
2022-02-09 |
2023-08-17 |
|
|
|
TW202342534A
(zh)
|
2022-02-10 |
2023-11-01 |
大陸商上海齊魯製藥研究中心有限公司 |
一種雙特異性抗原結合分子及其應用
|
|
WO2023151661A1
(zh)
|
2022-02-11 |
2023-08-17 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
WO2023154953A1
(en)
|
2022-02-14 |
2023-08-17 |
Ngm Biopharmaceuticals, Inc. |
Gdf15 polypeptides for treating and preventing autoimmune diseases
|
|
WO2023159220A1
(en)
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
|
WO2023156614A1
(en)
|
2022-02-21 |
2023-08-24 |
argenx BV |
Methods for treating myositis using fcrn antagonists
|
|
AU2023223455A1
(en)
|
2022-02-23 |
2024-08-29 |
Janssen Biotech, Inc. |
Anti-cd28 x anti-psma antibodies
|
|
US20230340128A1
(en)
|
2022-02-24 |
2023-10-26 |
Xencor, Inc. |
Anti-cd28 x anti-msln antibodies
|
|
WO2023164640A1
(en)
|
2022-02-24 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-trop2 antibodies
|
|
CN118742649A
(zh)
|
2022-02-25 |
2024-10-01 |
北京中因科技有限公司 |
表达盒组合及其应用
|
|
IL314678A
(en)
|
2022-02-27 |
2024-10-01 |
Boehringer Ingelheim Int |
Bispecific antibodies against DC277 and tumor antigen
|
|
IL314922A
(en)
|
2022-02-28 |
2024-10-01 |
Xilio Dev Inc |
Targeted cytokines and methods of using them
|
|
WO2023164286A1
(en)
|
2022-02-28 |
2023-08-31 |
Xilio Development, Inc. |
Engineered cd122 compositions and methods thereof
|
|
MX2024010773A
(es)
|
2022-03-03 |
2024-09-10 |
Pfizer Inc |
Anticuerpos multiespecificos y usos de estos.
|
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
AU2023232876A1
(en)
*
|
2022-03-11 |
2024-10-03 |
Elpiscience (Suzhou) Biopharma, Ltd. |
Modified antibodies and uses thereof
|
|
WO2023170291A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
|
KR20240156640A
(ko)
|
2022-03-11 |
2024-10-30 |
얀센 파마슈티카 엔브이 |
다중특이적 항체 및 이의 용도
|
|
AU2023232448A1
(en)
|
2022-03-11 |
2024-10-24 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
|
WO2023174925A1
(en)
|
2022-03-14 |
2023-09-21 |
Novimmune Sa |
Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
|
|
MX2024011128A
(es)
|
2022-03-14 |
2024-09-18 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Molecula de union a antigeno que se une especificamente a gprc5d y cd3 y su uso medico.
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
WO2023176881A1
(ja)
|
2022-03-16 |
2023-09-21 |
第一三共株式会社 |
多重特異的分子と免疫チェックポイント阻害剤の組み合わせ
|
|
IL315714A
(en)
|
2022-03-18 |
2024-11-01 |
Evolveimmune Therapeutics Inc |
Bispecific antibody fusion molecules and methods of using them
|
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
WO2023179740A1
(en)
|
2022-03-25 |
2023-09-28 |
Shanghai Henlius Biotech , Inc. |
Anti-msln antibodies and methods of use
|
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
|
IL316022A
(en)
|
2022-03-30 |
2024-11-01 |
Janssen Biotech Inc |
A method for the treatment of mild to moderate psoriasis with a specific IL-23 antibody
|
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
|
AU2022450448A1
(en)
|
2022-04-01 |
2024-10-10 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
|
WO2023192606A2
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Cd3-binding proteins and methods of use thereof
|
|
WO2023196905A1
(en)
|
2022-04-07 |
2023-10-12 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
WO2023193239A1
(en)
|
2022-04-08 |
2023-10-12 |
Peter Peizhi Luo |
Anti-cd28 antibodies and methods of use thereof
|
|
TW202408562A
(zh)
|
2022-04-13 |
2024-03-01 |
美商建南德克公司 |
治療性蛋白質之醫藥組成物及使用方法
|
|
US20230383012A1
(en)
|
2022-04-13 |
2023-11-30 |
Xencor, Inc. |
Antibodies that bind pd-l1, pd-l2, and/or cd28
|
|
IL315887A
(en)
|
2022-04-13 |
2024-11-01 |
F Hoffmann La Roche Ag |
Pharmaceutical preparations of anti-CD20/anti-CD3 bispecific antibodies and methods of use
|
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
AU2023259761A1
(en)
|
2022-04-26 |
2024-09-26 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
|
WO2023209124A1
(en)
|
2022-04-29 |
2023-11-02 |
Immatics Biotechnologies Gmbh |
Mammalian display platform for multispecific antigen binding proteins
|
|
WO2023213779A1
(en)
|
2022-05-02 |
2023-11-09 |
Novo Nordisk A/S |
Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
|
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2023220647A1
(en)
|
2022-05-11 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
|
WO2023230594A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
US20230416412A1
(en)
|
2022-05-31 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
|
WO2023235848A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
|
WO2023237690A2
(en)
|
2022-06-08 |
2023-12-14 |
Sanofi |
Methods for purification of multi-specific antibodies
|
|
WO2023242362A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
Fcrn/antigen-binding molecules and methods of use
|
|
WO2023245105A1
(en)
|
2022-06-17 |
2023-12-21 |
Genentech, Inc. |
Use of kosmotropes to enhance yield of an affinity chromatography purification step
|
|
TW202417042A
(zh)
|
2022-07-13 |
2024-05-01 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
US20240052065A1
(en)
|
2022-07-15 |
2024-02-15 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
|
TW202417474A
(zh)
|
2022-07-15 |
2024-05-01 |
美商艾希利歐發展股份有限公司 |
經改造之可裂解載體及其使用方法
|
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20240228664A9
(en)
|
2022-07-22 |
2024-07-11 |
Bristol-Myers Squibb Company |
Antibodies Binding to Human PAD4 and Uses Thereof
|
|
TW202417504A
(zh)
|
2022-07-22 |
2024-05-01 |
美商建南德克公司 |
抗ｓｔｅａｐ１抗原結合分子及其用途
|
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
WO2024023271A1
(en)
|
2022-07-27 |
2024-02-01 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
TW202405020A
(zh)
|
2022-07-29 |
2024-02-01 |
美商阿列克特有限責任公司 |
轉鐵蛋白受體抗原結合域及其用途
|
|
TW202426637A
(zh)
|
2022-08-01 |
2024-07-01 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
蛋白酶可切割受質及其使用方法
|
|
TW202424184A
(zh)
|
2022-08-01 |
2024-06-16 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
蛋白酶可切割部分及其使用方法
|
|
WO2024030845A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
|
WO2024030843A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
|
TW202424183A
(zh)
|
2022-08-01 |
2024-06-16 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
蛋白酶可切割受質及其使用方法
|
|
WO2024028386A1
(en)
|
2022-08-02 |
2024-02-08 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
|
US20240052047A1
(en)
|
2022-08-03 |
2024-02-15 |
Pfizer Inc. |
Anti- il27r antibodies and methods of use thereof
|
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
|
WO2024036139A2
(en)
|
2022-08-09 |
2024-02-15 |
Qlsf Biotherapeutics, Inc. |
Antibodies binding to clec12a
|
|
WO2024040247A1
(en)
|
2022-08-18 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
|
CN115353552B
(zh)
*
|
2022-08-19 |
2023-07-18 |
山东大学 |
一种降低蛋白质变性温度的方法及其突变体与应用
|
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
WO2024052922A1
(en)
|
2022-09-11 |
2024-03-14 |
Yeda Research And Development Co. Ltd. |
Anti-klk4 antibodies and uses thereof
|
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
WO2024062073A1
(en)
|
2022-09-22 |
2024-03-28 |
Hummingbird Bioscience Pte. Ltd. |
Treatment and prevention of cancer using vista antigen-binding molecules
|
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
|
US20240101718A1
(en)
|
2022-09-28 |
2024-03-28 |
Incyte Corporation |
Anti-pd-1/lag-3 bispecific antibodies and uses thereof
|
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
|
|
TW202430211A
(zh)
|
2022-10-10 |
2024-08-01 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法
|
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
|
|
WO2024079069A1
(en)
|
2022-10-12 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Method for classifying cells
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
WO2024086739A1
(en)
|
2022-10-20 |
2024-04-25 |
Synthekine, Inc. |
Methods and compositions of il12 muteins and il2 muteins
|
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|
|
US20240209100A1
(en)
|
2022-10-21 |
2024-06-27 |
Diagonal Therapeutics Inc. |
Heteromeric agonistic antibodies to il-18 receptor
|
|
TW202426494A
(zh)
|
2022-10-24 |
2024-07-01 |
瑞士商赫孚孟拉羅股份公司 |
預測對ｉｌ－６拮抗劑的反應
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
|
WO2024095173A1
(en)
|
2022-11-02 |
2024-05-10 |
Janssen Biotech, Inc. |
Methods of treating cancers
|
|
US20240190982A1
(en)
|
2022-11-03 |
2024-06-13 |
Incyte Corporation |
Combination therapies comprising an anti-gitr antibody for treating cancers
|
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
|
WO2024102693A2
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Il-18-fc fusion proteins
|
|
TW202428303A
(zh)
|
2022-11-07 |
2024-07-16 |
比利時商阿根思公司 |
使用ｆｃｒｎ拮抗劑治療原發性膜性腎病變之方法
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
|
WO2024102962A1
(en)
|
2022-11-10 |
2024-05-16 |
Immuvia Inc |
Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
WO2024104988A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Recombinant binding proteins with activatable effector domain
|
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
|
US20240226313A1
(en)
|
2022-11-17 |
2024-07-11 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
|
US20240199734A1
(en)
|
2022-11-22 |
2024-06-20 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
|
WO2024110426A1
(en)
|
2022-11-23 |
2024-05-30 |
F. Hoffmann-La Roche Ag |
Method for increasing recombinant protein expression
|
|
WO2024110905A1
(en)
|
2022-11-24 |
2024-05-30 |
Beigene, Ltd. |
Anti-cea antibody drug conjugates and methods of use
|
|
WO2024115349A1
(en)
|
2022-11-29 |
2024-06-06 |
F. Hoffmann-La Roche Ag |
Improved cancer immunotherapy
|
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
|
WO2024121798A1
(en)
|
2022-12-08 |
2024-06-13 |
Csl Behring Llc |
Dissociable envelope binding proteins and uses thereof
|
|
WO2024124107A2
(en)
|
2022-12-09 |
2024-06-13 |
Pfizer Inc. |
Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
|
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|
|
EP4385999A1
(en)
|
2022-12-14 |
2024-06-19 |
ModiQuest B.V. |
Antibodies
|
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
WO2024126660A1
(en)
|
2022-12-15 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Combination therapy for cancer treatment
|
|
WO2024130175A2
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
US20240199761A1
(en)
|
2022-12-19 |
2024-06-20 |
Astrazeneca Ab |
Treatment of autoimmune disease
|
|
US20240209107A1
(en)
|
2022-12-19 |
2024-06-27 |
Sanofi |
Cd28/ox40 bispecific antibodies
|
|
US20240252601A1
(en)
|
2022-12-23 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
WO2024145398A1
(en)
|
2022-12-27 |
2024-07-04 |
Yale University |
Antibody drug conjugates
|
|
WO2024141955A1
(en)
|
2022-12-28 |
2024-07-04 |
BioNTech SE |
Rna compositions targeting hiv
|
|
WO2024147074A1
(en)
|
2023-01-06 |
2024-07-11 |
argenx BV |
Methods for treating pots using fcrn antagonists
|
|
WO2024146957A1
(en)
|
2023-01-06 |
2024-07-11 |
Twain Therapeutics Pte. Ltd. |
Antigen-binding molecules
|
|
WO2024146955A1
(en)
|
2023-01-06 |
2024-07-11 |
Twain Therapeutics Pte. Ltd. |
Antigen-binding molecules
|
|
WO2024150073A1
(en)
|
2023-01-12 |
2024-07-18 |
argenx BV |
Methods for treating primary sjogren's syndrome using fcrn antagonists
|
|
US20240270836A1
(en)
|
2023-01-13 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
WO2024152014A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2024149821A1
(en)
|
2023-01-13 |
2024-07-18 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine
|
|
US20240360229A1
(en)
|
2023-01-18 |
2024-10-31 |
Genentech, Inc. |
Multispecific antibodies and uses thereof
|
|
TW202430570A
(zh)
|
2023-01-19 |
2024-08-01 |
英屬開曼群島商百濟神州有限公司 |
抗cmet抗體及使用方法
|
|
WO2024153722A1
(en)
|
2023-01-20 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
WO2024155982A2
(en)
|
2023-01-20 |
2024-07-25 |
Invetx, Inc. |
Bispecific binding agents for use in companion animals
|
|
WO2024158824A1
(en)
|
2023-01-23 |
2024-08-02 |
Yale University |
Antibody oligonucleotide conjugates
|
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
|
WO2024156759A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Payload-bearing multispecific antibodies
|
|
WO2024163494A1
(en)
|
2023-01-31 |
2024-08-08 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
|
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
|
WO2024165454A1
(en)
|
2023-02-06 |
2024-08-15 |
F. Hoffmann-La Roche Ag |
Combination therapy and uses thereof
|
|
WO2024165500A1
(en)
|
2023-02-06 |
2024-08-15 |
Merck Patent Gmbh |
Vhh-based nkp46 binders
|
|
WO2024167898A1
(en)
|
2023-02-07 |
2024-08-15 |
Go Therapeutics, Inc. |
ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
WO2024173607A2
(en)
|
2023-02-14 |
2024-08-22 |
Evolveimmune Therapeutics, Inc. |
Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
|
|
US20240368250A1
(en)
|
2023-02-17 |
2024-11-07 |
Ablynx N.V. |
Polypeptides binding to the neonatal fc receptor
|
|
WO2024178056A1
(en)
|
2023-02-21 |
2024-08-29 |
Teneobio, Inc. |
C-kit binding proteins, chimeric antigen receptors, and uses thereof
|
|
WO2024182455A2
(en)
|
2023-02-28 |
2024-09-06 |
Regeneron Pharmaceuticals, Inc. |
Multivalent anti-spike protein binding molecules and uses thereof
|
|
US20240287186A1
(en)
|
2023-02-28 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
T cell activators and methods of use thereof
|
|
WO2024183635A1
(en)
|
2023-03-03 |
2024-09-12 |
Beigene, Ltd. |
Muc1 and cd16a antibodies and methods of use
|
|
WO2024183637A1
(en)
|
2023-03-03 |
2024-09-12 |
Beigene Switzerland Gmbh |
Muc1 antibodies and methods of use
|
|
WO2024183636A1
(en)
|
2023-03-03 |
2024-09-12 |
Beigene Switzerland Gmbh |
Cd16a antibodies and methods of use
|
|
WO2024184811A1
(en)
|
2023-03-06 |
2024-09-12 |
Beigene Switzerland Gmbh |
Anti-cd3 multispecific antibodies and methods of use
|
|
WO2024184287A1
(en)
|
2023-03-06 |
2024-09-12 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|
|
WO2024184810A1
(en)
|
2023-03-06 |
2024-09-12 |
Beigene Switzerland Gmbh |
Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
|
|
WO2024184812A1
(en)
|
2023-03-06 |
2024-09-12 |
Beigene Switzerland Gmbh |
Anti-cldn6 antibodies and methods of use
|
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
|
WO2024188966A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4‑1bb (cd137) agonist
|
|
WO2024189430A1
(en)
|
2023-03-14 |
2024-09-19 |
argenx BV |
Methods for vaccination of a subject treated with an fcrn antagonist
|
|
WO2024192308A2
(en)
|
2023-03-14 |
2024-09-19 |
Xencor, Inc. |
Anti-cd28 compositions
|
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
WO2024197302A1
(en)
|
2023-03-23 |
2024-09-26 |
Yale University |
Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
|
|
WO2024206126A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Cd16-binding antibodies and uses thereof
|
|
US20240327522A1
(en)
|
2023-03-31 |
2024-10-03 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
WO2024208776A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
Agonistic split antibodies
|
|
WO2024208777A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
All-in-one agonistic antibodies
|
|
WO2024208898A1
(en)
|
2023-04-05 |
2024-10-10 |
Genmab A/S |
Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
|
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
EP4442275A1
(en)
|
2023-04-06 |
2024-10-09 |
ModiQuest B.V. |
Anti-type ii collagen antibodies
|
|
WO2024211796A1
(en)
|
2023-04-07 |
2024-10-10 |
Diagonal Therapeutics Inc. |
Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
|
|
WO2024211807A1
(en)
|
2023-04-07 |
2024-10-10 |
Diagonal Therapeutics Inc. |
Hinge-modified bispecific antibodies
|
|
WO2024216146A1
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|
|
WO2024216170A2
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
WO2024216194A1
(en)
|
2023-04-12 |
2024-10-17 |
Cytomx Therapeutics, Inc. |
Masking polypeptides, activatable cytokine constructs, and related compositions and methods
|
|
WO2024216226A1
(en)
|
2023-04-14 |
2024-10-17 |
Xencor, Inc. |
Anti-cd28 x anti-enpp3 antibodies
|
|
US20240343805A1
(en)
|
2023-04-14 |
2024-10-17 |
Incyte Corporation |
USE OF AN ANTI-TGFßR2/PD-1 BISPECIFIC ANTIBODY
|
|
WO2024216221A1
(en)
|
2023-04-14 |
2024-10-17 |
Xencor, Inc. |
Anti-cd28 x anti-trop2 antibodies
|
|
WO2024220546A2
(en)
|
2023-04-17 |
2024-10-24 |
Peak Bio, Inc. |
Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
|
|
WO2024220256A1
(en)
|
2023-04-18 |
2024-10-24 |
Qlsf Biotherapeutics, Inc. |
Antibodies binding to ly6g6d
|
|
EP4454706A1
(en)
|
2023-04-24 |
2024-10-30 |
Universität Stuttgart |
Novel egfr binding proteins
|
|
WO2024227002A2
(en)
|
2023-04-28 |
2024-10-31 |
Xencor, Inc. |
Orthogonal multimeric proteins
|
|
US12121587B1
(en)
|
2023-12-26 |
2024-10-22 |
Medicovestor, Inc. |
Dimeric antibodies
|
|
US12116410B1
(en)
|
2023-12-26 |
2024-10-15 |
Medicovestor, Inc. |
Methods of manufacturing dimeric antibodies
|
|
GB202402048D0
(en)
|
2024-02-14 |
2024-03-27 |
Bivictrix Ltd |
Therapeutic antibodies
|